Macrocyclic compounds and diagnostic uses thereof

Novel macrocyclic compounds enable stable radioimmunoconjugates with actinium-225 and cerium-134, addressing the challenge of tumor-specific targeting in radiotherapy by enhancing stability and efficacy through site-specific conjugation, facilitating precise localization of alpha-emitting radionuclides for improved cancer treatment and imaging.

JP2024543046APending Publication Date: 2024-11-19JANSSEN BIOTECH INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024527064
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-09
Filing Date
2022-11-08
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Current radiotherapy methods face challenges in enabling rapid visualization of tumor-specific targeting due to difficulties in selectively targeting cancer cells with radiopharmaceuticals for imaging or therapeutic purposes, and existing chelators like DOTA struggle with stability and ratio limitations when binding alpha-emitting radionuclides such as actinium-225.

Method used

Development of novel macrocyclic compounds that can bind radioactive metals like actinium-225 and cerium-134, allowing for the creation of stable radioimmunoconjugates with high specific activity, using site-specific conjugation methods like click chemistry to attach these compounds to targeting ligands such as antibodies, thereby enhancing the stability and efficacy of radiotherapy.

Benefits of technology

The new compounds provide stable radioimmunoconjugates that effectively target tumor cells with high specificity and stability, offering improved safety and efficacy in radiotherapy and diagnostic imaging by allowing for precise localization of alpha-emitting radionuclides.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543046000113
    Figure 2024543046000113
  • Figure 2024543046000114
    Figure 2024543046000114
  • Figure 2024543046000115
    Figure 2024543046000115
Patent Text Reader

Abstract

The present invention relates to compounds (macrocyclic compounds) and pharma- ceutically acceptable salts thereof, immunoconjugates thereof, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and their immunoconjugates, radioimmunoconjugates thereof, and the use of said compounds and their immunoconjugates, radioimmunoconjugates thereof in nuclear medicine as tracers and imaging agents.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 277,283, filed November 9, 2021, which is hereby incorporated by reference in its entirety.

[0002] (Reference to electronically submitted sequence listing) This application contains a computer readable sequence listing submitted herewith in XML file format, the entire contents of which are incorporated herein by reference in their entirety. The sequence listing XML file submitted herewith is entitled "JBI6639WOPCT1_SL.xml", was created on November 7, 2022, and is 36,946 bytes in size.

[0003] FIELD OF THEINVENTION The present invention relates to compounds (macrocyclic compounds) and pharma- ceutically acceptable salts thereof, immunoconjugates thereof, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and their immunoconjugates, radioimmunoconjugates thereof, and the use of said compounds and their immunoconjugates, radioimmunoconjugates thereof in nuclear medicine as tracers and imaging agents. [Background technology]

[0004] Alpha particle emitting radionuclides are very promising for cancer therapy due to the combination of high linear energy deposition and short-range action, offering the potential for potent killing that is mostly localized to tumor cells (Kim, Y Sand MW Brechbiel, An overview of targeted alpha therapy. Tumour Biol, 2012. 33(3): p. 573-90). Targeted delivery of alpha emitters using antibodies, scaffold proteins, small molecule ligands, aptamers, or other binding moieties specific for cancer antigens provides a method for selective delivery of radionuclides to tumors, enhancing their efficacy and reducing off-target effects. In common practice, the binding moiety is attached to a chelator that binds to an alpha emitting radiometal to generate a radiocomplex. Many such examples use monoclonal antibodies (mAbs) as targeting vectors to generate what are known as radioimmunoconjugates.

[0005] Actinium 225( 225 Actinium-225 (Ac) is an alpha-emitting radioisotope of particular interest for medical applications (Miederer et al., Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev, 2008. 60(12):71-82). 225 The half-life of Ac is 10 days, which is long enough to facilitate the generation of radioconjugates, but short enough to match the circulating pharmacokinetics of delivery vehicles such as antibodies, and therefore 225 Of particular interest are Ac radioimmunoconjugates. 225 Ac is a stable isotope 209 By the time we reach Bi, 225It decays in a series of steps emitting a total of four alpha particles per Ac decay, thereby increasing its potency. Another radioisotope of interest for medical applications is lutetium-177, which emits both gamma radiation suitable for imaging and medium-energy beta radiation suitable for radiotherapy. 177 Lu). 177 Lu-labeled peptides demonstrated reduced normal tissue damage, 177 Lu labeling has been shown to enable the use of a single radioactive labeling agent for both therapy and imaging (Kwekkeboom DJ et al., [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate:comparison with[ 111 In-DTPA 0 ]octreotide in patients. Eur J Nucl Med. 2001, 28: p. 1319-1325). Other radioisotopes used for therapeutic applications include, for example, beta-emitters or alpha-emitters, e.g. 32 P, 47 Sc, 67 Cu, 77 As, 89 Sr, 90 Y, 99 Tc, 105 Rh, 109 Pd, 111 Ag, 131 I, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 159 Gd, 165 Dy, 166 Ho, 169 Er, 186 Re, 188 Re, 194 Ir, 198 Au, 199 Au, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 255 Fm and 227Other radioisotopes used for imaging applications include, for example, 62 Cu, 64 Cu, 67 Ga, 68 Ga, 86 Y, 89 Zr, and 111 Included are gamma-ray and / or positron-emitting radioisotopes such as In.

[0006] Currently, the most widely used chelator for actinium-225 and lanthanides is DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, tetraxathene), and previous clinical and preclinical programs have primarily used 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for actinium chelation. However, it is well known that DOTA chelation of actinium can be difficult (Deal, KA et al., Improved in vivo stability of actinium-225 macrocyclic complexes. J Med Chem, 1999.42(15):p.2988-92). For example, DOTA only allows a maximum DOTA:actinium-225 chelation ratio of >500:1 when conjugated to a targeting ligand such as a protein or antibody, often requiring either harsh conditions or high levels of DOTA per antibody. Other macrocyclic chelators for lanthanides and actinium-225 are described, for example, in WO 2018 / 183906; Thiele et al., "An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy," Angew. Chem. Int. Ed. (2017) 56, 14712-14717; Roca-Sabio et al., "Macrocyclic Receptor Exhibiting Unprecedented Selectivity for Light Lanthanides," J. Am. Chem. Soc. (2009) 131, 3331-3341.

[0007] Site specificity has become a major area of ​​focus in the antibody-drug conjugate (ADC) field, as it has been demonstrated that site-specific approaches can enhance both the efficacy and safety of ADCs compared to random conjugation (Agarwal, P. and C.R. Bertozzi, Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development, Bioconjug Chem, 2015.26(2):p.176-92). It is believed that similar safety and efficacy benefits may be achieved with radioimmunoconjugates.

[0008] With the advancement of targeted alpha-emitting therapy using actinium and thorium radionuclides as an effective treatment for disease, there is a need to develop methods to image the location of radionuclide therapeutic agents within the body. Selective targeting of cancer cells with radiopharmaceuticals for either imaging or therapeutic purposes is difficult. 111 In, 90 Y, 68 Ga, 177 Lu, 99 Tc, 123 I and 131 It is well known that a variety of radionuclides, including I, are useful for radioimaging or cancer radiotherapy. Summary of the Invention [Problem to be solved by the invention]

[0009] New radio-imaging agents are needed that allow rapid visualization of tumor-specific targeting to enable radiotherapy. [Means for solving the problem]

[0010] Therefore, in the art, actinium-225( 225α-emitting radioactive metals such as cerium-134 ( 134 There is a need for novel compounds that can be used to bind radiometals, such as positron-emitting radiometals, such as Ce, and generate stable radioimmunoconjugates with high specific activity in high yields. The present invention relates to the binding of radiometals, such as alpha-emitting radiometals, regardless of their specific activity or the most common metal impurities, e.g. 225 Macrocyclic compounds capable of binding Ac, as well as imaging radiometals, e.g. 134 This need is met by providing the ability to chelate Ce. The compounds of the present invention can be used to generate radioimmunoconjugates with high stability in vitro and in vivo by conjugating to targeting ligands such as antibodies, proteins, aptamers, etc., preferably in a site-specific manner using "click chemistry". The radioimmunoconjugates generated by conjugating the compounds of the present invention to targeting ligands can be used for targeted radiotherapy, such as targeted radiotherapy of tumor cells, and / or targeted therapy of neoplastic diseases or disorders, including cancer. The radioimmunoconjugates of the present invention can also be used for diagnosis and tumor detection.

[0011] The present invention includes compounds capable of forming complexes with the radiometals, radiometal complexes and radioimmunoconjugates described herein.

[0012] In one embodiment of the present invention, a compound of formula (I):

[0013] [ka] [In the formula, R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, which is optionally substituted with -L1-R4; L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand, or a pharma- ceutically acceptable salt thereof.

[0014] In another embodiment, the present invention provides

[0015] [ka] With respect to one or more compounds independently selected from the group consisting of: During the ceremony, L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.

[0016] In certain embodiments, R4 is -NH2, -NCS, -NCO, -N3, alkynyl, cycloalkynyl, -C(O)R 13 , -COOR 13 , -CON(R 13 )2, maleimide, acyl halide, tetrazine, or trans-cyclooctene.

[0017] In certain embodiments, R4 is cyclooctynyl or a cyclooctynyl derivative selected from the group consisting of bicyclononynyl (BCN), difluorinated cyclooctynyl (DIFO), dibenzocyclooctynyl (DIBO), keto-DIBO, biarylazacyclooctynonyl (BARAC), dibenzoazacyclooctynyl (DIBAC, DBCO, ADIBO), dimethoxyazacyclooctynyl (DIMAC), difluorobenzocyclooctynyl (DIFBO), monobenzocyclooctynyl (MOBO), and tetramethoxy dibenzocyclooctynyl (TMDIBO).

[0018] In certain embodiments, R4 is DBCO or BCN.

[0019] In certain embodiments, R4 comprises a targeting ligand selected from the group consisting of an antibody, an antibody fragment (e.g., an antigen-binding fragment), a binding peptide, a binding polypeptide (e.g., a selective targeting oligopeptide comprising up to 50 amino acids), a binding protein, an enzyme, a nucleobase-containing moiety (e.g., an oligonucleotide, a DNA or RNA vector, or an aptamer), and a lectin.

[0020] In certain embodiments, the targeting ligand is an antibody or an antigen-binding fragment thereof.

[0021] In another embodiment, the present invention is a radiometal complex comprising a radiometal ion complexed to a compound of formula I.

[0022] In another embodiment, the present invention relates to a compound of formula (IM + ):

[0023] [ka] [In the formula, M + Actinium 225 ( 225 Ac), Radium 223 ( 233 Ra), Bismuth 213 ( 213 Bi), Pb-212( 212 Pb(II) and / or 212 Pb(IV)), Terbium-149( 149 Tb), Terbium-152 ( 152 Tb), terbium-155 ( 155 Tb), Fermium 255 ( 255 Fm), Thorium 227 ( 227 Th), Thorium 226 ( 226 Th 4+ ), Astatine 211( 211 At), Cerium-134 ( 134 Ce), Neodymium 144 ( 144 Nd), Lanthanum 132 ( 132 La), Lantern 135 ( 135 La), and Uranium-230 ( 230 U) is a radioactive metal ion selected from the group consisting of R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, which is optionally substituted with -L1-R4; L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand, or a pharma- ceutically acceptable salt thereof.

[0024] In some embodiments, R4 is -NH2, -NCS, -NCO, -N3, alkynyl, cycloalkynyl, -C(O)R 13 , -COOR 13 , -CON(R 13 )2, maleimide, acyl halide, tetrazine, or trans-cyclooctene.

[0025] In certain embodiments, R4 is cyclooctynyl or a cyclooctynyl derivative selected from the group consisting of bicyclononynyl (BCN), difluorinated cyclooctynyl (DIFO), dibenzocyclooctynyl (DIBO), keto-DIBO, biarylazacyclooctynonyl (BARAC), dibenzoazacyclooctynyl (DIBAC, DBCO, ADIBO), dimethoxyazacyclooctynyl (DIMAC), difluorobenzocyclooctynyl (DIFBO), monobenzocyclooctynyl (MOBO), and tetramethoxydibenzocyclooctynyl (TMDIBO).

[0026] In certain embodiments, R4 is DBCO or BCN.

[0027] In certain embodiments, the alpha-emitting radioactive metal ion is actinium-225 ( 225 Ac).

[0028] In another embodiment, the present invention relates to a compound of formula (IM + or a pharma- ceutically acceptable salt thereof. M + is a radioactive metal ion, M + Actinium 225 ( 225 Ac), Radium 223 ( 233 Ra), Bismuth 213 ( 213 Bi), Pb-212( 212 Pb(II) and / or 212 Pb(IV)), Terbium-149( 149 Tb), Terbium-152 ( 152 Tb), terbium-155 ( 155 Tb), Fermium 255 (255 Fm), Thorium 227 ( 227 Th), Thorium 226 ( 226 Th 4+ ), Astatine 211( 211 At), Cerium-134 ( 134 Ce), Neodymium 144 ( 144 Nd), Lanthanum 132 ( 132 La), Lantern 135 ( 135 La), and Uranium-230 ( 230 U) selected from the group consisting of R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, which is optionally substituted with -L1-R4; L1 is absent or a linker, R4 is a targeting ligand, where the targeting ligand is selected from the group consisting of an antibody, an antibody fragment (e.g., an antigen-binding fragment), a binding moiety, a binding peptide, a binding polypeptide (e.g., a selective targeting oligopeptide comprising up to 50 amino acids), a binding protein, an enzyme, a nucleobase-containing moiety (e.g., an oligonucleotide, a DNA or RNA vector, or an aptamer), and a lectin.

[0029] In certain embodiments, the alpha-emitting radioactive metal ion is actinium-225 ( 225 Ac).

[0030] In certain embodiments, the radioactive metal ion is cerium-134 ( 134 Ce).

[0031] In another embodiment, the present invention relates to an immunoconjugate comprising a compound of the present invention covalently attached via R4 to a targeting ligand, preferably an antibody or antigen-binding fragment thereof.

[0032] In a further embodiment, the radioimmunoconjugate comprises a radiometal complex of the invention covalently bound to an antibody or antigen-binding fragment thereof via a triazole moiety.

[0033] In another embodiment, the present invention relates to a method for preparing an immunoconjugate or radioimmunoconjugate of the present invention comprising covalently linking a compound or a radiometal complex of the present invention to a targeting ligand, preferably to an antibody or antigen-binding fragment thereof via R4 of the compound or radiometal complex of the present invention.

[0034] In another embodiment, the present invention relates to a pharmaceutical composition comprising a compound, immunoconjugate, or radioimmunoconjugate of the present invention and a pharma- ceutical acceptable carrier. The pharmaceutical composition may also include one or more pharma- ceutical acceptable carriers.

[0035] In another embodiment, the present invention also provides compositions (e.g., pharmaceutical compositions) and medicaments comprising any one of the compounds described herein (or a pharma- ceutically acceptable salt thereof) and a pharma- ceutically acceptable carrier or one or more excipients or fillers. In a similar embodiment, the present invention also provides compositions (e.g., pharmaceutical compositions) and medicaments comprising any one of the embodiments of the modified antibodies, modified antibody fragments, or modified binding peptides of the present technology disclosed herein and a pharma- ceutically acceptable carrier or one or more excipients or fillers.

[0036] In another embodiment, the present invention relates to methods of using the radioimmunoconjugates and pharmaceutical compositions of the present invention for targeted radiotherapy or radioimaging agents (useful for diagnosis and tumor detection). In one embodiment, the present invention relates to a method of selectively targeting tumor cells for radiotherapy or radioimaging in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of the present invention.

[0037] In one embodiment, the present invention relates to a method of treating a neoplastic disease or disorder in a subject in need of such treatment, comprising administering to the subject a pharmaceutical composition of the present invention.

[0038] In another embodiment, the present invention relates to the use of radiometal complexes and radioimmunoconjugates for the detection, treatment, and management of neoplastic diseases or disorders. [Brief description of the drawings]

[0039] The above Summary of the Invention and the following Detailed Description of the Invention will be better understood when read in conjunction with the accompanying drawings, in which it is understood that the invention is not limited to the precise embodiments shown in the drawings.

[0040] Of the drawings: [Figure 1A] HPLC (High Performance Liquid Chromatography) chromatograms of chelation studies with La3+ are shown. HPLC chromatograms of 6-((16-((6-carboxypyridin-2-yl)(phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (TOPA-[C7]-phenyl) before mixing (top) and after mixing with La3+ (middle) are shown. The shift in retention time from 14.137 min to 12.047 min after mixing with La3+ and Ac-225 indicates rapid chelation of La3+. [Figure 1B] HPLC (High Performance Liquid Chromatography) chromatograms of the chelation study with La3+ are shown. HPLC chromatograms of TOPA-[C7]-isopentyl before mixing (top) and after mixing with La3+ (bottom) are shown. The shift in retention time from 17.181 min to 15.751 min after mixing with La3+ indicates rapid chelation of La3+ and Ac-225 by TOPA-[C7]-isopentyl. [Diagram 2] 1 shows schematic diagrams of radiolabeling of antibodies to generate radioimmunoconjugates according to embodiments of the present invention by random conjugation methods (e.g., labeling of lysine residues, cysteine ​​residues, etc.) or site-specific conjugation methods (e.g., glycan-specific, conjugation tag, or engineered cysteine). A shows schematic diagram of random conjugation by one-step direct radiolabeling. B shows schematic diagram of random conjugation by click radiolabeling. C shows schematic diagram of site-specific conjugation by one-step direct radiolabeling. D shows schematic diagram of site-specific conjugation by click radiolabeling. [Figure 3A] HPLC chromatogram of Ac-225 chelation test. HPLC chromatogram of 6-((16-((6-carboxypyridin-2-yl)(phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (TOPA-[C7]-phenyl) chelated with Ac-225 (cut-count-reconstructed RA trace). [Figure 3B] HPLC chromatogram of Ac-225 chelation test. HPLC chromatogram of 6-((16-(1-(6-carboxypyridin-2-yl)-4-methylphenyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (TOPA-[C7]-isophenyl) chelated with Ac-225 (RA (radioactivity) trace by cut-count-reconstruction). [Figure 4A] Figure 2 shows the HPLC chromatogram of Ac-225 chelation test. Figure 2 shows the HPLC chromatogram of TOPA-[C7]-phenylthiourea-H11B6 chelated with Ac-225 (UV). [Figure 4B]HPLC chromatogram of Ac-225 chelation test. HPLC chromatogram of TOPA-[C7]-phenylthiourea-H11B6 chelated with Ac-225RA (radioactivity) (Cut-Count-Reconstructed RA (radioactivity) trace). [Diagram 5] 2 shows an instant Thin Layer Chromatography (iTLC) scan showing the percentage of Ac-225 bound to TOPA-[C7]-phenylthiourea-h11b6 in the presence of metal impurities, as described in Example 22. [Figure 6] 13 shows an iTLC scan showing the percentage of Ac-225 bound to TOPA-[C7]-phenylthiourea-h11b6 in the presence of metal impurities, as described in Example 22. [Figure 7] 13 shows an iTLC scan showing the percentage of Ac-225 bound to TOPA-[C7]-phenylthiourea-h11b6 in the presence of metal impurities, as described in Example 22. [Figure 8] 13 shows an iTLC scan showing the percentage of Ac-225 bound to TOPA-[C7]-phenylthiourea-h11b6 in the presence of metal impurities, as described in Example 22. [Figure 9] 23 shows an iTLC scan showing the percentage of Ac-225 chelated to DOTA-h11b6 in the presence of metal impurities, as described in Example 22. [Figure 10] 23 shows an iTLC scan showing the percentage of Ac-225 bound to DOTA-h11b6 in the presence of metal impurities, as described in Example 22. [Figure 11] 23 shows an iTLC scan showing the percentage of Ac-225 chelated to DOTA-h11b6 in the presence of metal impurities, as described in Example 22. [Figure 12] 23 shows an iTLC scan showing the percentage of Ac-225 bound to DOTA-h11b6 in the presence of metal impurities, as described in Example 22. [Figure 13]Shown is a scan of the iTLC analysis of purified 134Ce-TOPA-h11b6 and 134Ce-DOTA-h11b6 scanned immediately after elution. [Figure 14] Shown is a scan of the iTLC analysis of purified 134Ce-TOPA-h11b6 and 134Ce-DOTA-h11b6 scanned after 1 hour of elution. [Figure 15] Shows the iTLC scan of 134Ce-TOPA-h11b6. [Figure 16] Shows iTLC scan of 134Ce-DOTAA-h11b6. [Figure 17] Table B shows the immunoreactive fraction at T=0 hours for 134Ce-TOPA-h11b6 described in Example 23. [Figure 18] Table C shows the immunoreactive fraction at T=24 hours for 134Ce-TOPA-h11b6 as described in Example 23. [Figure 19] 1 shows Maximum Intensity Projections (MIP) of 134Ce-TOPA-1154 tumor targeting versus 134Ce-TOPA-isotype as described in Example 27. [Figure 20] Graph of Quantification of Region of Interest (ROI) over time in C4-2Bluc tumor-bearing NSG mice injected with the indicated [134Ce]-labeled antibodies (n=4, mean ± SD). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0041] Various publications, articles and patents are cited or described in the "Background" and throughout the specification, and each of these references is incorporated herein by reference in its entirety. The discussion of documents, operations, materials, devices, articles and the like which is included in the specification is for the purpose of providing a context for the present invention. Such discussion is not an admission that any or all of these items constitute part of the prior art to any invention disclosed or claimed.

[0042] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Unless otherwise specified, certain terms cited herein shall have the meanings set forth herein. All patents, published patent applications, and publications cited herein are incorporated by reference in their entirety as if set forth herein.

[0043] The following terms are used throughout as defined below.

[0044] As used herein and in the appended claims, in the context of describing elements (particularly in the context of the claims below), the use of the singular articles "a," "an," and "the," and similar demonstratives, shall be construed to encompass both the singular and the plural, unless otherwise indicated herein or clearly contradicted by the context. The description of ranges of values ​​in the present invention is merely intended to serve as a shorthand way of referring individually to each value falling within the range, unless otherwise indicated herein, and each value is incorporated into the specification as if it were individually recited herein. All methods described herein may be performed in any suitable order, unless otherwise indicated herein or clearly contradicted by the context. The use of any and all examples, i.e., exemplary language (e.g., "such as") provided herein is merely to facilitate understanding of the embodiments and does not pose a limitation on the scope of the claims, unless otherwise claimed. Absence of a language in the specification must be construed as indicating an element that is not included in any claim that is essential.

[0045] In general, a reference to a particular element, such as hydrogen or H, is meant to include all isotopes of that element. For example, if an R group is defined to include hydrogen or H, it also includes deuterium and tritium. Thus, tritium, C 14, P 32 and S 35 Compounds containing radioisotopes such as are within the scope of the present technology. Procedures for inserting such labels into the compounds of the present technology will be readily apparent to those of skill in the art based on the disclosure herein.

[0046] The term "substituted" means that at least one hydrogen atom is replaced with a non-hydrogen group, provided that all normal valences are maintained and the replacement results in a stable compound. When a particular group is "substituted," the group may have one or more substituents, preferably 1 to 5 substituents, more preferably 1 to 3 substituents, and most preferably 1 to 2 substituents, independently selected from a list of substituents. For example, "substituted" refers to an organic group (e.g., an alkyl group) as defined below, in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to a non-hydrogen or non-carbon atom. Substituted groups also include groups in which one or more bonds to a carbon atom(s) or hydrogen atom(s) are replaced by a heteroatom with one or more bonds, including double or triple bonds. Thus, unless otherwise specified, a substituted group is substituted with one or more substituents. In some embodiments, a substituted group is substituted with 1, 2, 3, 4, 5, or 6 substituents. Examples of substituents include halogens (i.e., F, Cl, Br, and I), hydroxyl, alkoxy, alkenoxy, aryloxy, aralkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, and heterocyclylalkoxy groups, carbonyl (oxo), carboxylates, esters, urethanes, oximes, hydroxylamines, alkoxyamines, aralkoxyamines, thiols, sulfides, sulfoxides, sulfones, sulfonyls, pentafluorosulfanyl (i.e., SF), sulfonamides, amines, N-oxides, hydrazines, hydrazides, hydrazones, azides, amides, ureas, amidines, guanidines, enamines, imides, isocyanates, isothiocyanates, cyanates, thiocyanates, imines, nitro groups, nitriles (i.e., CN), and the like. The term "independently," when used in reference to substituents, means that when more than one of such substituents is possible, such substituents can be the same or different from each other.

[0047] Substituted ring groups, such as substituted cycloalkyl, aryl, heterocyclyl, and heteroaryl groups, also include rings and ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Thus, substituted cycloalkyl, aryl, heterocyclyl, and heteroaryl groups can also be substituted with substituted or unsubstituted alkyl, alkenyl, and alkynyl groups as defined below.

[0048] As used herein, C1-C 11 Cm-Cn, such as C1-C8 or C1-C6, when used before a group, refers to the group containing m to n carbon atoms.

[0049] Alkyl groups include linear and branched alkyl groups having 1 to 12 carbon atoms, typically 1 to 10 carbon atoms, or in some embodiments 1 to 8, 1 to 6, or 1 to 4 carbon atoms. Examples of linear alkyl groups include groups such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups. Alkyl groups may be substituted or unsubstituted. Representative substituted alkyl groups may be substituted one or more times with substituents such as those listed above, including, but not limited to, haloalkyl (e.g., trifluoromethyl), hydroxyalkyl, thioalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, carboxyalkyl, and the like.

[0050] Cycloalkyl groups include monocyclic, bicyclic, or tricyclic alkyl groups having 3 to 12 carbon atoms in the ring(s), or in some embodiments, 3 to 10, 3 to 8, or 3 to 4, 5, or 6 carbon atoms. Exemplary monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, cycloalkyl groups have 3 to 8 ring members, while in other embodiments, the number of ring carbon atoms ranges from 3 to 5, 3 to 6, or 3 to 7. Bicyclic and tricyclic ring systems include both bridged cycloalkyl groups and fused rings, such as, but not limited to, bicyclo[2.1.1]hexane, adamantyl, decalinyl, and the like. Cycloalkyl groups may be substituted or unsubstituted. Substituted cycloalkyl groups may be substituted one or more times with non-hydrogen and non-carbon groups as defined above. However, substituted cycloalkyl groups also include rings substituted with straight chain or branched chain alkyl groups as defined above. Representative substituted cycloalkyl groups may be mono-substituted or substituted two or more times, such as, but not limited to, 2,2-, 2,3-, 2,4-2,5-, or 2,6-disubstituted cyclohexyl groups, which may be substituted with substituents such as those listed above.

[0051] Cycloalkylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkyl group as defined above. In some embodiments, the cycloalkylalkyl group has 4 to 16 carbon atoms, 4 to 12 carbon atoms, typically 4 to 10 carbon atoms. The cycloalkylalkyl group may be substituted or unsubstituted. Substituted cycloalkylalkyl groups may be substituted at the alkyl portion, the cycloalkyl portion, or both the alkyl and cycloalkyl portions of the group. Representative substituted cycloalkylalkyl groups may be mono-substituted or substituted more than once, for example, but not limited to, mono-, di-, or tri-substituted with the substituents listed above.

[0052] Alkenyl groups include straight chain and branched chain alkyl groups as defined above, except that at least one double bond is present between two carbon atoms. Alkenyl groups have 2 to 12 carbon atoms, typically 2 to 10 carbons, or in some embodiments, 2 to 8, 2 to 6, or 2 to 4 carbon atoms. In some embodiments, an alkenyl can have one carbon-carbon double bond, or multiple carbon-carbon double bonds, such as 2, 3, 4, or more carbon-carbon double bonds. Examples of alkenyl groups include, but are not limited to, methenyl, ethenyl, propenyl, butenyl, and the like. Alkenyl groups may be substituted or unsubstituted. Representative substituted alkenyl groups may be mono-substituted or substituted more than once, for example, but not limited to, mono-, di-, or tri-substituted with the substituents listed above.

[0053] Cycloalkenyl groups include cycloalkyl groups as defined above, with at least one double bond between two carbon atoms. Cycloalkenyl groups can be monocyclic or polycyclic alkyl groups with 3 to 12, more preferably 3 to 8, carbon atoms in the ring(s) and with at least one double bond between two carbon atoms. Cycloalkenyl groups can be substituted or unsubstituted. In some embodiments, cycloalkenyl groups can have one, two, or three double bonds, or multiple carbon-carbon double bonds, such as two, three, four, or more carbon-carbon double bonds, but do not include aromatic compounds. Cycloalkenyl groups have 3 to 14 carbon atoms, or in some embodiments, 5 to 14 carbon atoms, 5 to 10 carbon atoms, or even 5, 6, 7, or 8 carbon atoms. Examples of cycloalkenyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, cyclobutadienyl, and cyclopentadienyl.

[0054] Cycloalkenylalkyl groups are alkyl groups as defined above, in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above. Cycloalkenylalkyl groups may be substituted or unsubstituted. Substituted cycloalkenylalkyl groups may be substituted at the alkyl portion, the cycloalkenyl portion, or both the alkyl and cycloalkenyl portions of the group. Representative substituted cycloalkenylalkyl groups may be substituted one or more times with a substituent, such as those listed above.

[0055] Alkynyl groups include straight chain and branched chain alkyl groups as defined above, except that at least one triple bond is present between two carbon atoms. Alkynyl groups have 2-12 carbon atoms, typically 2-10 carbons, or in some embodiments, 2-8, 2-6, or 2-4 carbon atoms. In some embodiments, alkynyl groups have 1, 2, or 3 carbon-carbon triple bonds. Examples include, but are not limited to, -C=CH, -C=CCH3, -CH2C=CCH3, -C=CCH2CH(CH2CH3)2, among others. Alkynyl groups may be substituted or unsubstituted. A terminal alkyne has at least one hydrogen atom bonded to a triple bonded carbon atom. Representative substituted alkynyl groups may be mono-substituted or substituted more than once, for example, but not limited to, mono-, di-, or tri-substituted with the substituents listed above. A "cyclic alkyne" or "cycloalkynyl" is a cycloalkyl ring containing at least one triple bond between two carbon atoms. Examples of cyclic alkyne or cycloalkynyl groups include, but are not limited to, cyclooctyne, bicyclononyne (BCN), difluorinated cyclooctyne (DIFO), dibenzocyclooctyne (DIBO), keto-DIBO, biarylazacyclooctyne (BARAC), dibenzoazacyclooctyne (DIBAC), dimethoxyazacyclooctyne (DIMAC), difluorobenzocyclooctyne (DIFBO), monobenzocyclooctyne (MOBO), and tetramethoxyDIBO (TMDIBO).

[0056] An aryl group is a cyclic aromatic hydrocarbon that does not contain heteroatoms. Aryl groups herein include monocyclic, bicyclic, and tricyclic ring systems. Thus, aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, fluorenyl, phenanthrenyl, anthracenyl, indenyl, indanyl, pentalenyl, and naphthyl groups. In some embodiments, aryl groups contain 6-14 carbons, and in other cases, 6-12, or even 6-10 carbon atoms in the ring portion of the group. In some embodiments, the aryl group is phenyl or naphthyl. Aryl groups may be substituted or unsubstituted. The phrase "aryl groups" includes groups that contain fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, etc.). Representative substituted aryl groups may be mono-substituted or substituted more than once. For example, monosubstituted aryl groups include, but are not limited to, di-, tri-, tetra-, penta-, or hexasubstituted phenyl or naphthyl groups, which may be substituted with substituents such as those listed above. Aryl moieties are well known and are described, for example, in Lewis, RJ, ed., Hawley's Condensed Chemical Dictionary, 13 th Edition, John Wiley & Sons, Inc., New York (1997). Aryl groups can be a single ring structure (i.e., monocyclic) or can contain multiple ring structures (i.e., polycyclic) that are fused ring structures. Preferably, the aryl group is a monocyclic aryl group.

[0057] An alkoxy group is a hydroxyl group (-OH) in which the bond to the hydrogen atom is replaced by a bond to a carbon atom of a substituted or unsubstituted alkyl group as defined above. Examples of linear alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, and the like. Examples of branched alkoxy groups include, but are not limited to, isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, isohexoxy, and the like. Examples of cycloalkoxy groups include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like. An alkoxy group may be substituted or unsubstituted. Representative substituted alkoxy groups may be substituted one or more times with a substituent, such as those listed above.

[0058] Similarly, alkylthio or thioalkoxy refers to the group -SR, where R is an alkyl attached to the parent molecule via a sulfur bridge, e.g., -S-methyl, -S-ethyl, etc. Representative examples of alkylthio include, but are not limited to, -SCH, -SCHCH, and the like.

[0059] As used herein, the term "halogen" refers to bromine, chlorine, fluorine, or iodine. Correspondingly, the term "halo" means fluoro, chloro, bromo, or iodo. In some embodiments, the halogen is fluorine. In other embodiments, the halogen is chlorine or bromine.

[0060] The terms "hydroxy" and "hydroxyl" may be used interchangeably and refer to --OH.

[0061] The term "carboxy" refers to --COOH.

[0062] The term "cyano" refers to --CN.

[0063] The term "nitro" refers to --NO.

[0064] The term "isothiocyanate" refers to -N=C=S.

[0065] The term "isocyanate" refers to --N.dbd.C.dbd.O.

[0066] The term "azido" refers to --N3.

[0067] The term "amino" refers to -NH2. The term "alkylamino" refers to an amino group in which one or both of the hydrogen atoms attached to the nitrogen are replaced with an alkyl group. An alkylamine group may be represented as -NR2, where each R is independently hydrogen or an alkyl group. For example, alkylamines include methylamine (-NHCH3), dimethylamine (-N(CH3)2), -NHCH2CH3, and the like. As used herein, the term "aminoalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups substituted with one or more amino groups. Representative examples of aminoalkyl groups include, but are not limited to, -CH2NH2, -CH2CH2NH2, and -CH2CH(NH2)CH3.

[0068] As used herein, "amide" refers to -C(O)N(R)2, where each R is independently an alkyl group or hydrogen. Examples of amides include, but are not limited to, -C(O)NH2, -C(O)NHCH3, and -C(O)N(CH3)2.

[0069] The terms "hydroxylalkyl" and "hydroxyalkyl" are used interchangeably and refer to an alkyl group substituted with one or more hydroxyl groups. The alkyl can be a branched or straight chain aliphatic hydrocarbon. Examples of hydroxylalkyl include, but are not limited to, hydroxylmethyl (-CHOH), hydroxylethyl (-CHCHOH), and the like.

[0070] As used herein, the term "heterocyclyl" includes stable monocyclic and polycyclic hydrocarbons containing at least one heteroatom ring member, such as sulfur, oxygen, or nitrogen. As used herein, the term "heteroaryl" includes stable monocyclic and polycyclic aromatic hydrocarbons containing at least one heteroatom ring member, such as sulfur, oxygen, or nitrogen. Heteroaryls can be monocyclic or polycyclic, e.g., bicyclic or tricyclic. Each ring of a heteroatom-containing heterocyclyl or heteroaryl group can contain one or two oxygen or sulfur atoms and / or one to four nitrogen atoms, provided that the total number of heteroatoms in each ring is four or less, and each ring has at least one carbon atom. Heteroaryl groups that are polycyclic, e.g., bicyclic or tricyclic, must contain at least one fully aromatic ring, but the other fused rings or rings can be aromatic or non-aromatic. The heterocyclyl or heteroaryl group may be attached to any available nitrogen or carbon atom of any ring of the heterocyclyl or heteroaryl group. Preferably, the term "heteroaryl" refers to 5- or 6-membered monocyclic and 9- or 10-membered bicyclic groups having at least one heteroatom (O, S, or N) in at least one of the rings, the heteroatom-containing ring preferably having 1, 2, or 3 heteroatoms, more preferably having 1 or 2 heteroatoms selected from O, S, and / or N. The nitrogen heteroatom(s) of a heteroaryl may be substituted or unsubstituted. Additionally, the nitrogen and sulfur heteroatom(s) of a heteroaryl may be optionally oxidized (i.e., N→O and S(O)).r where r is 0, 1, or 2.

[0071] The term "ester" refers to -C(O)R, where R is alkyl.

[0072] The term "carbamate" refers to -OC(O)NR2, where each R is independently alkyl or hydrogen.

[0073] The term "aldehyde" refers to -C(O)H.

[0074] The term "carbonate" refers to -OC(O)OR, where R is alkyl.

[0075] The term "maleimide" refers to a group having the chemical formula H2C2(CO)2NH. The term "maleimido" refers to a maleimide group covalently bonded to another group or molecule. Preferably, the maleimide group is N-bonded, for example:

[0076] [ka]

[0077] The term "acyl halide" refers to -C(O)X, where X is halo (e.g., Br, Cl). Exemplary acyl halides include acyl chlorides (-C(O)Cl) and acyl bromides (-C(O)Br).

[0078] According to the convention used in the art,

[0079] [ka] is used in structural formulas herein to indicate a bond that is the point of attachment of a moiety, functional group, or substituent to a core, parent, or backbone structure, such as a compound of the invention or a targeting ligand.

[0080] When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0 to 3 R groups, that group may be optionally substituted with up to 3 R groups, and each occurrence R is independently selected from the definitions of R.

[0081] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring.

[0082] As used herein, the term "radiometal ion" or "radioactive metal ion" refers to one or more isotopes of an element that emit particles and / or photons. Any radioactive metal ion known to one of skill in the art in light of the present disclosure may be used in the present invention. Examples of radioactive metal ions suitable for use in the present invention include: 47 Sc, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 86 Y, 89 Zr, 89 Sr, 90 Y, 99 Tc, 105 Rh, 109 Pd, 111 Ag, 111 In, 117 Sn, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 159 Gd, 165 Dy, 166 Ho, 169 Er, 177Lu, 186 Re, 188 Re, 194 Ir, 198 Au, 199 Au, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 225 Ac, 227 Th, and 255 Examples include, but are not limited to, Fm.

[0083] The radioactive metal ion may be a "therapeutic emitter," which means a radioactive metal ion that is useful in therapeutic applications. Examples of therapeutic emitters include beta emitters or alpha emitters, e.g., 132 La, 135 La, 134 Ce, 144 Nd, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 159 Gd, 165 Dy, 166 Ho, 169 Er, 177 Lu, 186 Re, 188 Re, 194 Ir, 198 Au, 199 Au, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 225 Ac, 255 Fm and 227 Th, 226 Th, 230 Preferably, the radioactive metal ion used in the present invention is an alpha-emitting radioactive metal ion, such as actinium 225 ( 225 Ac).

[0084] The radioactive metal ion may be a "diagnostic isotope," which means a radioactive metal ion that is useful for diagnostic purposes. Examples of diagnostic isotopes include: 11 C. 13 N, 18 F, 64 Cu, 68 Ga, 82 Rb, 99m Tc, 111 In, 149 Tb, 152 Tb, 155 Tb, 67 Ga, 123 I, 131 I, 201 Tl, 134 The radioactive metal ions used in the present invention include, but are not limited to, positron emitters such as Ce. Preferably, the radioactive metal ions used in the present invention are positron emitting radioactive metal ions such as cerium-134 ( 134 Ce).

[0085] The compounds of the present invention refer to macrocyclic compounds to which metals, preferably radioactive metals, can be complexed. In certain embodiments, the compounds are macrocyclic or macrocyclic rings that contain one or more heteroatoms, such as oxygen and / or nitrogen, as ring atoms. Preferably, the compounds are macrocyclic rings that are derivatives of 4,13-diaza-18-crown-6.

[0086] As used herein, "radiometal complex" refers to a complex comprising a radioactive metal ion associated with a macrocycle. The radioactive metal ion is bound or coordinated to the macrocycle by a coordinative bond. Heteroatoms of the macrocycle may participate in the coordinative bonding of the radioactive metal ion to the macrocycle. The macrocycle may be substituted with one or more substituents which may also participate in the coordinative bonding of the radioactive metal ion to the macrocycle in addition to or instead of the heteroatoms of the macrocycle.

[0087] As used herein, "radio-imaging agent" refers to a radiometal complex or radioimmunoconjugate comprising a radioactive metal ion associated with a macrocyclic compound useful for imaging or diagnostic purposes. The radioactive metal ion is bound or coordinated to the macrocycle by a coordinate bond. A heteroatom of the macrocycle may participate in the coordinate binding of the radioactive metal ion to the macrocyclic compound. The macrocycle may be substituted with one or more substituents which may also participate in the coordinate binding of the radioactive metal ion to the macrocyclic compound in addition to or instead of the heteroatom of the macrocycle.

[0088] As used herein, the term "TOPA" refers to the macrocycle known in the art as H2bp18c6, which may alternatively be referred to as N,N'-bis[(6-carboxy-2-pyridyl)methyl]-4,13-diaza-18-crown-6. See, for example, Roca-Sabio et al., "Macrocyclic Receptor Exhibiting Unprecedented Selectivity for Light Lanthanides," J. Am. Chem. Soc. (2009) 131, 3331-3341, incorporated herein by reference.

[0089] As used herein, the term "click chemistry" refers to a chemical principle introduced by Sharpless that describes tailored chemistry to rapidly and reliably generate covalent bonds by linking together small units that contain reactive groups (see Kolb et al., Angewandte Chemie International Edition (2001) 40:2004-2021). Click chemistry does not refer to a specific reaction, but rather to a concept that includes, but is not limited to, reactions that mimic reactions found in nature. In some embodiments, click chemistry reactions are modular, have a wide range, give high chemical yields, produce inactive by-products, are stereospecific, exhibit large thermodynamic driving forces that favor reactions with a single reaction product, and / or can be performed under physiological conditions. In some embodiments, click chemistry reactions can be performed under simple reaction conditions, use readily available starting materials and reagents, use non-toxic solvents or use innocuous or easily removed solvents such as water, and / or provide simple product isolation by non-chromatographic methods such as crystallization or distillation.

[0090] Click chemistry reactions utilize reactive groups that are rarely found in naturally occurring biomolecules and are chemically inert to biomolecules, but when click chemistry partners are reacted together, the reaction can occur efficiently under biologically relevant conditions, such as cell culture conditions, without the presence of excessive heat and / or harsh reagents. In general, click chemistry reactions require at least two molecules, including click reaction partners that can react with each other. Such click reaction partners that are reactive with each other are sometimes referred to herein as click chemistry handle pairs, or click chemistry pairs. In some embodiments, the click reaction partners are azides and strained alkynes, such as cycloalkynes, such as cyclooctyne or cyclooctyne derivatives, or any other alkynes. In other embodiments, the click reaction partners are reactive dienes and suitable tetrazine dienophiles. For example, trans-cyclooctene, norbornene, or biscyclononene can be paired with suitable tetrazine dienophiles as click reaction pairs. In yet other embodiments, tetrazole can act as a potential source of nitrile imine that can be paired with unactivated alkenes in the presence of UV light to create a click reaction pair called a "photo-click" reaction pair. In other embodiments, the click reaction partners are cysteine ​​and maleimide. For example, a cysteine ​​from a peptide (e.g., GGGC (SEQ ID NO: 33)) can be reacted with a maleimide associated with a chelator (e.g., NOTA). Other suitable click chemistry handles are known to those of skill in the art (see, e.g., Spicer et al., Selective chemical protein modification. Nature Communications. 2014, 5: p. 4740). In other embodiments, the click reaction partners are Staudinger ligation components such as phosphines and azides.In other embodiments, the click reaction partners are Diels-Alder reaction components such as dienes (e.g., tetrazines) and alkenes (e.g., trans-cyclooctene (TCO) or norbornene). Exemplary click reaction partners are described in U.S. Patent Publication No. 20130266512 and WO2015073746, the relevant descriptions of which are incorporated herein by reference.

[0091] According to a preferred embodiment, the click chemistry reaction utilizes an azide group and an alkyne group, more preferably a strained alkyne group, such as a cycloalkyne, such as a cyclooctyne or a cyclooctyne derivative, as a click chemistry pair or reaction partner. In such an embodiment, the click chemistry reaction is a Huisgen cycloaddition between an azide (-N3) and an alkyne moiety, or a 1,3-dipolar cycloaddition to form a 1,2,3-triazole linker. The click chemistry reaction between an alkyne and an azide typically requires the addition of a copper catalyst to promote the 1,3-cycloaddition reaction, and is known as the copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction. However, click chemistry reactions between cyclooctyne or cyclooctyne derivatives and azides typically do not require the addition of a copper catalyst, but instead proceed via a strain-promoted azide-alkyne cycloaddition (SPAAC) reaction (Debets, MF et al., Bioconjugation with strained alkenes and alkynes. Acc Chem Res, 2011. 44(9): p. 805-15).

[0092] As used herein, the term "targeting ligand" refers to any molecule that enhances affinity for a selected target, e.g., an antigen, cell, cell type, tissue, organ, region of the body, or compartment (e.g., a cell, tissue, or organ compartment). Targeting ligands include, but are not limited to, antibodies or antigen-binding fragments thereof, aptamers, polypeptides, and scaffold proteins. Preferably, the targeting ligand is a polypeptide, more preferably an antibody or antigen-binding fragment thereof, an engineered domain, or a scaffold protein.

[0093] As used herein, the term "antibody" or "immunoglobulin" is used in a broad sense and includes immunoglobulin or antibody molecules, including polyclonal antibodies, monoclonal antibodies, including murine, human, human-adapted, humanized, and chimeric monoclonal antibodies, and antigen-binding fragments thereof.

[0094] In general, an antibody is a protein or peptide chain that exhibits binding specificity for a specific antigen (herein referred to as "target"). The structure of an antibody is well known. Immunoglobulins can be assigned to five major classes, namely IgA, IgD, IgE, IgG, and IgM, depending on the amino acid sequence of the heavy chain constant domain. IgA and IgG are further subclassified as isotypes IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4. Antibodies used in the present invention can be of any of the five major classes or corresponding subclasses. Antibody light chains of any vertebrate species can be assigned to one of two clearly distinct types, namely kappa and lambda, based on the amino acid sequence of their constant domain. According to certain embodiments, antibodies used in the present invention include heavy and / or light chain constant regions of murine or human antibodies. Each of the four IgG subclasses has a distinct biological function, known as the effector function. These effector functions are generally mediated by interaction with Fc receptors (FcγR) or by binding of C1q and fixation of complement. Binding to FcγR can result in antibody-dependent cell-mediated cytolysis, whereas binding to complement factors can result in complement-mediated cytolysis. Antibodies useful in the present invention may have no or minimal effector functions, but retain their ability to bind FcRn.

[0095] As used herein, the term "antigen-binding fragment" refers to an antibody fragment such as, for example, a diabody, Fab, Fab', F(ab')2, Fv fragment, disulfide-stabilized Fv fragment (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabody (ds diabody), single-chain antibody molecule (scFv), single domain antibody (sdab), scFv dimer (bivalent diabody), multispecific antibody formed from a portion of an antibody comprising one or more CDRs, camelized single domain antibody, nanobody, domain antibody, bivalent domain antibody, or any other antibody fragment that binds to an antigen but does not include the complete antibody structure. An antigen-binding fragment can bind to the same antigen to which the parent antibody or parent antibody fragment binds. As used herein, the term "single-chain antibody" refers to a single-chain antibody conventionally known in the art, which comprises a heavy chain variable region and a light chain variable region connected by a short peptide of about 15 to about 20 amino acids. As used herein, the term "single domain antibody" refers to a single-domain antibody conventionally known in the art, which comprises a heavy chain variable region and a heavy chain constant region, or comprises only a heavy chain variable region.

[0096] As used herein, the term "scaffold" or "scaffold protein" refers to any protein that has a target binding domain and can bind to a target. A scaffold comprises a "framework" that is mostly structural, and a "binding domain" that contacts the target and provides specific binding. The binding domain of a scaffold does not have to be defined by one continuous sequence of the scaffold. In certain cases, a scaffold may be part of a larger binding protein, which itself may be part of a multimeric binding protein that includes multiple scaffolds. Certain binding proteins may be bispecific or multispecific in that they can bind to two or more different epitopes. A scaffold may be derived from a single chain antibody, or the scaffold may not be derived from an antibody.

[0097] As used herein, the term "aptamer" refers to a single-stranded oligonucleotide (a single-stranded DNA molecule or a single-stranded RNA molecule) that can specifically bind to its target with high affinity. Aptamers can be used as targeting molecules for a variety of organic and inorganic substances.

[0098] Pharmaceutically acceptable salts of the compounds described herein are within the scope of the present technology and include acid or base addition salts that retain the desired pharmacological activity and are not biologically undesirable (e.g., the salts are not overly toxic, allergenic, or irritating and are bioavailable). When the compounds of the present technology have a basic group, such as an amino group, they can form pharma- ceutically acceptable salts with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g., alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, and p-toluenesulfonic acid), or acidic amino acids (e.g., aspartic acid and glutamic acid). When the compounds of the present technology have an acidic group, such as a carboxylic acid group, they can form pharma- ceutically acceptable salts with alkali metals and alkaline earth metals (e.g., Na +, Li + , K + , Ca 2+ , Mg 2+ , Zn 2+ ), ammonia or organic amines (e.g., dicyclohexylamine, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine), or basic amino acids (e.g., arginine, lysine and ornithine). Such salts can be prepared in situ during the isolation and purification of the compounds, or by separately reacting the purified compound in its free base or free acid form, respectively, with a suitable acid or base and isolating the salt thereby formed.

[0099] Those skilled in the art will understand that the compounds of the present technology may exhibit the phenomenon of tautomerism, conformational isomerism, geometric isomerism, and / or stereoisomerism.The drawings of formulae in this specification and claims may represent only one of the possible tautomeric, conformational isomerism, stereoisomeric, or geometric isomerism, so it should be understood that the present technology encompasses any tautomeric, conformational isomerism, stereoisomeric, and / or geometric isomerism of the compounds having one or more of the utilities described herein, as well as mixtures of these various different forms.

[0100] Stereoisomers (also called optical isomers) of a compound include all chiral, diastereomeric, and racemic forms of a structure unless a specific stereochemistry is explicitly indicated. Thus, the compounds used in the present technology include enriched or resolved optical isomers at any or all asymmetric atoms, as is clear from the depiction. Both racemic and diastereomeric mixtures, as well as individual optical isomers, may be isolated or synthesized to be substantially free of their enantiomeric or diastereomeric partners, and all of these stereoisomers are within the scope of the present technology.

[0101] The present technology provides new macrocyclic complexes that are substantially more stable than those of the prior art. Thus, these new complexes can advantageously target cancer cells more effectively, and have substantially lower toxicity to non-targeted tissues than the complexes of the prior art. Furthermore, the new complexes can be advantageously produced at room temperature, in contrast to DOTA-type complexes that generally require high temperatures (e.g., at least 80°C) for complexation with radionuclides. The present technology also specifically uses alpha-emitting radionuclides instead of beta-emitting radionuclides. Alpha-emitting radionuclides are much more energetic than beta-emitting radionuclides, and therefore are substantially more powerful.

[0102] Although certain embodiments have been illustrated and described, those of skill in the art, after reading the foregoing specification, may make modifications, equivalent substitutions, and other types of alterations to the compounds of the present technology described herein or their salts, pharmaceutical compositions, derivatives, prodrugs, metabolites, tautomers, or racemic mixtures. Each of the above aspects and embodiments may also include or incorporate the variations or aspects disclosed with respect to any or all of the other aspects and embodiments.

[0103] The present technology is not limited with respect to the specific embodiments described herein, which are intended as single descriptions of individual aspects of the technology. Many modifications and variations of the present technology can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods within the scope of the present technology will be apparent to those skilled in the art from the foregoing description, in addition to those recited herein. Such modifications and variations are intended to fall within the scope of the appended claims. It is to be understood that the present technology is not limited to specific methods, reagents, compounds, compositions, labeled compounds, or biological systems, which can, of course, vary. It is also to be understood that the terms used herein are for the purpose of describing particular embodiments only, and are not intended to be limiting. Thus, it is intended that the specification be considered only as exemplary, with the breadth, scope, and spirit of the present technology being indicated only by the appended claims, the definitions therein, and any equivalents thereof.

[0104] Although the embodiments are illustratively disclosed herein, they may suitably be practiced in the absence of any element or limitation not specifically disclosed herein. Thus, for example, terms such as "comprising," "including," "containing," and the like, are to be understood expansively and without limitation. Furthermore, the terms and expressions used herein are used for purposes of explanation and not limitation, and it is recognized that in the use of such terms and expressions, there is no intention to exclude any equivalents of the illustrated and described features (or portions thereof), and various modifications are possible within the scope of the claimed technology. Furthermore, the phrase "consisting essentially of" is understood to include the elements specifically recited and additional elements that do not materially affect the basic and novel characteristics of the claimed technology. The phrase "consisting of" excludes any elements not specified.

[0105] All publications, patent applications, issued patents, and other documents (e.g., journals, articles, and / or textbooks) mentioned herein are incorporated by reference herein as if each individual publication, patent application, issued patent, or other document was specifically and individually indicated to be incorporated by reference in its entirety. Definitions contained in the texts incorporated by reference are excluded to the extent they conflict with definitions in this disclosure.

[0106] Compounds of the Invention (Macrocyclic Compounds) In one embodiment, the present invention provides a method for the preparation of a compound of formula (I):

[0107] [ka] [In the formula, R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, which is optionally substituted with -L1-R4; L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand, or a pharma- ceutically acceptable salt thereof.

[0108] In some embodiments, L is absent. When L is absent, R is directly bonded to the compound (e.g., via a covalent bond).

[0109] In some embodiments, L1 is a linker. As used herein, the term "linker" refers to a chemical moiety that connects the compounds of the present invention to a nucleophilic moiety, an electrophilic moiety, or a targeting ligand. In view of the present disclosure, any suitable linker known to one of skill in the art may be used in the present invention. The linker may have, for example, a substituted or unsubstituted alkyl, a substituted or unsubstituted heteroalkyl moiety, a substituted or unsubstituted aryl or heteroaryl, a polyethylene glycol (PEG) linker, a peptide linker, a sugar-based linker, or a cleavable linker, for example, a disulfide bond or a protease cleavage site, for example, valine-citrulline-p-aminobenzyl (PAB). Exemplary linker structures suitable for use in the present invention include:

[0110] [ka] In the formula, m is an integer of 0 to 12, but is not limited thereto.

[0111] In some embodiments, R4 is a nucleophilic moiety or an electrophilic moiety. A "nucleophilic moiety" or "nucleophilic group" refers to a functional group that donates an electron pair to form a covalent bond in a chemical reaction. An "electrophilic moiety" or "electrophilic group" refers to a functional group that accepts an electron pair to form a covalent bond in a chemical reaction. A nucleophilic group reacts with an electrophilic group to form a new covalent bond in a chemical reaction, and vice versa. The nucleophilic or electrophilic group of the compound of the present invention can be reacted with a targeting ligand or other chemical moiety (e.g., a linker) including a corresponding reaction partner, thereby allowing the targeting ligand or chemical moiety to be covalently attached to the compound of the present invention.

[0112] Illustrative examples of nucleophilic groups include, but are not limited to, azides, amines, and thiols. Illustrative examples of electrophilic groups include, but are not limited to, amine-reactive groups, thiol-reactive groups, alkynyls, and cycloalkynyls. Amine-reactive groups preferably react with primary amines, including those present at the N-terminus of each polypeptide chain and in the side chains of lysine residues. Examples of amine-reactive groups suitable for use in the present invention include, but are not limited to, N-Hydroxy Succinimide (NHS), substituted NHS (such as sulfo-NHS), isothiocyanate (-NCS), isocyanate (-NCO), esters, carboxylic acids, acyl halides, amides, alkylamides, and tetrafluorophenyl esters and perfluorophenyl esters. Thiol-reactive groups react with thiols or sulfhydryls, preferably with thiols present in the side chains of cysteine ​​residues of polypeptides. Examples of thiol reactive groups suitable for use in the present invention include, but are not limited to, Michael acceptors (e.g., maleimides), haloacetyls, acyl halides, activated disulfides, and phenyloxadiazole sulfones.

[0113] In certain embodiments, R4 is -NH2, -NCS (isothiocyanate), -NCO (isocyanate), -N3 (azide), alkynyl, cycloalkynyl, carboxylic acid, ester, amide, alkylamide, maleimide, acyl halide, tetrazine, or trans-cyclooctene, more specifically, -NCS, -NCO, -N3, alkynyl, cycloalkynyl, -C(O)R 13 , -COOR 13 , -CON(R 13 )2, maleimide, acyl halide (e.g., —C(O)Cl, —C(O)Br), tetrazine, or trans-cyclooctene, where each R 13 is independently hydrogen or alkyl.

[0114] In some embodiments, R4 is an alkynyl group, a cycloalkynyl group, or an azide group, which allows the compound of the present invention to be linked to a targeting ligand or other chemical moiety (e.g., a linker) using a click chemistry reaction. In such embodiments, the click chemistry reaction that can be performed is a Huisgen cycloaddition or a 1,3-dipolar cycloaddition between an azide (-N3) and an alkynyl group or a cycloalkynyl group to form a 1,2,4-triazole linker or moiety. In one embodiment, the compound of the present invention comprises an alkynyl group or a cycloalkynyl group, and the targeting ligand or other chemical moiety comprises an azide group. In another embodiment, the compound of the present invention comprises an azide group, and the targeting ligand or other chemical moiety comprises an alkynyl group or a cycloalkynyl group.

[0115] In certain embodiments, R4 is an alkynyl group, more preferably a terminal alkynyl group or a cycloalkynyl group, which is particularly reactive with azide groups via strain-promoted azide-alkyne cycloaddition (SPAAC). Examples of cycloalkynyl groups that can react with azide groups via SPAAC include, but are not limited to, cyclooctynyl or bicyclononyl (BCN), difluorinated cyclooctynyl (DIFO), dibenzocyclooctynyl (DIBO), keto-DIBO, biarylazacyclooctynonyl (BARAC), dibenzoazacyclooctynyl (DIBAC, DBCO, ADIBO), dimethoxyazacyclooctynyl (DIMAC), difluorobenzocyclooctynyl (DIFBO), monobenzocyclooctynyl (MOBO) and tetramethoxydibenzocyclooctynyl (TMDIBO).

[0116] In certain embodiments, R4 has the following structure:

[0117] [ka] In the embodiment where R4 is DBCO, the DBCO may be covalently bonded to the compound directly or indirectly via a linker, but is preferably bonded to the compound indirectly via a linker.

[0118] In certain embodiments, R4 is a targeting ligand. The targeting ligand can be directly bound to the compound by covalent bond or indirectly bound to the compound through a linker. The targeting ligand can be a polypeptide, such as an antibody or an antigen-binding fragment thereof, an aptamer, or a scaffold protein. In a preferred embodiment, the targeting ligand is an antibody or an antigen-binding fragment thereof, such as a monoclonal antibody (mAb) or an antigen-binding fragment thereof, which specifically binds to an antigen associated with a neoplastic disease or neoplastic disorder, such as a cancer antigen, and can be Prostate-Specific Membrane Antigen (PSMA), BCMA, Her2, EGFR, KLK2, CD19, CD22, CD30, CD33, CD79b, or Nectin-4.

[0119] According to certain embodiments, the targeting ligand specifically binds to a prostate specific antigen (e.g., PSMA or KLK2). For example, the targeting ligand is an anti-PSMA mab or an anti-KLK2 mAb.

[0120] In another embodiment, the present invention provides a compound of formula (II):

[0121] [ka] [In the formula, L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand, or a pharma- ceutically acceptable salt thereof.

[0122] In another embodiment, the present invention provides a compound of formula (III):

[0123] [ka] [In the formula, L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand, or a pharma- ceutically acceptable salt thereof.

[0124] In another embodiment, the present invention relates to a compound, or a pharma- ceutically acceptable salt thereof, wherein R1 is -L1-R4, R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, L1 is absent or is a linker, and R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.

[0125] In a further embodiment, the present invention relates to a compound, or a pharma- ceutically acceptable salt thereof, wherein R1 is H, and R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl substituted with -L1-R4, where L1 is absent or a linker, and R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.

[0126] Further embodiments include those in which R4 is a targeting ligand, the targeting ligand being selected from the group consisting of an antibody, an antigen-binding fragment of an antibody, a scaffold protein, and an aptamer.

[0127] In one embodiment, the compound of the invention is

[0128] [ka]

[0129] [ka] wherein n is 1 to 10.

[0130] The compounds can be covalently attached to a targeting ligand (e.g., an antibody or antigen-binding fragment thereof) to form an immunoconjugate or radioimmunoconjugate (when complexed with a metal) by reacting the compound with an azide-labeled targeting ligand via a click chemistry reaction, described in more detail below, to form a 1,2,3-triazole linker.

[0131] The compounds of the present invention can be produced by any method known in the art in light of this disclosure, for example, the pendant aromatic / heteroaromatic groups can be attached to the macrocyclic moiety by methods known in the art, such as those exemplified and described below.

[0132] Radioactive metal complexes In certain embodiments, the present invention relates to radiometal complexes that include a radiometal ion complexed to a compound of the present invention by a coordinate bond. Any of the compounds of the present invention described herein may include a radiometal ion.

[0133] Preferably, the radioactive metal ion is a positron emitting radioactive metal ion, preferably 134 The compounds of the present invention can be used to produce radioactive metal ions, particularly radioactive metal ions such as iron, magnesium, manganese, sodium, calcium, copper, nickel, zinc, aluminum, cobalt, etc., at any specific activity, regardless of specific metal impurities. 134 It can form a complex with Ce, thus forming a radiometal complex that has high chelation stability in vivo and in vitro and is stable to loading agents such as diethylene triamine pentaacetic acid (DTPA).

[0134] The radioactive metal ion is a therapeutic alpha-emitting radioactive metal ion, preferably 225 The compounds of the present invention are capable of reacting with radioactive metal ions, particularly 1,2-dichloro-1,2-trifluoromethyl-1,2-di ... 225Ac can be complexed to form radiometal complexes that have high chelating stability in vivo and in vitro and are stable to challenge agents such as diethylenetriaminepentaacetic acid (DTPA).

[0135] In certain embodiments, the present invention provides a compound of formula (IM + ):

[0136] [ka] [In the formula, M + Cerium-134 ( 134 is a radioactive metal ion, R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, which is optionally substituted with -L1-R4; L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand, or a pharma- ceutically acceptable salt thereof.

[0137] In another embodiment, the present invention relates to a compound of formula (II-M + ):

[0138] [ka] [In the formula, M + Cerium-134 ( 134 is a radioactive metal ion, L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand, or a pharma- ceutically acceptable salt thereof.

[0139] In another embodiment, the present invention relates to a compound of formula (III-M + ):

[0140] [ka] [In the formula, M + Cerium-134( 134 is a radioactive metal ion, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand, or a pharma- ceutically acceptable salt thereof.

[0141] In another embodiment, the present invention provides a radiometal complex comprising: M + Cerium-134( 134 is a radioactive metal ion, R1 is -L1-R4, R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl; L1 is absent or a linker, R4 is a radiometal complex which is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand; or a pharma- ceutically acceptable salt thereof.

[0142] In a further embodiment, the present invention provides a radiometal complex comprising: M + Cerium-134( 134 is a radioactive metal ion, R1 is H, R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl substituted with -L1-R4; L1 is absent or a linker, R4 is a radiometal complex which is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand; or a pharma- ceutically acceptable salt thereof.

[0143] In a particular embodiment, the present invention provides a method for producing

[0144] [ka]

[0145] [ka] The present invention relates to one or more radioactive metal complexes selected from the group consisting of: In the formula, n is 1 to 10, and M + is a radioactive metal ion, where M + Cerium-134 ( 134 It is a radioactive metal ion, which is

[0146] The radiometal complexes may be produced by any method known in the art in light of the present disclosure. For example, a macrocyclic compound of the present invention may be mixed with a radiometal ion and the mixture incubated to form the radiometal complex. In one exemplary embodiment, the compound is 225 Ac(NO3)3 or 134 It was mixed with a solution of CeCl3 and bonded to the compound via coordinate bonds. 225 Ac or 134 As mentioned above, the compounds of the present invention form radioactive complexes with radiometals, particularly 225 Ac or 134 Thus, in certain embodiments, the compounds of the present invention are combined with the compounds of the present invention at a ratio of 1:1000, 1:500, 1:400, 1:300, 1:200, 1:100, 1:50, 1:10, or 1:5, preferably 1:5 to 1:200, more preferably 1:5 to 1:100. 225 Ac ion or 134 Depending on the concentration ratio with Ce ions, 225 Ac ion or 134 Thus, in some embodiments, the compounds of the present invention can be used to form radioactive metal complexes. 225Ac or 134 The ratio of Ce to other well-known 225 Ac or 134 This is much lower than the ratio that can be achieved with Ce chelators (e.g., DOTA). The radiocomplexes can be characterized by instant thin layer chromatography (e.g., iTLC-SG), HPLC, LC-MS, etc. Exemplary methods are described herein, e.g., in the Examples below.

[0147] Immunoconjugates and radioimmunoconjugates In another embodiment, the present invention relates to immunoconjugates and radioimmunoconjugates. The compounds of the present invention and the radiometal complexes of the present invention can be conjugated (i.e., covalently attached) to targeting ligands, such as immunoagents, to produce immunoconjugates and / or radioimmunoconjugates suitable for medical applications in subjects (e.g., humans), such as targeted radiotherapy or radioimaging.

[0148] The macrocyclic compounds, radioactive metal complexes and radioimmunoconjugates of the invention may be used to specifically label targeting ligands, particularly antibodies or antigen-binding fragments thereof capable of specifically binding to a target of interest (such as cancer cells), with radioactive metal ions to produce radioimmunoconjugates. In particular, the compounds of the invention and / or the radioactive metal complexes of the invention may be used to specifically label radioactive metal ions, particularly 225 Ac or 134 Radioimmunoconjugates with high yield conjugation of Ce) and desirable compound-to-antibody ratios (CAR) can be produced.

[0149] According to certain embodiments, the methods of the invention provide an average CAR of less than 10, less than 8, less than 6, or less than 4, or a CAR of from about 2 to about 8, or from about 2 to about 6, or from about 2 to about 4, or from about 2 to about 3, or a CAR of about 2, or about 3, or about 4, or about 5, or about 6, or about 7, or about 8.

[0150] As used herein, an "immunoconjugate" is an antibody or antigen-binding fragment thereof conjugated (e.g., covalently linked) to a second molecule, such as a toxin, a drug, a radioactive metal ion, a radioactive metal complex, etc. A "radioimmunoconjugate" (sometimes also referred to as a radioconjugate) is specifically an immunoconjugate in which the antibody or antigen-binding fragment thereof is labeled with a radioactive metal or conjugated to a radioactive metal complex.

[0151] In certain embodiments of the invention, the immunoconjugate comprises a compound of the invention (e.g., a compound of formula (I) as described herein) covalently attached to an antibody or antigen-binding fragment thereof, preferably via a linker. Depending on the reactive functional groups (i.e., nucleophilic and electrophilic) on the compound of formula (I) and the antibody or antigen-binding fragment thereof, many conjugation configurations are possible with various linkages between the compound of the invention and the antibody or antigen-binding fragment thereof.

[0152] In certain embodiments of the invention, a radioimmunoconjugate comprises a radiometal complex of the invention, e.g., a radiometal complex described herein, covalently attached, preferably via a linker, to an antibody or antigen-binding fragment thereof.

[0153] Any of the compounds or radiometal complexes of the invention described herein can be used to produce an immunoconjugate or radioimmunoconjugate of the invention.

[0154] In certain embodiments, the radiometal complexes or radioimmunoconjugates of the invention comprise an alpha-emitting radiometal ion coordinated to the compound portion of the radiocomplex. For example, the alpha-emitting radiometal ion is 225 It is Ac.

[0155] In certain embodiments, the radiometal complexes or radioimmunoconjugates of the invention comprise one or more radionuclides suitable for use as radioimaging agents. Preferably, the positron-emitting radiometal ions are 134 It is Ce.

[0156] One embodiment of the present invention provides a method for imaging cancer cells, such as prostate cancer cells, in a patient's body (e.g., for detecting the level of cancer cells), comprising administering to the patient a radioimmunoconjugate described herein that includes Ce-134 as a radioactive metal ion (e.g., the radioimmunoconjugate includes a PSMA-targeting antibody or a KLK2-targeting antibody as a targeting ligand) and using a nuclear imaging technique such as Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT). Such techniques may allow for detection of the distribution of the radioimmunoconjugate in or a portion of the body. Such methods may be used to diagnose a patient with cancer. Such methods may also be used to determine the location of cancer cells (e.g., the location of a tumor) in the patient's body. Such methods may be used to detect tumors in the patient. Such methods may be used to quantify the levels of cancer cells in a patient's body, allowing the determination of a therapeutically effective dose of an agent (such as radiation therapy) for that patient based on such quantification.

[0157] Useful methods for imaging are positron emission tomography (PET) or single photon emission computed tomography (SPECT).

[0158] In certain embodiments, the antibody or antigen-binding fragment in the immunoconjugate or radioimmunoconjugate of the present application may specifically bind to a tumor antigen. Preferably, the antibody or antigen-binding fragment specifically binds to a cancer antigen. Examples of cancer antigens include, but are not limited to, Prostate-Specific Membrane Antigen (PSMA), BCMA, Her2, EGFR, KLK2, CD19, CD22, CD30, CD33, CD79b, and Nectin-4.

[0159] In one embodiment, the antibody specifically binds to PSMA and may be referred to herein as "anti-PSMA mAb". According to one embodiment, the antibody is PSMB127. The human IgG4 antibody that binds to human prostate specific membrane antigen (PSMA), designated "PSMB127", has a heavy chain (HC) CDR1 sequence of SEQ ID NO: 3, a HC CDR2 sequence of SEQ ID NO: 4, a HC CDR3 sequence of SEQ ID NO: 5, a light chain (LC) CDR1 sequence of SEQ ID NO: 6, a LC CDR2 sequence of SEQ ID NO: 7, and a LC CDR3 sequence of SEQ ID NO: 8, and has a HC sequence of SEQ ID NO: 9 and a LC sequence of SEQ ID NO: 10. PSMB127 was expressed and purified using standard chromatographic methods. The antibody PSMB127, its biological activity, its uses, or other related information are described, for example, in US Patent Publication No. 20200024360(A1), the contents of which are incorporated herein by reference in their entirety.

[0160] In another embodiment, the antibody specifically binds to human kallikrein-2 (KLK2), and may be referred to herein as anti-KLK2 mAb. KLK2 may be referred to as hK2. Preferably, the antibody is H11B6 (also referred to as h11B6 or h11b6). H11B6 antibody, biological activity, uses, or other related information are described in U.S. Patent No. 10,100,125, the contents of which are incorporated herein by reference in their entirety. As described herein, the H11B6 antibody polypeptide comprises a heavy chain (HC) variable region comprising the amino acid sequences of SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, and a light chain (LC) variable region comprising the amino acid sequences of SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16.

[0161] Thus, according to a particular embodiment, the radioconjugate of the present invention comprises the h11B6 antibody, which comprises (a) a heavy chain variable region (VH) comprising a VH CDR1 having the amino acid sequence of SEQ ID NO: 11 (SDYAWN), a VH CDR2 having the amino acid sequence of SEQ ID NO: 12 (YISYSGSTTYNPSLKS), and a VH CDR3 having the amino acid sequence of SEQ ID NO: 13 (GYYYGSGF), and (b) a light chain variable region (VL) comprising a VL CDR1 having the amino acid sequence of SEQ ID NO: 14 (KASESVEYFGTSLMH), a VL CDR2 having the amino acid sequence of SEQ ID NO: 15 (AASNRES), and a VL CDR3 having the amino acid sequence of SEQ ID NO: 16 (QQTRKVPYT).

[0162] The H11B6 antibody may further have a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18, or a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 19 and a light chain constant region comprising the amino acid sequence of SEQ ID NO: 20, or a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 21 and a light chain constant region comprising the amino acid sequence of SEQ ID NO: 22.

[0163] The Kabat numbering scheme (Kabat et al., 1991) is used throughout this description (Sequences of Immunological Interest, 5th edition, NIH, Bethesda, Md., the disclosure of which is incorporated herein by reference).

[0164] According to certain embodiments, the antibodies of the invention comprise a heavy chain variable region (VH) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 17, and / or a light chain variable region (VL) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 18.

[0165] According to certain embodiments, an antibody of the invention comprises a heavy chain constant region having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 19, and / or a light chain constant region having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence of SEQ ID NO:20.

[0166] According to certain embodiments, an antibody of the invention comprises a heavy chain having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence of SEQ ID NO:21, and / or a light chain having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence of SEQ ID NO:22.

[0167] In one embodiment, the antibody of the present invention is PSMB1154 or a variant thereof. PSMB1154 is a human IgG1 mAb that binds to human prostate-specific membrane antigen (PSMA), e.g., as further described in Example 24. The antibody PSMB1154, its biological activity, its uses, or other related information are described, e.g., in U.S. Patent Application No. 17 / 895,295, which is incorporated herein by reference.

[0168] PSMB1154 is composed of the sequences listed in Tables 1 to 5, including: (i) a heavy chain (HC) variable region having the amino acid sequences of SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25, and a light chain (LC) variable region having the amino acid sequences of SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28; (ii) a heavy chain variable region (VH) having the amino acid sequence of SEQ ID NO: 29, and a light chain variable region (VL) having the amino acid sequence of SEQ ID NO: 30; and (iii) a heavy chain having the amino acid sequence of SEQ ID NO: 31, and a light chain having the amino acid sequence of SEQ ID NO: 32.

[0169] The antibody of the present invention (i) a heavy chain (HC) variable region comprising the amino acid sequences of SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25, and a light chain (LC) variable region comprising the amino acid sequences of SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO:28, and / or (ii) a heavy chain variable region (VH) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 29, and / or a light chain variable region having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 30, and / or (ii) a heavy chain having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 31, and / or a light chain having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 32.

[0170] [Table 1]

[0171] [Table 2]

[0172] [Table 3]

[0173] [Table 4]

[0174] [Table 5]

[0175] In one embodiment, the antibody of the invention is B23B62, which was used as an isotype control. B23B62 is a human IgG1 that binds to viral proteins.

[0176] According to certain embodiments, an antibody of the invention (eg, h11B6) comprises or consists of an intact (ie, whole) antibody, such as an IgA, IgD, IgE, IgG, or IgM molecule.

[0177] According to certain embodiments, the antibodies of the invention (e.g., h11B6) comprise or consist of an intact IgG molecule, or a variant thereof. The IgG molecule may be of any of the known subtypes, e.g., IgG1, IgG2, IgG3, or IgG4.

[0178] According to a specific embodiment, the antibody of the present invention comprises an h11B6 antibody that is an IgG1 antibody. According to a specific embodiment, the antibody of the present invention comprises an h11B6 antibody that is an IgG1 kappa isotype. According to a specific embodiment, the antibody of the present invention comprises an h11B6 antibody that is an IgG1 antibody or a variant thereof (e.g., an Fc variant).

[0179] In any of the embodiments disclosed herein (for brevity, hereinafter referred to as "in any embodiment disclosed herein" etc.), the antibody may be selected from the group consisting of belimumab, mogamulizumab, blinatumomab, ibritumomab tiuxetan, obinutuzumab, ofatumumab, rituximab, inotuzumab ozogamicin, moxetumomab pasudotox, brentuximab vedotin, daratumumab, ipilimumab, cetuximab, necitumumab, panitumumab, dinutuximab, pertuzumab, trastuzumab, trastuzumab emtansine, siltuzumab, schizophrenia ... These may include, but are not limited to, ximab, cemiplimab, nivolumab, pembrolizumab, olaratumab, atezolizumab, avelumab, durvalumab, capromab pendetide, elotuzumab, denosumab, zib-aflibercept, bevacizumab, ramucirumab, tositumomab, gemtuzumab ozogamicin, alemtuzumab, cixutumumab, girentuximab, nimotuzumab, catumaxomab, or etaracizumab. In any of the embodiments disclosed herein, the antibody fragment is selected from the group consisting of belimumab, mogamulizumab, blinatumomab, ibritumomab tiuxetan, obinutuzumab, ofatumumab, rituximab, inotuzumab ozogamicin, moxetumomab pasudotox, brentuximab vedotin, daratumumab, ipilimumab, cetuximab, necitumumab, panitumumab, dinutuximab, pertuzumab, trastuzumab, trastuzumab emtansine, and the like. In some cases, the antigen-binding fragment of the antibody may include an antigen-binding fragment of rivaroxaban, siltuximab, cemiplimab, nivolumab, pembrolizumab, olaratumab, atezolizumab, avelumab, durvalumab, capromab pendetide, elotuzumab, denosumab, zib-aflibercept, bevacizumab, ramucirumab, tositumomab, gemtuzumab ozogamicin, alemtuzumab, cixutumumab, girentuximab, nimotuzumab, catumaxomab, or etaracizumab.In any of the embodiments disclosed herein, the binding peptide may include, but is not limited to, a prostate-specific membrane antigen ("PSMA") binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment thereof.

[0180] The immunoconjugates and radioimmunoconjugates of the present invention may be prepared by any method known in the art, including chemical and / or enzymatic methods, in view of the present disclosure for conjugating ligands (e.g., antibodies) to the compounds of the present invention. For example, the immunoconjugates and radioimmunoconjugates may be prepared by coupling reactions, including but not limited to formation of esters, thioesters, or amides from activated acids or acyl halides, nucleophilic substitution reactions (e.g., nucleophilic substitution of a ring halide or ring opening of a ring system with strain), azide-alkyne Huisgen cycloadditions (e.g., 1,3 dipolar cycloadditions between azides and alkynes to form 1,2,3-triazole linkers), thiophosphorus addition reactions, imine formation, Diels-Alder reactions between tetrazines and trans-cycloctenes (TCO), and Michael additions (e.g., maleimide additions). Many other addition modes with different linkages are possible, depending on the reactive functional groups used. Binding of the ligand can be to a compound that is coordinated to a radioactive metal ion or to a compound that is not coordinated to a radioactive metal ion.

[0181] In one embodiment, radioimmunoconjugates may be generated by covalently attaching a radiometal complex of the invention to an antibody or antigen-binding fragment thereof, for example, by a click chemistry reaction (see, e.g., Figures 2B and 2D, referred to as "click radiolabeling"). Alternatively, radioimmunoconjugates may be generated by first preparing an immunoconjugate of the invention, for example, by covalently attaching a compound of the invention to an antibody or antigen-binding fragment thereof, by a click chemistry reaction, and subsequently labeling the immunoconjugate with a radiometal ion to generate the radioimmunoconjugate (see, e.g., Figures 2A and 2C, referred to as "one-step direct radiolabeling"). Both residue-specific (e.g., Figures 2A and 2B) and site-specific (e.g., Figures 2C and 2D) methods of conjugation may be used to generate the immunoconjugates and radioimmunoconjugates of the invention.

[0182] Residue-specific methods for conjugation to proteins are well established, most commonly involving either lysine side chains using activated esters or isothiocyanates, or cysteine ​​side chains with maleimides, haloacetyl derivatives, or activated disulfides (Brinkley Bioconjugate Chem 1992:2). Because most proteins have multiple lysine and cysteine ​​residues, heterogeneous mixtures of products with different numbers of conjugate molecules at various amino acid positions are typically obtained using such methods. Additional methods have been established, including tyrosine-specific conjugation (Ban et al., Bioconjugate Chemistry 2013:520), methionine-specific methods (Lin et al., Science 2017(355)597), and approaches focused on additional cysteines (Toda et al., Angew Chemie 2013:12592).

[0183] More recently, site-selective and site-specific conjugation methods have been established for monoclonal antibodies and other proteins (Agarwal, P. and C.R. Bertozzi, Bioconjug Chem, 2015.26(2):p.176-92; Rabuka et al., Curr Opin Chem Biol 2010:790). These include the incorporation of unnatural amino acids, fusion of the protein of interest to a "self-labeling tag" such as SNAP or DHFR or a tag that is specifically recognized and modified by another enzyme such as sortase A, lipoic acid ligase and formylglycine generating enzyme, and enzymatic modification of the glycan to allow conjugation of the payload of interest (Hu et al., Chem Soc Rev 2016:1691), the use of microbial transglutaminase to selectively recognize defined locations on antibodies, and additional methods that use molecular recognition and / or chemical approaches to affect selective conjugation (Yamada et al., 2019:5592; Park et al., Bioconjugate Chem 2018:3240; Pham et al., Chembiochem 2018:799).

[0184] In certain embodiments, the immunoconjugates or radioimmunoconjugates of the invention are generated using residue-specific methods for conjugating the compounds of the invention to antibodies or antigen-binding fragments thereof. Such residue-specific methods typically result in immunoconjugates or radioimmunoconjugates that are covalently attached to the compounds or radiometal complexes of the invention at various positions on the antibody. In view of the present disclosure, any residue-specific method for forming protein or antibody conjugates known to those of skill in the art may be used. Examples of residue-specific methods for conjugation that may be used include, but are not limited to, conjugation of the compounds or radiometal complexes of the invention to lysine residues of antibodies, e.g., using compounds or radiometal complexes of the invention that comprise an activated ester or isothiocyanate group; conjugation to cysteine ​​residues of antibodies, e.g., using compounds or radiometal complexes of the invention that comprise a maleimide, a haloacetyl derivative, an acyl halide, an activated disulfide group or a methylsulfonylphenyloxadiazole group; conjugation to tyrosine residues of antibodies, e.g., using compounds or radiometal complexes of the invention that comprise 4-phenyl-3H-1,2,4-triazoline-3,5-(4H)-dione (PTAD); and conjugation to methionine residues of antibodies, e.g., using compounds or radiometal complexes of the invention that comprise an oxaziridine derivative. It is also possible to label the antibody at a specific residue with a biorthogonal reactive functional group using one or more of the above methods before conjugating to the compound of the invention or the radiometal complex of the invention. For example, a tyrosine residue can be site-specifically labeled at a biorthogonal reactive functional group using an oxaziridine derivative coupled to a biorthogonal reactive functional group, such as azide, alkynyl, or cycloalkynyl, and then the antibody containing the labeled tyrosine residue can be conjugated to the compound of the invention or the radiometal complex of the invention using a compound of the invention or a radiometal complex of the invention with a compatible reactive functional group.

[0185] In certain embodiments, the immunoconjugates or radioimmunoconjugates of the invention may be generated using site-specific or site-selective methods for conjugating the compounds of the invention to an antibody or antigen-binding fragment thereof. In contrast to residue-specific methods, "site-specific" or "site-selective" methods typically result in immunoconjugates or radioimmunoconjugates covalently attached to the compounds or radiometal complexes of the invention at specific positions on the antibody. In view of the present disclosure, any site-specific method for forming protein or antibody conjugates known to those of skill in the art may be used. For example, a mutant aminoacyl-tRNA synthetase capable of selectively aminoacylating a tRNA bearing the unnatural amino acid of interest may be used to site-specifically incorporate an unnatural amino acid (e.g., an azido or alkynyl amino acid) into an antibody. A mutant acylated tRNA together with an amber suppressor tRNA may then be used to site-specifically incorporate the unnatural amino acid into a protein in response to an amber nonsense codon. Antibodies that have been site-specifically labeled by one or more of the above methods can subsequently be conjugated with a compound of the invention or a radiometal complex of the invention bearing a compatible reactive functional group.

[0186] In a particular embodiment, the present invention relates to a method for preparing a radioimmunoconjugate comprising reacting a compound of the present invention, where R4 is a nucleophilic or electrophilic moiety, or a radiocomplex of the present invention, with an antibody or antigen-binding fragment thereof, or a modified antibody or antigen-binding fragment thereof comprising a nucleophilic or electrophilic moiety.

[0187] In one embodiment, the present invention relates to a method comprising reacting a compound of the present invention with an antibody or antigen-binding fragment thereof, or a modified antibody or antigen-binding fragment thereof comprising a nucleophilic or electrophilic functional group to form an immunoconjugate having a covalent bond between the compound of the present invention and the antibody or antigen-binding fragment thereof, or the modified antibody or antigen-binding fragment, and reacting the immunoconjugate with a radioactive metal ion such that the radioactive metal ion is bound to the compound of the present invention of the immunoconjugate by a coordinate bond, thereby forming a radioimmunoconjugate. This embodiment may be referred to as a "one-step direct radiolabeling" method (e.g., as shown diagrammatically in FIG. 2C) since there is only one chemical reaction step involving a radioactive metal.

[0188] In another embodiment, the present invention relates to a method comprising reacting a radioactive complex of the present invention with an antibody or antigen-binding fragment thereof, or a modified antibody or antigen-binding fragment thereof comprising a nucleophilic or electrophilic functional group, thereby forming a radioimmunoconjugate. This embodiment may be referred to as the "click radiolabeling" method (e.g., as shown diagrammatically in FIG. 2D). The modified antibody or antigen-binding fragment thereof may be generated by any method known in the art in view of the present disclosure, for example, by labeling an antibody with an orthogonally reactive functional group at a specific residue using one or more of the methods described above, or by site-specifically incorporating an unnatural amino acid (e.g., an azido or alkynyl amino acid) into the antibody using one or more of the methods described above. The degree of labeling (DOL), sometimes referred to as the degree of substitution (DOS), is a particularly useful parameter for characterizing and optimizing bioconjugates such as antibodies modified with unnatural amino acids. It is expressed as the average number of unnatural amino acids attached to a protein molecule (such as an antibody) or as a molar ratio in the form of label / protein. The DOL can be determined from the absorption spectrum of the labeled antibody by any method known in the art.

[0189] In certain embodiments of the present invention, the immunoconjugates and radioimmunoconjugates of the present invention are prepared using click chemistry reactions. For example, the radioimmunoconjugates of the present invention can be prepared using a click chemistry reaction referred to as "click radiolabeling" (see, for example, Figures 2B and 2D). Click radiolabeling uses click chemistry reaction partners, preferably azides and alkynes (e.g., cyclooctyne or cyclooctyne derivatives), to form a triazole covalent bond between a radiocomplex (a radioactive metal ion bound to a compound of the present invention) and an antibody or an antigen-binding fragment thereof. Methods for click radiolabeling of antibodies are described, for example, in International Application No. US18 / 65913, entitled "Radiolabeling of Polypeptides," the relevant description of which is incorporated herein by reference. In other embodiments, referred to as "one-step direct radiolabeling," an immunoconjugate is prepared using a click chemistry reaction between an antibody or antigen-binding fragment thereof and a compound of the invention, and the immunoconjugate is then contacted with a radioactive metal ion to form a radioimmunoconjugate (see, e.g., Figures 2A and 2C).

[0190] In one embodiment, the present invention relates to a method for preparing a radioimmunoconjugate comprising binding (eg, by coordinating) a radioactive metal ion to a compound of the present invention.

[0191] In one embodiment, the "one-step direct radiolabeling" method of preparing a radioimmunoconjugate comprises contacting an immunoconjugate (i.e., a polypeptide-compound of the invention complex) with a radioactive metal ion, thereby forming a radioimmunoconjugate, which comprises a compound of the invention. According to certain embodiments, the immunoconjugate is formed by a click chemistry reaction between a compound of the invention and a polypeptide. According to certain embodiments, the radioimmunoconjugate is formed without metal-free conditions (e.g., without any step(s) that remove or actively eliminate common metal impurities from the reaction mixture). This is in contrast to certain conventional methods that require radiolabeling of antibodies under strict metal-free conditions to avoid competitive (non-productive) chelation of common metals such as iron, zinc and copper, which poses significant challenges to the manufacturing process.

[0192] In one embodiment, the present invention is directed to a method for preparing a radioimmunoconjugate (including a "one-step direct radiolabeling" method), the method comprising: (i) reacting a modified polypeptide with a compound of the invention, the modified polypeptide being an antibody or antigen-binding fragment thereof comprising an azide group, thereby obtaining an immunoconjugate; (ii) reacting the immunoconjugate with a radioactive metal ion to obtain a radioactive immunoconjugate.

[0193] In another embodiment, the present invention is directed to a method for preparing a radioimmunoconjugate (including a "one-step direct radiolabeling" method), the method comprising: (i) reacting a modified antibody or antigen-binding fragment thereof comprising an azide group with a compound of formula I to obtain an immunoconjugate; (ii) reacting the immunoconjugate with a radioactive metal ion to obtain a radioactive immunoconjugate.

[0194] In certain embodiments, the present invention is directed to a method of preparing a radioimmunoconjugate (including, for example, a "click radiolabeling" method as shown in FIG. 2D), the method comprising: (i) reacting the modified antibody or antigen-binding fragment thereof with a radioactive complex under conditions in which the azido group reacts with the alkynyl or cycloalkynyl group, thereby obtaining a radioimmunoconjugate.

[0195] Conditions for carrying out click chemistry reactions are well known in the art, and any conditions for carrying out click chemistry reactions known to one of skill in the art in light of this disclosure may be used in the present invention. Exemplary conditions include, but are not limited to, incubation of the modified polypeptide and radioactive complex in a ratio of 1:1 to 1000:1 at a pH of 4 to 10 and a temperature of 20° C. to 70° C.

[0196] The click radiolabeling method described above allows for the conjugation of radioactive metal ions under low or high pH and / or high temperature conditions to maximize efficiency, which can be achieved without the risk of inactivating the alkyne reaction partner. Efficient conjugation between azide-labeled antibodies or antigen-binding fragments thereof and radioactive complexes and efficient SPAAC reactions allow for the production of radioactive immunoconjugates with high radiochemical yields even at low azide:antibody ratios. The only step that must exclude trace metals is the radioactive metal ion conjugation to the macrocyclization moiety, and the antibody production, purification, and conjugation steps do not need to be performed under metal-free conditions.

[0197] The compounds and radiometal complexes of the present invention can also be used to generate site-specific radiolabeled polypeptides (e.g., antibodies). The click radiolabeling method described herein utilizes an established method for site-specifically introducing azide groups onto antibodies, facilitating the site-specific generation of radioimmunoconjugates (Li, X. et al., Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew Chem Int Ed Engl, 2014. 53(28): p. 7179-82; Xiao, H. et al., Genetic incorporation of multiple unnatural amino acids into proteins in mammalian cells. Angew Chem Int Ed Engl, 2013. 52(52): p. 14080-3). Methods for attaching molecules to proteins or antibodies in a site-specific manner are well known in the art, and any method for site-specific labeling of antibodies known to one of skill in the art may be used in the present invention in light of the present disclosure. Examples of methods for site-specific modification of antibodies suitable for use in the present invention include, but are not limited to, the incorporation of modified cysteine ​​residues (e.g., THIOMAB™), the use of unnatural amino acids or glycans (e.g., selenocysteine, p-AcPhe, formylglycine generating enzyme (FGE, SMARTag™), etc.), and enzymatic methods (e.g., glycotransferases, endoglycosidases, microbial or bacterial transglutaminases (MTG or BTG), sortase A, etc.).

[0198] In a particular embodiment, modified antibodies or antigen-binding fragments thereof for use in generating immunoconjugates or radioimmunoconjugates of the invention are obtained by trimming the antibody or antigen-binding fragment thereof with a bacterial endoglycosidase specific for β-1,4 linkages between core GlcNAc residues at the Fc-glycosylation site of the antibody, e.g., GlycINATOR (Genovis), which leaves the innermost GlcNAc on the Fc intact and allows site-specific incorporation of an azido sugar at that site. The truncated antibody or antigen-binding fragment thereof can then be reacted with an azido-labeled sugar, such as UDP-N-azidoacetylgalactosamine (UDP-GalNAz) or UDP-6-azido6-deoxyGalNAc, in the presence of a glycosyltransferase, such as GalT galactosyltransferase or GalNAc transferase, thereby obtaining the modified antibody or antigen-binding fragment thereof.

[0199] In other embodiments, modified antibodies or antigen-binding fragments thereof for use in generating immunoconjugates or radioimmunoconjugates of the invention can be obtained by deglycosylating the antibody or antigen-binding fragment thereof with an amidase. The resulting deglycosylated antibody or antigen-binding fragment thereof can then be reacted with an azidoamine, preferably 3-azidopropylamine, 6-azidohexylamine or any azido linker amine or any azidoalkyl / heteroalkylamine, such as azido-polyethylene glycol (PEG)-amine, such as O-(2-aminoethyl)-O'-(2-azidoethyl)tetraethylene glycol, O-(2-aminoethyl)-O'-(2-azidoethyl)pentaethylene glycol, O-(2-aminoethyl)-O'-(2-azidoethyl)triethylene glycol, or in the presence of microbial transglutaminase to obtain the modified antibody or antigen-binding fragment thereof.

[0200] Any of the radiometal complexes described herein can be used to generate the radioimmunoconjugates of the present invention. In certain embodiments, the radiometal complex has the formula (IM + ) structure.

[0201] In certain embodiments, the radioimmunoconjugate comprises:

[0202] [ka] any one or more structures independently selected from the group consisting of: During the ceremony, M + is a radioactive metal ion, where M + Cerium-134 ( 134 Ce), L1 is absent or a linker, A mAb is an antibody or an antigen-binding fragment thereof.

[0203] In another embodiment, the radioimmunoconjugate comprises

[0204] [ka] wherein mAb is an antibody or an antigen-binding fragment thereof.

[0205] It should be noted that in the radioimmunoconjugate structures shown herein that include a "mAb," the structures do not show the residues of the mAb that bind to the radiometal complex (e.g., lysine residues of the mAb).

[0206] One embodiment of the present invention has the following structure:

[0207] [ka] [In the formula, M + Cerium-134 ( 134The present invention provides a radioimmunoconjugate having the formula (I) (Ce).

[0208] According to certain embodiments, the mAb has binding specificity for a prostate cancer antigen, such as PSMA or hK2. For example, the mAb may comprise an anti-PSMA antibody or an anti-hK2 antibody. According to one example, (i) the mAb is an H11B6 antibody comprising a heavy chain (HC) variable region comprising the amino acid sequences of SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, and a light chain (LC) variable region comprising the amino acid sequences of SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16; and / or (ii) the mAb comprises a heavy chain variable region (VH) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17, and / or a light chain variable region (VL) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18.

[0209] One embodiment of the present invention has the following structure:

[0210] [ka] [wherein (i) the mAb is an H11B6 antibody comprising a heavy chain (HC) variable region comprising the amino acid sequences of SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, and a light chain (LC) variable region comprising the amino acid sequences of SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16; and / or (ii) the mAb comprises a heavy chain variable region (VH) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17, and / or a light chain variable region (VL) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18.

[0211] Radioimmunoconjugates produced by the methods described herein can be analyzed using methods well known to those of skill in the art in view of the present disclosure. For example, LC / MS analysis can be used to determine the ratio of compound to labeled polypeptide, e.g., antibody or antigen-binding fragment thereof, analytical size-exclusion chromatography can be used to determine the oligomeric state of polypeptides and polypeptide conjugates, e.g., antibodies and antibody conjugates, radiochemical yield can be determined by instant thin layer chromatography (e.g., iTLC-SG), and radiochemical purity can be determined by size-exclusion HPLC. Exemplary methods are described herein, e.g., in the Examples below.

[0212] Pharmaceutical Compositions and Methods of Use In another embodiment, the present invention relates to a pharmaceutical composition comprising a compound of the present invention, a radiometal complex, an immunoconjugate, or a radioimmunoconjugate of the present invention, and a pharma- ceutical composition may also include one or more pharma- ceutical acceptable carriers.

[0213] In one embodiment, the pharmaceutical composition comprises a compound of the invention and a pharma- ceutically acceptable carrier.

[0214] In one embodiment, the pharmaceutical composition comprises a radiometal complex of the present invention and a pharma- ceutically acceptable carrier.

[0215] In another embodiment, a pharmaceutical composition comprises an immunoconjugate of the invention and a pharma- ceutically acceptable carrier.

[0216] In another embodiment, a pharmaceutical composition comprises a radioimmunoconjugate of the present invention and a pharma- ceutically acceptable carrier.

[0217] As used herein, the term "carrier" refers to any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, oil, lipid, lipid-containing vesicle, microsphere, liposomal encapsulation, or other material known in the art for use in pharmaceutical formulations. It will be understood that the characteristics of the carrier, excipient, or diluent will depend on the route of administration for a particular application. As used herein, the term "pharmaceutical acceptable carrier" refers to a non-toxic material that does not interfere with the efficacy of the composition according to the invention or the biological activity of the composition according to the invention. According to certain embodiments, any pharmaceutical acceptable carrier suitable for use in antibody-based or radiocomplex-based pharmaceutical compositions in light of the present disclosure may be used in the present invention.

[0218] According to certain embodiments, the compositions described herein are formulated to be suitable for the intended route of administration to a subject. For example, the compositions described herein can be formulated to be suitable for parenteral administration, such as intravenous, subcutaneous, intramuscular or intratumoral administration.

[0219] In certain embodiments, the present invention relates to radiation therapy and methods of selectively targeting tumor cells to treat neoplastic diseases or disorders. Any of the radiocomplexes or radioimmunoconjugates described herein and pharmaceutical compositions thereof may be used in the methods of the present invention.

[0220] A "neoplasm" is an abnormal mass of tissue that occurs when cells divide unnecessarily or do not die when they should. Tumors can be benign (not cancer) or malignant (cancer). Neoplasm is also called tumor. A neoplastic disease or disorder is a disease or disorder associated with a tumor, such as cancer. Examples of neoplastic diseases or disorders include, but are not limited to, disseminated cancer and solid tumor cancer.

[0221] In certain embodiments, the present invention is directed to a method of treating prostate cancer (e.g., metastatic prostate cancer, or metastatic castration-resistant prostate cancer) in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of an immunoconjugate or radioimmunoconjugate described herein, the immunoconjugate or radioimmunoconjugate comprising a radiometal complex described herein conjugated to H11B6.

[0222] The embodiments of the present invention are particularly useful for treating patients diagnosed with prostate cancer, for example, patients with advanced prostate cancer. According to one embodiment, the cancer is non-localized prostate cancer. According to another embodiment, the cancer is metastatic prostate cancer. According to another embodiment, the cancer is castration-resistant prostate cancer (CRPC). According to another embodiment, the cancer is metastatic castration-resistant prostate cancer (mCRPC). According to another embodiment, the cancer is mCRPC with adenocarcinoma.

[0223] In one embodiment, the present invention is directed to a method of selectively targeting tumor cells for radiation therapy, the method comprising administering to a subject a radioimmunoconjugate or pharmaceutical composition of the present invention.

[0224] In one embodiment, the present invention is directed to a method of treating a neoplastic disease or disorder, the method comprising administering to a subject in need of treatment a radioimmunoconjugate or pharmaceutical composition of the present invention to the subject.

[0225] The compounds, radioactive metal complexes and radioimmunoconjugates of the present invention may be radioisotopes, such as radionuclides, e.g., Ce-134( 134 According to certain embodiments, a method of detecting tumor cells in a patient includes administering the radioimmunoconjugate to a patient (e.g., a patient diagnosed with or suspected of having cancer) and using a nuclear imaging technique, such as positron emission tomography (PET) or single photon emission computed tomography (SPECT), to image (e.g., detect the distribution of) the radioimmunoconjugate in the patient.

[0226] According to one embodiment, a method of detecting prostate cancer cells in a patient comprises administering a radioimmunoconjugate described herein that comprises Ce-134, wherein the radioimmunoconjugate comprises a PSMA-targeting antibody or a KLK2-targeting antibody (e.g., the radioimmunoconjugate has the formula (IM + ), (II-M + ), or (III-M + ), + Ce 134 wherein the radioactive metal complex is conjugated to an antibody that targets PSMA or KLK2), administering the radioimmunoconjugate and using a nuclear imaging technique, such as positron emission tomography (PET) or single photon emission computed tomography (SPECT), to detect the distribution of the radioimmunoconjugate within the body or a portion thereof.

[0227] Further, embodiments of the present invention relate to a chelator as described herein (e.g., a compound of Formula (I), (II) or (III), or a pharma- ceutically acceptable salt thereof) for the manufacture of a radioimaging agent for imaging cancer cells, such as prostate cancer cells, or for diagnosing any one of the diseases, disorders, or medical conditions described herein, such as prostate cancer (e.g., CRPC or mCRPC).

[0228] Further embodiments of the present invention relate to the use of a radioactive metal complex as described herein (e.g., a compound represented by the formula (IM)) for the manufacture of a radioimaging agent for imaging of cancer cells, such as prostate cancer cells, or for diagnosing any one of the diseases, disorders, or medical conditions described herein, such as prostate cancer (e.g., CRPC or mCRPC). + ), (II-M + ), or (III-M + ) or a pharma- ceutically acceptable salt thereof).

[0229] Further embodiments of the invention relate to an antibody (e.g., an antibody having the formula (IM + ), (II-M + ) or (III-M + ) wherein M + Ce 134 wherein the radioactive metal complex is conjugated to an antibody that targets an antigen found on prostate cancer cells, e.g., a PSMA-targeting antibody or an h11B6-targeting antibody.

[0230] Further embodiments of the present invention relate to a radioimmunoconjugate as described herein (e.g., a compound represented by the formula (IM)) for use as a radioimaging agent for imaging cancer cells, such as prostate cancer cells, or for diagnosing any one of the diseases, disorders, or medical conditions described herein, such as prostate cancer (e.g., CRPC or MCrPC).+ ), (II-M + ) or (III-M + ) wherein M + Ce 134 wherein the radiometal complex is conjugated to an antibody that targets an antigen found on prostate cancer cells, such as a PSMA-targeting antibody or a h11B6-targeting antibody.

[0231] In one embodiment, the present invention is directed to a method of treating cancer in a subject in need thereof, comprising administering to the subject a radioimmunoconjugate or pharmaceutical composition of the present invention.

[0232] The radioimmunoconjugates deliver radiation directly, e.g., to cells targeted by a targeting ligand. For example, the radioimmunoconjugates 225 Alpha-emitting radioactive metal ions, such as Ac, may also be delivered. Upon targeting, the alpha-emitting radioactive metal ions, e.g. 225 Alpha particles from Ac and its daughters are delivered to targeted cells and cause a cytotoxic effect on the cells, thereby selectively targeting tumor cells for radiation therapy and / or treatment of a neoplastic disease or disorder.

[0233] The present invention further includes a pre-targeting approach to selectively target tumor cells for radiation therapy and to treat neoplastic diseases or disorders. According to the pre-targeting approach, an azide-labeled antibody or antigen-binding fragment thereof is administered, binds to cells bearing the antibody's target antigen, and is removed from the circulation over time or with a removal agent. Subsequently, a radioactive metal complex of the present invention, preferably a radioactive metal complex comprising a cyclooctyne or cyclooctyne derivative (e.g., DBCO), is administered to undergo a SPAAC reaction with the azide-labeled antibody bound to the target site, and the remaining unbound radioactive metal complex is rapidly removed from the circulation. This pre-targeting technique provides a method to enhance radioactive metal ion localization at the target site in a subject.

[0234] In other embodiments, the modified polypeptide, e.g., an azide-labeled antibody or antigen-binding fragment thereof, and the radiometal complex of the invention are administered in the same composition or in different compositions to a subject in need of targeted radiation therapy or treatment of a neoplastic disease or disorder.

[0235] As used herein, the term "therapeutically effective amount" refers to an amount of an active ingredient or component that elicits a desired biological or pharmacological response in a subject. Therapeutically effective amounts can be determined empirically and in a routine manner for the described purpose. For example, in vitro assays can be optionally used to help identify optimal dosage ranges. Selection of a specific effective dose can be determined (e.g., by clinical trials) by those skilled in the art based on consideration of several factors, including the disease being treated or prevented, the associated symptoms, the patient's weight, the patient's immune status, and other factors well known to those skilled in the art. The exact dose to be used in the formulation also depends on the route of administration and the severity of the disease, and should be determined according to the physician's judgment and each patient's circumstances. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.

[0236] An "effective amount" of a radiological imaging agent described herein, such as a radioimmunoconjugate comprising Ce-134 (or a pharmaceutical composition comprising same), may refer to a detectable amount that allows imaging of a neoplastic disease or disorder in a subject.

[0237] As used herein, the terms "treat", "treating" and "treatment" are all intended to refer to the improvement or restoration of at least one measurable physical parameter associated with a disease, disorder or condition that may be discernible in a subject, but not necessarily discernible in the subject, for which administration of a radioactive metal ion may be beneficial, such as a neoplastic disease or disorder. The terms "treat", "treating" and "treatment" may also refer to causing regression, preventing the progression or at least slowing the progression of a disease, disorder or condition. In certain embodiments, "treat", "treating" and "treatment" refer to the amelioration, prevention of the development or onset, or shortening of the duration of one or more symptoms associated with a disease, disorder or condition that may be discernible in a subject, such as a neoplastic disease or disorder, for which administration of a radioactive metal ion may be beneficial. In certain embodiments, "treat", "treating" and "treatment" refer to the prevention of recurrence of a neoplastic disease, disorder or condition. In certain embodiments, "treat", "treating" and "treatment" refer to increasing the survival rate of a subject having a neoplastic disease, disorder or condition. In certain embodiments, "treat", "treating" and "treatment" refer to the elimination of a neoplastic disease, disorder or condition in a subject.

[0238] In some embodiments, a therapeutically effective amount of a radioimmunoconjugate or pharmaceutical composition of the present invention is administered to a subject to treat a neoplastic disease or disorder in the subject, such as cancer.

[0239] In other embodiments of the invention, the radioimmunoconjugates and pharmaceutical compositions of the present invention may be administered in combination with other agents effective in the treatment of neoplastic diseases or disorders.

[0240] In additional embodiments, the present invention relates to the radioimmunoconjugates and pharmaceutical compositions described herein for use in selectively targeting tumor cells for radiation therapy and / or treatment of a neoplastic disease or disorder, and to the use of the radioimmunoconjugates or pharmaceutical compositions described herein in the manufacture of a medicament for selectively targeting tumor cells for radiation therapy and / or treatment of a neoplastic disease or disorder.

[0241] Although certain embodiments have been illustrated and described, those of skill in the art, after reading the foregoing specification, may make modifications, equivalent substitutions, and other types of alterations to the compounds of the present technology described herein or their salts, pharmaceutical compositions, derivatives, prodrugs, metabolites, tautomers, or racemic mixtures. Each of the above aspects and embodiments may also include or incorporate the variations or aspects disclosed with respect to any or all of the other aspects and embodiments.

[0242] Numbered embodiments Numbered exemplary embodiments of the present invention are provided below.

[0243] 1. Formula (I):

[0244] [ka] [In the formula, R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, which is optionally substituted with -L1-R4; L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand. 2.Formula (II):

[0245] [ka] [In the formula, L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand. 3.Formula (III):

[0246] [ka] [In the formula, L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand. 4. R1 is -L1-R4, R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl; L1 is absent or a linker, The compound of embodiment 1, wherein R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand. or a pharma- ceutically acceptable salt thereof. 5. R1 is H, R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl substituted with -L1-R4; L1 is absent or a linker, The compound of embodiment 1, wherein R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand. or a pharma- ceutically acceptable salt thereof. 6. R4 is -NH2, -NCS, -NCO, -N3, alkynyl, cycloalkynyl, -C(O)R 13 , -COOR 13 , -CON(R 13 2, a maleimide, an acyl halide, a tetrazine, or a trans-cyclooctene. 7. The compound of embodiment 1, wherein R4 is selected from the group consisting of cyclooctynyl, bicyclononynyl (BCN), difluorinated cyclooctynyl (DIFO), dibenzocyclooctynyl (DIBO), keto-DIBO, biarylazacyclooctynyl (BARAC), dibenzoazacyclooctynyl (DIBAC, DBCO, ADIBO), dimethoxyazacyclooctynyl (DIMAC), difluorobenzocyclooctynyl (DIFBO), monobenzocyclooctynyl (MOBO) and tetramethoxydibenzocyclooctynyl (TMDIBO). 8. The compound according to embodiment 7, wherein R4 is DBCO or BCN. 9. The compound of embodiment 1, wherein R4 comprises a targeting ligand, the targeting ligand being selected from the group consisting of an antibody, an antigen-binding fragment of an antibody, a scaffold protein, and an aptamer. 10. L1,

[0247] [ka] wherein m is an integer from 0 to 12. 11.

[0248] [ka]

[0249] [ka] The compound of embodiment 1, wherein the compound is selected from the group consisting of: 12. The compound of embodiment 1, wherein the compound binds to a radioactive metal ion to form a radioactive metal complex. 13. Expression (IM + ):

[0250] [ka] [In the formula, M + Cerium-134 ( 134 is a radioactive metal ion, R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, which is optionally substituted with -L1-R4; L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand, or a pharma- ceutically acceptable salt thereof. 14.Formula (II-M + ):

[0251] [ka] [In the formula, M + Cerium-134 ( 134 is a radioactive metal ion, L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand, or a pharma- ceutically acceptable salt thereof. 15.Formula (III-M + ):

[0252] [ka] [In the formula, M + Cerium-134 ( 134 is a radioactive metal ion, L1 is absent or a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand, or a pharma- ceutically acceptable salt thereof. 16. M + Cerium-134 ( 134 is a radioactive metal ion, R1 is -L1-R4, R2 and R3 together with the carbon atom to which they are attached form a 5-membered cycloalkyl; L1 is absent or a linker, The radiometal complex of embodiment 13, wherein R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand. or a pharma- ceutically acceptable salt thereof. 17. M + Cerium-134 ( 134 is a radioactive metal ion, R1 is H, R2 and R3 together with the carbon atom to which they are attached form a 6-membered cycloalkyl substituted with -L1-R4; L1 is absent or a linker, The radiometal complex of embodiment 13, wherein R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand. or a pharma- ceutically acceptable salt thereof. 18.

[0253] [ka]

[0254] [ka] wherein n is 1 to 10; M + Cerium-134 ( 134 14. The radiometal complex of embodiment 13, wherein the radiometal ion is Ce. 19. An immunoconjugate comprising the compound of embodiment 9 conjugated to an antibody or an antigen-binding fragment thereof. 20. The immunoconjugate of embodiment 19, wherein the antibody or antigen-binding fragment thereof is attached to R4 via a triazole moiety. twenty one.

[0255] [ka] is selected from the group consisting of During the ceremony, L1 is absent or a linker, mAb is an immunoconjugate that is an antibody or an antigen-binding fragment thereof. 22. The immunoconjugate of embodiment 21, wherein the mAb is h11B6 or PSMB-127. twenty three.

[0256] [ka] is selected from the group consisting of The immunoconjugate of embodiment 21, wherein the mAb is an antibody or an antigen-binding fragment thereof. 24. The immunoconjugate of embodiment 23, wherein the mAb is h11B6 or PSMB-127. 25. A radioimmunoconjugate, in which the radiometal complex according to embodiment 13 is conjugated to an antibody or an antigen-binding fragment thereof. 26. The radioimmunoconjugate according to embodiment 25, wherein the antibody or antigen-binding fragment thereof is attached to R4 of the radiometal complex via a triazole moiety. 27. The radioimmunoconjugate of embodiment 25, wherein the antibody is h11B6 or PSMB-127. 28.

[0257] [ka] is selected from the group consisting of During the ceremony, M + Cerium-134 ( 134 is a radioactive metal ion, L1 is absent or a linker, mAb is an antibody or an antigen-binding fragment thereof; a radioimmunoconjugate. 29. A radioimmunoconjugate according to embodiment 28, wherein the mAb is h11B6 or PSMB-127. 30.

[0258] [ka] is selected from the group consisting of During the ceremony, M + Cerium-134 ( 134 is a radioactive metal ion, 29. The radioimmunoconjugate of embodiment 28, wherein the mAb is an antibody or an antigen-binding fragment thereof. 31. A radioimmunoconjugate according to embodiment 30, wherein the mAb is h11B6. 32. A method for preparing a radioimmunoconjugate according to embodiment 25, comprising reacting an immunoconjugate according to embodiment 19 with a radioactive metal ion. 33. The method of embodiment 32, wherein the targeting ligand is an antibody or an antigen-binding fragment thereof. 34. The method of embodiment 33, wherein the antibody is h11B6 or PSMB-127. 35. Expression (IM + A method for preparing a radioimmunoconjugate of

[0259] [ka] During the ceremony, M + Cerium-134 ( 134 is a radioactive metal ion, R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, which is optionally substituted with -L1-R4; L1 is absent or a linker, R4 is alkynyl or cycloalkynyl; The method comprises: (i) reacting a modified polypeptide with the compound of claim 1, the modified polypeptide being an antibody or an antigen-binding fragment thereof comprising an azide group, thereby obtaining an immunoconjugate; (ii) reacting the immunoconjugate with a radioactive metal ion to form a compound of the formula (IM + and obtaining a radioimmunoconjugate of said compound. 36. The method of embodiment 35, wherein the antibody is h11B6. 37. Expression (IM + A method for preparing a radioimmunoconjugate of

[0260] [ka] During the ceremony, M + Cerium-134( 134 Ce), R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, which is optionally substituted with -L1-R4; L1 is absent or a linker, R4 is alkynyl or cycloalkynyl; The method comprises: (i) reacting a modified antibody or antigen-binding fragment thereof comprising an azide group with a compound according to claim 1 to obtain an immunoconjugate; (ii) reacting the immunoconjugate with a radioactive metal ion to form a compound of the formula (IM + and obtaining a radioimmunoconjugate of said compound. 38. The method of embodiment 25, wherein R4 is selected from the group consisting of cyclooctynyl, bicyclononynyl (BCN), difluorinated cyclooctynyl (DIFO), dibenzocyclooctynyl (DIBO), keto-DIBO, biarylazacyclooctynyl (BARAC), dibenzoazacyclooctynyl (DIBAC, DBCO, ADIBO), dimethoxyazacyclooctynyl (DIMAC), difluorobenzocyclooctynyl (DIFBO), monobenzocyclooctynyl (MOBO) and tetramethoxydibenzocyclooctynyl (TMDIBO). 39. The method of embodiment 37, wherein the antibody is h11B6 or PSMB-127. 40. A pharmaceutical composition comprising the radioimmunoconjugate according to embodiment 25 and a pharma- ceutically acceptable carrier. 41. A method for selectively targeting tumor cells for radioimaging in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition described in embodiment 40. 42. A method for imaging a tumor disease or tumor disorder in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition described in embodiment 40. 43. A method for imaging prostate cancer cells in a patient, comprising administering to the patient an effective amount of the pharmaceutical composition described in embodiment 40 and detecting a radioimmunoconjugate in the patient using a nuclear imaging technique (e.g., PET or SPECT), wherein the radioimmunoconjugate comprises an antibody targeting a prostate cancer antigen (e.g., PSMA or KLK2). 44. A method of imaging cancer cells in a patient, comprising: The structure:

[0261] [ka] [In the formula, M + Cerium-134 ( 134 Ce) to said patient. 45. A method for imaging prostate cancer cells in a patient, comprising: The structure:

[0262] [ka] [In the formula, M + Cerium-134 ( 134 Ce), wherein the mAb is an anti-PSMA antibody or an anti-KLK2 antibody, to the patient. 46. ​​The method of embodiment 44 or 45, wherein the mAb is an anti-PSMA antibody. 47. The method of any one of embodiments 44 to 46, further comprising using nuclear imaging techniques to detect distribution of the radioimmunoconjugate within the patient. 48. The method according to any one of embodiments 44 to 47, wherein the nuclear imaging technique is selected from positron emission tomography (PET) and single photon emission computed tomography (SPECT). EXAMPLES

[0263] The following examples are provided to aid in the understanding of the present invention and are not intended, and should not be construed, as in any way limiting the invention described in the claims appended hereto.

[0264] In the Examples below, synthesis products are listed that were isolated as a residue. Those of skill in the art will understand that the term "residue" is not intended to be limiting of the physical state from which the product is isolated, and may include, for example, solids, oils, foams, gums, syrups, and the like.

[0265] Abbreviations used herein, particularly in the Schemes and Examples, are as listed in Table A below.

[0266] [Table 6-1]

[0267] [Table 6-2]

[0268] As used herein, unless otherwise specified, the term "isolated form" is intended to mean that the compound exists in a form separated from any solid mixture with other compound(s), solvent system, or biological environment. In one embodiment of the present invention, any of the compounds described herein exists in an isolated form.

[0269] As used herein, unless otherwise specified, the term "substantially pure form" shall mean that the mole percent of impurities in the isolated compound is less than about 5 mole percent, preferably less than about 2 mole percent, more preferably less than about 0.5 mole percent, and most preferably less than about 0.1 mole percent. In one embodiment of the present invention, the compound of formula (I) is present in a substantially pure form.

[0270] As used herein, unless otherwise specified, the term "substantially free of a corresponding salt form(s)" when used to describe a compound of formula (I) means that the mole percent of the corresponding salt form(s) in the isolated base of formula (I) is less than about 5 mole percent, preferably less than about 2 mole percent, more preferably less than about 0.5 mole percent, and most preferably less than about 0.1 mole percent. In one embodiment of the present invention, the compound of formula (I) is present in a form that is substantially free of the corresponding salt form(s).

[0271] Example 1 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (TOPA-[C-7]-phenyl-carboxylic acid)

[0272] [ka]

[0273] [ka]

[0274] Step 1: To a mixture of methyl 6-formylpicolinate (4.00 g, 24.2 mmol), (4-(tert-butoxycarbonyl)phenyl)boronic acid (10.7 g, 48.5 mmol), PdCl2 (0.21 g, 1.2 mmol), tri(naphthalen-1-yl)phosphine (0.50 g, 1.2 mmol) and potassium carbonate (10.0 g, 72.7 mmol) in a 500 mL three-neck round bottom flask under nitrogen at −78° C., tetrahydrofuran (100 mL) was added in one portion. The mixture was purged with nitrogen and stirred at room temperature for 30 min, then heated at 65° C. for 24 h. The reaction mixture was cooled to room temperature, filtered through a pad of Celite, and the filtrate was concentrated to dryness. The crude product was purified by silica gel chromatography (0-50% EtOAc / petroleum ether) to give methyl 6-((4-(tert-butoxycarbonyl)phenyl)(hydroxy)methyl)picolinate as a yellow oil (2.5 g, 30% yield).

[0275] Step 2: A stir bar, methyl 6-((4-(tert-butoxycarbonyl)phenyl)(hydroxy)methyl)picolinate (2.50 g, 7.30 mmol), PPh3 (3.43 g, 13.1 mmol), N-bromosuccinimide (2.13 g, 12.0 mmol) and dichloromethane (30 mL) were added to a 250 mL three-neck round bottom flask at room temperature under nitrogen atmosphere and stirred for 1 h. The reaction solution was loaded onto a silica gel column and purified by chromatography (0-30% EtOAc / petroleum ether) to obtain the compound methyl 6-(bromo(4-(tert-butoxycarbonyl)phenyl)methyl)picolinate as a yellow oil (1.65 g, 56% yield).

[0276] Step 3: A stir bar, methyl 6-(bromo(4-(tert-butoxycarbonyl)phenyl)methyl)picolinate (1.52 g, 3.69 mmol), methyl 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (1.50 g, 3.69 mmol), Na2CO3 (1.17 g, 11.1 mmol), and acetonitrile (30 mL) were added to a 250 mL three-neck round-bottom flask and the resulting heterogeneous mixture was heated at 90 °C under a nitrogen atmosphere for 16 h. The reaction mixture was then cooled to room temperature, filtered through a Celite pad, and concentrated to dryness in vacuo to give the crude product. The crude product was purified by silica gel chromatography (0-10% MeOH / dichloromethane) to give methyl 6-((4-(tert-butoxycarbonyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate as a brown oil (1.2 g, 44%).

[0277] Step 4: A stir bar, methyl 6-((4-(tert-butoxycarbonyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (1.2 g, 1.6 mmol), TFA (0.62 mL, 8.1 mmol) and DCM (20 mL) were added to a 100 mL three-neck round bottom flask at room temperature and stirred for 1 h. The reaction mixture was concentrated to dryness and the resulting crude product was purified by preparative HPLC (column: XBRIDGE C18 (19×150 mm) 5.0 μm, mobile phase: 0.1% TFA aqueous solution / ACN, flow rate: 15.0 mL / min) to give TOPA-[C-7]-phenyl-carboxylic acid as a brown oil (0.8 g, 72%). LC-MS APCI:C 35 H 44 N4O 10 Calculated value 680.31, observed value m / z [M+H] +681.5. Purity by LC-MS: 99.87%. Purity by HPLC: 97.14% (97.01% at 210 nm, 97.20% at 254 nm and 97.21% at 280 nm). Column: Atlantis dC18 (250×4.6 mm), 5 μm, Mobile phase A: 0.1% TFA in water, Mobile phase B: acetonitrile, Flow rate: 1.0 mL / min. 1 H NMR(400MHz,DMSO-d6):δ8.12-8.07(m,4H),8.00-7.98(m,2H),7.75-7.73(m,4H),6.10 (s,1H),4.67(s,2H),3.96(s,3H),3.91(s,3H),3.82(s,8H),3.56(s,8H),3.52(s,8H).

[0278] Example 2 6-((16-((6-carboxypyridin-2-yl)(4-((2-(2-(2-isothiocyanatoethoxy)ethoxy)ethyl)carbamoyl)phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid

[0279] [ka]

[0280] [ka]

[0281] Step 1: A stir bar, 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (0.40 g, 0.60 mmol), tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (0.15 g, 0.60 mmol), triethylamine (0.18 g, 0.76 mmol), HATU (0.33 g, 0.90 mmol), and DCM (4.0 mL) were added to a 25 mL three-neck round bottom flask under nitrogen atmosphere at 0° C. The mixture was stirred at room temperature overnight. The reaction was treated with water (10 mL) and extracted with dichloromethane (10 mL x 3). The combined extracts were washed with 10% aqueous NaHCO3 (10 mL), brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give an oil, which was purified by silica gel chromatography (0-10% MeOH / DCM) to give methyl 6-((4-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.18 g).

[0282] Step 2: A stir bar, methyl 6-((4-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.18 g, 0.20 mmol), MeOH (1.8 mL), and HCl in methanol (4 M, 1.0 mL, 4.0 mmol) were added to a 10 mL single-neck round-bottom flask at 0° C., then allowed to warm to room temperature and stirred for 2 h. The volatiles were removed in vacuo to give methyl 6-((4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.15 g), which was used without purification.

[0283] Step 3: A stir bar, methyl 6-((4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.10 g, 0.12 mmol), triethylamine (37 mg, 0.37 mmol), dry DCM (2 mL), and carbon disulfide (14 mg, 0.18 mmol) were added to a pressure vial at room temperature under a nitrogen atmosphere. The vial was irradiated in a microwave at 90° C. for 30 minutes (power 150 W). The vial was then cooled to room temperature and the reaction mixture was diluted with dichloromethane (10 mL) and then washed successively with water (5 mL), 1 M HCl (5 mL), and water (5 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give methyl 6-((4-((2-(2-(2-isothiocyanatoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (100 mg), which was used without purification.

[0284] Step 4: A stir bar, methyl 6-((4-((2-(2-(2-isothiocyanatoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.10 g, 0.12 mmol), and aqueous HCl (6N, 0.4 mL, 2.34 mmol) were added to a 10 mL one-neck round bottom flask and stirred at 50° C. for 3 h. The reaction mixture was cooled to room temperature and concentrated to dryness under vacuum to give an oil, which was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm, 5.0 μm, mobile phase: 0.1% aqueous TFA / acetonitrile, flow rate: 15.0 mL / min) to give 6-((16-((6-carboxypyridin-2-yl)(4-((2-(2-(2-isothiocyanatoethoxy)ethoxy)ethyl)carbamoyl)phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (5.0 mg). LC-MS APCI:C 40 H 52 NO 11 Calculated S: 824.34, observed m / z [M+H] + 824.8. 1 H NMR(400MHz,CD3OD):δ8.22-8.20(m,2H),8.14-8.05(m,2H),7.94(d,J=8.00Hz,2H),7.79(d,J=8.00Hz,2H),7.73 -7.67(m,2H),6.16(s,1H),4.77(s,2H),3.93-4.00(m,8H),3.59-3.70(m,27H),3.47-3.44(m,2H).

[0285] Example 3 6-((4-((6-aminohexyl)carbamoyl)phenyl)(16-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid and Example 4 6-((16-((6-carboxypyridin-2-yl)(4-((6-isothiocyanatohexyl)carbamoyl)phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid

[0286] [ka]

[0287] [ka]

[0288] Step 1: A stir bar, 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (0.12 g, 0.18 mmol), tert-butyl(6-aminohexyl)carbamate (38 mg, 0.18 mmol), triethylamine (54 mg, 0.54 mmol), HATU (0.10 g, 0.27 mmol), and DCM (4.0 mL) were added to a 25 mL three-neck round bottom flask at 0° C. under nitrogen atmosphere. The reaction mixture was then warmed to room temperature and stirred overnight. The reaction mixture was then treated with water (10 mL) and extracted with dichloromethane (10 mL×3). The combined extracts were washed with 10% aqueous NaHCO3 (10 mL), brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness to give an oil which was purified by silica gel chromatography (0-10% MeOH / DCM) to give methyl 6-((4-((6-((tert-butoxycarbonyl)amino)hexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (70 mg) as a gummy oil.

[0289] Step 2: A stir bar, methyl 6-((4-((6-((tert-butoxycarbonyl)amino)hexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (70 mg, 0.080 mmol), MeOH (1.5 mL), and HCl in methanol (4 M, 0.4 mL, 1.6 mmol) were added to a 25 mL round bottom flask at 0° C., followed by bringing to room temperature and stirring for 2 h. The volatiles were removed in vacuo to give methyl 6-((4-((6-aminohexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (30 mg), which was used without purification.

[0290] Step 3: A stir bar, methyl 6-((4-((6-aminohexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (30 mg, 0.038 mmol), aqueous LiOH (1.1 mL, 0.1 N, 0.11 mmol), and MeOH (1.0 mL) were added to an 8 mL reaction vial and stirred at room temperature overnight. The reaction mixture was then treated with acetic acid to pH 6.5 and subsequently concentrated to dryness under vacuum at room temperature. The resulting product was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm, 5.0 μm, mobile phase: 10 mM aqueous ammonium acetate / ACN, flow rate: 15.0 mL / min) to give Example 3: 6-((4-((6-aminohexyl)carbamoyl)phenyl)(16-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (10 mg). LC-MS APCI:C 39 H 54 Calculated for N6O9, 750.40, Observed m / z [M+H] + 751.3. 1H NMR(400MHz,CD3OD):δ8.22(d,J=1.60Hz,2H),8.21-8.06(m,2H),7.92(d,J=8.40Hz,2H),7.80(d,J=8.40Hz,2H),7.75-7.69(m,2H),6.20(s ,1H),4.70(s,2H),4.02-3.92(m,8H),3.76-3.62(m,14H),3.51-3.32 (m,4H),2.93(t,J=8.00Hz,2H),1.67-1.64(m,4H),1.46-1.45(m,4H).

[0291] Step 4: A stir bar, methyl 6-((4-((6-aminohexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.10 g, 0.13 mmol), triethylamine (39 mg, 0.38 mmol), dry DCM (2 mL), and carbon disulfide (15 mg, 0.19 mmol) were added to a pressure vial at room temperature under a nitrogen atmosphere. The vial was irradiated in a microwave at 90° C. for 30 minutes (power 150 W). The vial was then cooled to room temperature and the reaction mixture was diluted with dichloromethane (10 mL), washed with water (5 mL), 1 M HCl (5 mL), and water (5 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give methyl 6-((4-((6-isothiocyanatohexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.1 g), which was used without purification.

[0292] Step 5: A stir bar, methyl 6-((4-((6-isothiocyanatohexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.10 g, 0.12 mmol), and aqueous HCl (6N, 0.4 mL, 2.4 mmol) were added to a 10 mL round bottom flask and then stirred at 50° C. for 3 hours. The reaction mixture was then cooled to room temperature and concentrated to dryness under vacuum to give a residue, which was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm, 3.5 μm, mobile phase: 0.1% TFA aqueous solution / acetonitrile, flow rate: 2.0 mL / min) to give Example 4: 6-((16-((6-carboxypyridin-2-yl)(4-((6-isothiocyanatohexyl)carbamoyl)phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (15 mg). LC-MS APCI:C 40 H 52 Calculated for N6O9S: 792.35, observed m / z [M+H] + 792.8. 1 H NMR(400MHz,CD3OD):δ8.23-8.20(m,2H),8.15-8.06(m,2H),7.92(d,J=8.40Hz,2H),7.79(d,J=8.40Hz,2H),7.74-7.68(m,2H) ),6.17(s,1H),4.77(s,2H),4.01-3.93(m,8H),3.75-3.56(m,16H),3.42-3.33(m,5H),1.74-1.64(m,4H),1.50-1.44(m,4H).

[0293] Example 5 6-((16-((6-carboxypyridin-2-yl)(4-((4-isothiocyanatophenethyl)carbamoyl)phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid

[0294] [ka]

[0295] [ka]

[0296] Step 1: A stir bar, 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (0.25 g, 0.37 mmol), 4-(2-aminoethyl)aniline (60 mg, 0.37 mmol), TEA (0.11 g, 0.15 mL, 1.1 mmol), HATU (0.21 g, 0.55 mmol), and DCM (5 mL) were added to a 25 mL three-neck round bottom flask under nitrogen atmosphere at 0° C. The reaction mixture was stirred at room temperature overnight and then diluted with water (1 The mixture was treated with 100 mL of 10% aqueous NaHCO3 (10 mL) and extracted with dichloromethane (10 mL x 3). The combined extracts were washed with 10% aqueous NaHCO3 (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the product, which was purified by silica gel chromatography (0-10% MeOH / DCM) to give methyl 6-((4-((4-aminophenethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.12 g).

[0297] Step 2: A stir bar, methyl 6-((4-((4-aminophenethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.12 g, 0.15 mmol), TEA (45 mg, 65 μL, 0.45 mmol), DCM (3 mL), and CS2 (17 mg, 0.23 mmol) were added to a 10 mL microwave pressure vial at room temperature under nitrogen atmosphere. The reaction mixture was irradiated in a microwave (power 150 W) at 90 °C for 30 minutes. The reaction mixture was then cooled to room temperature, diluted with dichloromethane (10 mL), washed successively with water (5 mL), 1 M HCl (5 mL), and water (5 mL), dried over anhydrous Na2SO4, and concentrated to dryness to give methyl 6-((4-((4-isothiocyanatophenethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.12 g), which was used without purification.

[0298] Step 3: A stir bar, methyl 6-((4-((4-isothiocyanatophenethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.12 g, 0.14 mmol), and aqueous HCl (0.50 mL, 6N, 2.8 mmol) were added to a 10 mL single-neck round bottom flask and stirred at 50° C. for 3 h. The reaction mixture was cooled to room temperature, concentrated to dryness under reduced pressure, and the crude product was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm, 5.0 μm, mobile phase: 0.1% TFA aqueous solution / acetonitrile, flow rate: 15.0 mL / min) to give 6-((16-((6-carboxypyridin-2-yl)(4-((4-isothiocyanatophenethyl)carbamoyl)phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (30 mg). LC-MS APCI:C42 H 48 N5O 10 Calculated value of S, 812.32, observed m / z [M+H] + 812.9. 1 H NMR(400MHz,CD3OD):δ8.22(d,J=0.80Hz,2H),8.06-8.21(m,2H),7.85(d,J=8.40Hz,2H),7.68-7.78(m,4H),7.31(d,J=8.40Hz,2H) ),7.21(d,J=2.00Hz,2H),6.18(s,1H),4.77(s,2H),3.70-4.00(m,7H),3.60-3.67(m,16H),3.44-3.49(m,2H),2.90-3.10(m,3H).

[0299] Example 6 (S-6,6'-((2-(((2-isothiocyanatoethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinic acid

[0300] [ka]

[0301] [ka]

[0302] Step 1: A stir bar, 1(methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate) (0.10 g, 0.15 mmol), MeOH (0.5 mL) and HCl in methanol (4 M, 0.6 mL, 4.0 mmol) were added to a 25 mL one-neck round bottom flask at 0° C., then brought to room temperature and stirred for 2 h. The volatiles were removed in vacuo to give dimethyl 6,6'-((2-(((2-aminoethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (55 mg), which was used in the next step without purification.

[0303] Step 2: A stir bar, dimethyl 6,6'-((2-(((2-aminoethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (50 mg, 0.10 mmol), triethylamine (24 mg, 0.24 mmol), DCM (2 mL) and carbon disulfide (12 mg, 0.16 mmol) were added to a microwave vial under nitrogen at room temperature. The vial was irradiated in a microwave at 90° C. for 30 minutes (power 150 W). The vial was then cooled to room temperature and the reaction mixture was diluted with dichloromethane (10 mL), washed successively with water (5 mL), 1 M HCl (5 mL), water (5 mL), dried over anhydrous Na2SO4, concentrated to dryness and subjected to silica gel chromatography (0-10% MeOH / DCM) to give dimethyl 6,6'-((2-(((2-isothiocyanatoethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene)) (S)-dipicolinate as a yellow solid (20 mg).

[0304] Step 3: A stir bar, dimethyl 6,6'-((2-(((2-isothiocyanatoethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (20 mg, 0.030 mmol) and aqueous HCl (6 N, 0.1 mL, 0.6 mmol) were added to a 10 mL single-neck round bottom flask and stirred at room temperature overnight. The reaction mixture was concentrated to dryness in vacuo, and the resulting residue was purified by preparative HPLC (column: XBRIDGE C18 (19×150 mm) 5.0 μm, mobile phase: 0.1% TFA aqueous solution / acetonitrile, flow rate: 15.0 mL / min) to give (S)-6,6′-((2-(((2-isothiocyanatoethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinic acid (6 mg). LC-MS APCI: 30 H 41 Calculated for N5O8S2: 663.24, observed m / z [M+H] + 664.2. 1 H NMR (400MHz, DMSO-d6): δ9.78(s,1H),8.10(s,4H),7.78(d,J=6.00Hz,2H),4. 69(s,4H),3.96-3.52(m,23H),2.85(t,J=6.40Hz,2H),2.70(t,J=8.00Hz,2H).

[0305] Example 7 (S)-6,6'-((2-(((5-isothiocyanatopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinic acid

[0306] [ka]

[0307] [ka]

[0308] Step 1: A stir bar, dimethyl 6,6'-((2-(((5-((tert-butoxycarbonyl)amino)pentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.12 g, 0.15 mmol), MeOH (0.5 mL), and HCl in methanol (4 M, 0.6 mL, 4.0 mmol) were added to a 25 mL single-neck round bottom flask at 0° C., brought to room temperature, and stirred for 2 h. The volatiles were then removed in vacuo to give dimethyl 6,6'-((2-(((5-aminopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (70 mg), which was used without purification.

[0309] Step 2: A stir bar, dimethyl 6,6'-((2-(((5-aminopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (70 mg, 0.10 mmol), triethylamine (20 mg, 0.20 mmol), dry DCM (2 mL) and carbon disulfide (15 mg, 0.20 mmol) were added to a microwave vial at room temperature under nitrogen atmosphere. The reaction mixture was subjected to microwave irradiation (power 150 W) at 90°C for 30 minutes. The vial was brought to room temperature and the reaction mixture was diluted with dichloromethane (10 mL), washed successively with water (5 mL), 1 M HCl (5 mL) and water (5 mL), dried over anhydrous sodium sulfate (Na2SO4), filtered and concentrated to dryness to give a residue. The residue was subjected to silica gel chromatography (0-10% MeOH / DCM) to give dimethyl 6,6'-((2-(((5-isothiocyanatopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene)) (S)-dipicolinate as a yellow solid (30 mg).

[0310] Step 3: A stir bar, dimethyl 6,6'-((2-(((5-isothiocyanatopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (30 mg, 0.040 mmol), and aqueous HCl (6 N, 0.2 mL, 0.8 mmol) were added to a 10 mL single-neck round-bottom flask and stirred at room temperature overnight. The reaction mixture was concentrated to dryness under vacuum, and the concentrate was purified by HPLC (column: XBRIDGE C18 19×150 mm, 5.0 μm, mobile phase: 0.1% TFA aqueous solution / acetonitrile, flow rate: 15.0 mL / min) to give (S)-6,6′-((2-(((5-isothiocyanatopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinic acid (12 mg). LC-MS APCI: 33 H 47 Calculated for N5O8S2: 705.29, observed m / z [M+H] + 706.2. 1 H NMR(400MHz,DMSO-d6):δ13.40(s,1H),9.90(s,1H),8.17-8.09(m,4H),7.78(d,J=6.80Hz,2H),4.70(s ,4H),3.93-3.17(m,27H),2.68-2.67(m,2H),1.64-1.60(m,2H),1.53-1.49(m,2H),1.40-1.38(m,2H).

[0311] Example 8 (S)-6,6'-((2-((2-(2-(4-isothiocyanatophenoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinic acid

[0312] [ka]

[0313] [ka]

[0314] Scheme 7a, step 1a: A stir bar, tert-butyl (4-hydroxyphenyl)carbamate (4.5 g, 22 mmol), 1-bromo-2-(2-bromoethoxy)ethane (5.0 g, 22 mmol), K2CO3 (4.6 g, 43 mmol) and ACN (45 mL) were added to a 250 mL three-neck round bottom flask under nitrogen atmosphere and the resulting reaction mixture was heated at 80° C. under nitrogen atmosphere for 16 h. The reaction mixture was cooled to room temperature, filtered through Celite® and concentrated to dryness in vacuo to give a concentrate which was purified by silica gel chromatography (0-20% EtOAc / petroleum ether) to give the product tert-butyl (4-(2-(2-bromoethoxy)ethoxy)phenyl)carbamate (2.0 g).

[0315] Step 2a: A stir bar, tert-butyl (4-(2-(2-bromoethoxy)ethoxy)phenyl)carbamate (2.0 g, 5.6 mmol), ethanethio S-acid (0.42 g, 5.6 mmol), K2CO3 (1.5 g, 11 mmol) and ACN (50 mL) were added to a 250 mL three-neck round bottom flask under nitrogen atmosphere. The reaction mixture was stirred at 80 °C for 2 h, then cooled to room temperature, filtered through Celite® and concentrated to dryness in vacuo. The concentrate was purified using neutral alumina chromatography (0-50% EtOAc / petroleum ether) to give S-(2-(2-(4-((tert-butoxycarbonyl)amino)phenoxy)ethoxy)ethyl)ethanethioate (1.8 g).

[0316] Step 3a: A stir bar, S-(2-(2-(4-((tert-butoxycarbonyl)amino)phenoxy)ethoxy)ethyl)ethanethioate (1.8 g, 5.1 mmol), ethanol (20 mL) and hydrazine monohydrate (0.24 g, 0.24 mL, 7.6 mmol) were added to a 250 mL one-neck round bottom flask under nitrogen and stirred at 80° C. for 1 h. The reaction mixture was then cooled to room temperature and concentrated to dryness in vacuo to give a concentrate which was purified by silica gel chromatography (5-10% EtOAc / petroleum ether) to give tert-butyl (4-(2-(2-mercaptoethoxy)ethoxy)phenyl)carbamate (0.5 g) as a colorless oil.

[0317] Scheme 7, Step 1: A solution of tert-butyl (4-(2-(2-mercaptoethoxy)ethoxy)phenyl)carbamate (0.40 g, 1.0 mmol) and DMF (3.0 mL) was added dropwise over 5 min to a 50 mL three-neck round bottom flask containing a suspension of sodium hydride (0.060 g, 60% in mineral oil, 1.5 mmol) in DMF (3.0 mL) under nitrogen at 0° C. After complete addition, the reaction mixture was allowed to warm to room temperature and stirred for 15 min. The mixture was recooled to 0° C. and a solution of dimethyl 6,6'-((2-(((methylsulfonyl)oxy)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.5 g, 0.7 mmol) and DMF (3.0 mL) was added dropwise. Once the addition was complete, the reaction mixture was allowed to warm slowly to room temperature and stirred for 1.5 h. The reaction was slowly treated with saturated NH4Cl (0.2 mL) and then concentrated to dryness to give an oil. The oil was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm 5.0 μm, mobile phase: 0.1% TFA aqueous solution / acetonitrile, flow rate: 15.0 mL / min) to give dimethyl 6,6′-((2-(((2-(2-(4-((tert-butoxycarbonyl)amino)phenoxyl)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate as a brown oil (0.15 g).

[0318] Step 2: A stir bar, dimethyl 6,6'-((2-(((2-(2-(4-((tert-butoxycarbonyl)amino)phenoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.15 g, 0.16 mmol), MeOH (1.0 mL) and HCl in methanol (4 M, 0.80 mL, 3.2 mmol) were added to a 25 mL one-neck round bottom flask at 0° C., then brought to room temperature and stirred for 3 h. The volatiles were removed under reduced pressure to give dimethyl 6,6'-((2-(((2-(2-(4-aminophenoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.12 g), which was used without purification.

[0319] Step 3: A stir bar, dimethyl 6,6'-((2-(((2-(2-(4-aminophenoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.12 g, 0.15 mmol), triethylamine (46 mg, 0.46 mmol), dry DCM (3 mL) and carbon disulfide (17 mg, 0.22 mmol) were added to a pressure vial under nitrogen atmosphere at room temperature. The reaction mixture was irradiated in a microwave (power 150 W) at 90° C. for 30 minutes. The reaction mixture was cooled to room temperature, diluted with dichloromethane (10 mL), washed successively with water (5 mL), 1 M HCl (5 mL) and water (5 mL), dried over anhydrous Na2SO4 and concentrated to dryness to give dimethyl 6,6'-((2-(((2-(2-(4-isothiocyanatophenoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.12 g), which was used without purification.

[0320] Step 4: A stir bar, dimethyl 6,6'-((2-(((2-(2-(4-isothiocyanatophenoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.12 g, 0.15 mmol) and aqueous HCl (6N, 0.51 mL, 3.1 mmol) were added to a 10 mL single-neck round bottom flask and stirred at 50 °C for 3 h. The reaction mixture was cooled to room temperature and concentrated to dryness under reduced pressure, and the concentrate was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm 5.0 μm, mobile phase: 0.1% TFA aqueous solution / acetonitrile, flow rate: 15.0 mL / min) to give (S)-6,6′-((2-(((2-(2-(4-isothiocyanatophenoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinic acid (40 mg, 37%). LC-MS APCI:C 38 H 49 N5O 10 Calculated for S2: 799.29, observed m / z [M+H] + 799.9. 1 H NMR(400MHz,CD3OD):δ8.23-8.20(m,2H),8.15-8.09(m,2H),7.74-7.71(m,2H),7.19(d,J=8.80Hz,2H),6.92(d,J=9.20Hz,2H), 4.81(s,2H),4.77(s,2H),4.09-4.11(m,4H),3.92-3.95(m,6H),3.79(t,J=4.00Hz,3H),3.66-3.71(m,16H),2.70-2.76(m,4H).

[0321] Example 9 (S)-6,6'-((2-((2-(2-(2-(4-isothiocyanatophenoxy)ethoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinic acid

[0322] [ka]

[0323] [ka]

[0324] Scheme 8a, step 1a: A stir bar, tert-butyl (4-hydroxyphenyl)carbamate (3.5 g, 17 mmol), 1,2-bis(2-bromoethoxy)ethane (4.6 g, 17 mmol), K2CO3 (4.6 g, 33 mmol), and ACN (40 mL) were placed in a 250 mL three-neck round-bottom flask and stirred under nitrogen at 80° C. for 48 h. The reaction mixture was cooled to room temperature, filtered through Celite®, and concentrated to dryness in vacuo to give a concentrate that was purified by silica gel chromatography (0-10% MeOH / DCM) to give tert-butyl (4-(2-(2-(2-bromoethoxy)ethoxy)ethoxy)phenyl)carbamate as a brown oil (4.0 g).

[0325] Step 2a: A stir bar, tert-butyl (4-(2-(2-(2-bromoethoxy)ethoxy)ethoxy)phenyl)carbamate (4.0 g, 9.9 mmol), ethanethio S-acid (0.75 g, 9.9 mmol), K2CO3 (2.7 g, 20 mmol) and ACN (50 mL) were added to a 250 mL three-neck round bottom flask under nitrogen atmosphere and the reaction mixture was heated at 60 °C under nitrogen atmosphere for 2 h. The reaction mixture was cooled to room temperature, filtered through Celite®, concentrated to dryness in vacuo and the concentrate was purified by alumina chromatography (0-50% EtOAc / petroleum ether) to give S-(2-(2-(2-(4-((tert-butoxycarbonyl)amino)phenoxy)ethoxy)ethoxy)ethyl)ethanethioate as a brown oil (3.0 g).

[0326] Step 3a: A stir bar, S-(2-(2-(2-(4-((tert-butoxycarbonyl)amino)phenoxy)ethoxy)ethoxy)ethyl)ethanethioate (3.0 g, 7.5 mmol), ethanol (50 mL) and hydrazine monohydrate (0.36 g, 0.36 mL, 11 mmol) were added to a 250 mL one-neck round bottom flask under nitrogen and stirred at 80° C. for 1 h. The reaction mixture was cooled to room temperature, concentrated to dryness in vacuo, and the concentrate was purified by silica gel chromatography (5-10% EtOAc / petroleum ether) to give tert-butyl (4-(2-(2-(2-mercaptoethoxy)ethoxy)ethoxy)phenyl)carbamate (1.0 g) as a colorless oil.

[0327] Scheme 7, Step 1: A solution of tert-butyl (4-(2-(2-(2-mercaptoethoxy)ethoxy)ethoxy)phenyl)carbamate (0.40 g, 1.0 mmol) and DMF (3.0 mL) was added dropwise over 5 min to a 50 mL three-neck round bottom flask containing a suspension of sodium hydride (0.060 g, 60% in mineral oil, 1.5 mmol) in DMF (3.0 mL) at 0° C. under a nitrogen atmosphere. After the addition was complete, the reaction mixture was allowed to reach room temperature and was continuously stirred for 15 min. The mixture was recooled to 0° C. and a solution of dimethyl 6,6'-((2-(((methylsulfonyl)oxy)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.5 g, 0.7 mmol) and DMF (3.0 mL) was added dropwise over 10 min. After the addition was complete, the reaction mixture was allowed to warm slowly to room temperature and stirred for 1.5 h. The reaction mixture was then slowly treated with saturated aqueous NH4Cl (0.2 mL) and concentrated to dryness to give an oil. The oil was purified by preparative HPLC (column: XBRIDGE C18 (19×150 mm) 5.0 μm, mobile phase: 0.1% TFA aqueous solution / acetonitrile, flow rate: 15.0 mL / min) to give dimethyl 6,6′-((2-(((2-(2-(2-(4-((tert-butoxycarbonyl)amino)phenoxy)ethoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate as a brown oil (0.15 g, 21%).

[0328] Step 2: A stir bar, dimethyl 6,6'-((2-(((2-(2-(2-(4-((tert-butoxycarbonyl)amino)phenoxy)ethoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.15 mg, 0.16 mmol), MeOH (1.0 mL) and HCl in methanol (4 M, 0.80 mL, 3.2 mmol) were added to a 25 mL single neck round bottom flask at 0° C. The reaction mixture was allowed to warm to room temperature and stirred for 3 h. The volatiles were removed in vacuo to give dimethyl 6,6'-((2-(((2-(2-(2-(4-aminophenoxy)ethoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.12 g), which was used in the next step without purification.

[0329] Step 3: A stir bar, dimethyl 6,6'-((2-(((2-(2-(2-(4-aminophenoxy)ethoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.12 g, 0.14 mmol), triethylamine (44 mg, 0.43 mmol), dry DCM (5 mL) and carbon disulfide (17 mg, 0.22 mmol) were added to a microwave vial under nitrogen atmosphere at room temperature. The reaction mixture was irradiated in a microwave at 90° C. for 30 minutes (power 150 W). The reaction mixture was then cooled to room temperature, diluted with dichloromethane (10 mL), washed successively with water (5 mL), 1 M HCl (5 mL), and water (5 mL), dried over anhydrous Na2SO4, and concentrated to dryness to give dimethyl 6,6'-((2-(((2-(2-(2-(4-isothiocyanatophenoxy)ethoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.12 g), which was used in the next step without purification.

[0330] Step 4: A stir bar, dimethyl 6,6'-((2-(((2-(2-(2-(4-isothiocyanatophenoxy)ethoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.12 mg, 0.14 mmol) and aqueous HCl (6N, 0.50 mL, 2.8 mmol) were added to a 10 mL single-neck round bottom flask and stirred at 50 °C for 3 h. The reaction mixture was cooled to room temperature and concentrated to dryness under reduced pressure to give a residue, which was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm 5.0 μm, mobile phase: 0.1% TFA aqueous solution / acetonitrile, flow rate: 15.0 mL / min) to give (S)-6,6′-((2-(((2-(2-(2-(4-isothiocyanatophenoxy)ethoxy)ethoxy)ethyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinic acid (50 mg). LC-MS APCI:C 40 H 53 N5O 11 Calculated for S2: 843.32, observed m / z [M+H] + 843.9. 1 H NMR(400MHz,CD3OD):δ8.24-8.21(m,2H),8.21-8.11(m,2H),7.74(d,J=7.60Hz,2H),7.23-7.20(m,2H),6.97- 6.95(m,2H),4.84-4.79(m,5H),4.14-4.12(m,4H),3.97-3.94(m,6H),3.83-3.59(m,23H),2.75-2.67(m,4H).

[0331] Example 10 6-((4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid

[0332] [ka]

[0333] [ka]

[0334] Step 1: A stir bar, 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (0.40 g, 0.60 mmol), tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (0.15 g, 0.60 mmol), triethylamine (0.18 g, 0.76 mmol), HATU (0.33 g, 0.90 mmol), and DCM (4.0 mL) were added to a 25 mL three-neck round bottom flask under nitrogen atmosphere at 0° C. The mixture was stirred at room temperature overnight, diluted with water (10 mL), and extracted with dichloromethane (10 mL×3). The combined extracts were washed with 10% aqueous NaHCO3 (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give a concentrate which was purified by silica gel chromatography (0-10% MeOH / DCM) to give methyl 6-((4-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.18 g).

[0335] Step 2: A stir bar, methyl 6-((4-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.18 g, 0.20 mmol), MeOH (1.8 mL), and HCl in methanol (4 M, 1.0 mL, 4.0 mmol) were added to a 10 mL one-neck round bottom flask at 0° C., then brought to room temperature and stirred for 2 h. The volatiles were removed in vacuo to give methyl 6-((4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.15 g), which was used without purification.

[0336] Step 3: A stir bar, methyl 6-((4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.1 g, 0.1 mmol), aqueous LiOH (3 mL, 0.1 N, 0.3 mmol), and MeOH (1.0 mL) were added to an 8 mL reaction vial at room temperature and stirred overnight. The reaction mixture was adjusted to pH 6.5 with acetic acid and then concentrated to dryness under vacuum at room temperature to give a concentrate, which was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm, 5.0 μm, mobile phase: 0.1% TFA aqueous solution / ACN, flow rate: 15.0 mL / min) to give 6-((4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (40 mg). LC-MS APCI:C 39 H 54 NO 11Calculated for 782.39, observed m / z [M+H]+ 783.0.

[0337] Example 11 6,6'-((18-(((2-(2-aminoethoxy)ethyl)thio)methyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinic acid and Example 12 N-Acyl-DBCO tagged 6,6'-((18-(((2-(2-aminoethoxy)ethyl)thio)methyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinic acid

[0338] [ka]

[0339] [ka]

[0340] Step 1: A stir bar, methylcyclopent-3-ene-1-carboxylate (25.0 g, 198 mmol), THF (600 mL), methanol (12.6 g, 16.0 mL, 397 mmol) and lithium borohydride (198 mL, 2.0 M in THF, 397 mmol) were added to a 3000 mL three-neck round bottom flask at 0° C. After completion of the addition, the reaction mixture was stirred at 70° C. for 6 h. The reaction mixture was then cooled to room temperature, slowly treated with ice water (250 mL), further cooled to 0° C., and brought to pH ≈2 with 1.5 N HCl (pH ≈2), and then extracted with DCM (1000 mL×3). The combined extracts were washed with water (500 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness to obtain the concentrate. This was purified by silica gel chromatography (50-80% EtOAc / petroleum ether) to give cyclopent-3-en-1-ylmethanol (13.8 g).

[0341] Step 2: A solution of cyclopent-3-en-1-ylmethanol (13.7 g, 139 mmol) and DMF (50 mL) was added dropwise over 30 min to a 1000 mL three-necked round bottom flask containing a suspension of sodium hydride (6.69 g, 60% in mineral oil, 167 mmol) in DMF (50 mL) at 0° C. under nitrogen atmosphere. After the addition was complete, the reaction mixture was allowed to warm slowly to room temperature and stirring was continued for 30 min, after which the mixture was recooled to 0° C. and treated dropwise over 15 min with a solution of benzyl bromide (19.8 g, 167 mmol) and DMF (50 mL). After the addition was complete, the reaction mixture was allowed to warm slowly to room temperature and then stirred for 16 h. The reaction mixture was slowly treated with saturated NH4Cl (50 mL) and then extracted with ethyl acetate (1000 mL×3). The combined extracts were washed with water (500 mL x 3), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give a concentrate which was purified by silica gel chromatography (0-20% EtOAc / petroleum ether) to give ((cyclopent-3-en-1-ylmethoxy)methyl)benzene (21.0 g).

[0342] Step 3: A stir bar, NMO (38.0 g, 50 wt% in HO, 158 mmol), THF (180 mL) and osmium tetroxide (16.2 g, 3.21 mL, 2.5 wt% in t-butanol, 0.158 mmol) were added to a 1000 mL three-neck round bottom flask at 0° C. The reaction mixture was allowed to come to room temperature, stirred for 10 min and re-cooled to 0° C. After cooling, the mixture was treated dropwise over 15 min with a solution of ((cyclopent-3-en-1-ylmethoxy)methyl)benzene (20.0 g, 158 mmol) and THF (180 mL). The reaction was allowed to come to room temperature and stirred for 16 h before being treated with saturated aqueous NaHCO (100 mL) and extracted with DCM (1000 mL×3). The combined extracts were washed with water (500 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give a concentrate. This was purified by silica gel chromatography (0-20% EtOAc / petroleum ether) to give 4-((benzyloxy)methyl)cyclopentane-1,2-diol as a colorless oil. The isomers were separated by SFC (Apparatus: PIC 100, Column: Chiralpak OXH (250×30) mm, 5 μm, Mobile phase: CO2:0.5% isopropylamine in IPA (60:40), Total flow rate: 70 g / min, Back pressure: 100 bar, Wavelength: 220 nm, Cycle time: 8.0 min), which gave both cis-1,2 isomers of 4-((benzyloxy)methyl)cyclopentane-1,2-diol: the first eluting isomer (10 g), and the second eluting isomer (5 g).

[0343] Step 4: A solution of the first eluting isomer of 4-((benzyloxy)methyl)cyclopentane-1,2-diol (10.0 g, 45.0 mmol) and DMF (60 mL) was added dropwise over 1 h to a 250 mL three-neck round bottom flask containing a suspension of sodium hydride (8.62 g, 60% in mineral oil, 225 mmol) in DMF (60 mL) at 0° C. under nitrogen atmosphere. After the addition was complete, the reaction mixture was allowed to come to room temperature and stirred for 30 min, after which the mixture was recooled to 0° C. and treated dropwise over 15 min with a solution of 2-(2-bromoethoxy)tetrahydro-2H-pyran (47.0 g, 225 mmol) and DMF (60 mL). After the addition was complete, the reaction mixture was allowed to slowly warm to room temperature and stirred for 2 h. The mixture was then slowly treated with saturated aqueous NH4Cl (50 mL) and then extracted with ethyl acetate (500 mL×3). The combined extracts were washed with water (500 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness to give an oil which was purified by silica gel chromatography (0-30% EtOAc / petroleum ether) to give 2,2'-((((4-((benzyloxy)methyl)cyclopentane-1,2-diyl)bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(tetrahydro-2H-pyran) (21.0 g).

[0344] Step 5: A stir bar, 2,2'-((((4-((benzyloxy)methyl)cyclopentane-1,2-diyl)bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(tetrahydro-2H-pyran) (29.0 g, 61.0 mmol), MeOH (200 mL) and HCl in 1,4-dioxane (4 M, 3.0 mL, 12.0 mmol) were added to a 1000 mL three-neck round bottom flask and then heated to reflux for 1 h. The flask was then cooled to room temperature and the volatiles removed under vacuum to give 2,2'-((4-((benzyloxy)methyl)cyclopentane-1,2-diyl)bis(oxy))bis(ethan-1-ol) (20.0 g) as a residue which was used without purification.

[0345] Step 6: Under a nitrogen atmosphere, a 1000 mL round bottom flask was charged with a stir bar, 2,2'-((4-((benzyloxy)methyl)cyclopentane-1,2-diyl)bis(oxy))bis(ethan-1-ol) (20.0 g) (20.0 g, 64.4 mmol), DCM (200 mL) and triethylamine (32.6 mL, 322 mmol) and the resulting mixture was cooled to 10° C. The mixture was then treated with pTsCl (36.9 g, 193 mmol) in portions and then allowed to reach room temperature. After the addition was complete, the reaction mixture was stirred for 16 h during which time a precipitate formed. The mixture was then diluted with DCM (500 mL), washed with cold aqueous HCl (1 M, 500 mLx3) and ice-cold water (500 mLx2), dried over anhydrous Na2SO4, filtered and concentrated to dryness to give a residue which was purified by silica gel chromatography (0-30% EtOAc / petroleum ether) to give ((4-((benzyloxy)methyl)cyclopentane-1,2-diyl)bis(oxy))bis(ethane-2,1-diyl)bis(4-methylbenzenesulfonate) (26.0 g).

[0346] Step 7: A stir bar, N,N'-((ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(4-methylbenzenesulfonamide) (21.0 g, 42.0 mmol), Cs2CO3 (41.3 g, 126 mmol) and dry DMF (250 mL) were added to a 2000 mL three-neck round bottom flask under nitrogen atmosphere and the resulting heterogeneous mixture was stirred at room temperature for 1.5 h. The mixture was then treated dropwise over 2 h with a solution of ((4-((benzyloxy)methyl)cyclopentane-1,2-diyl)bis(oxy))bis(ethane-2,1-diyl)bis(4-methylbenzenesulfonate) (26.0 g, 42.0 mmol) and DMF (250 mL). Stirring was continued for 20 h, after which the mixture was concentrated to dryness in vacuo to give a pasty solid. The paste was suspended in DCM (1000 mL), stirred for 30 min, and filtered by vacuum filtration. The filtrate was concentrated to dryness under vacuum to give a concentrate which was purified by silica gel chromatography (0-40% EtOAc / petroleum ether) to give 18-((benzyloxy)methyl)-4,13-ditosyltetradecahydro-2H,11H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine (24 g).

[0347] Step 8: A solution of HBr in HOAc (50%, 112 mL, 695 mmol) was added to a 500 mL round bottom flask containing a stir bar and 18-((benzyloxy)methyl)-4,13-ditosyltetradecahydro-2H,11H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine (24.0 g, 32.8 mmol) under nitrogen atmosphere. The mixture was stirred at room temperature until homogeneous and then treated with phenol (16.3 g, 174 mmol). The reaction mixture was then heated at 60° C. for 6 hours, after which it was cooled to room temperature and concentrated to dryness in vacuo to give a concentrate. The concentrate was purified by reverse-phase column chromatography (column: Revelries C18-330 g, mobile phase A: 0.1% TFA aqueous solution, mobile phase B: acetonitrile, flow rate: 60 mL / min) to give methyl (tetradecahydro-2H,11H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecin-18-yl)acetate (8.0 g).

[0348] Step 9: A stir bar, (tetradecahydro-2H,11H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecin-18-yl)methyl acetate (8.0 g, 21 mmol), methyl 6-(chloromethyl)picolinate (12.2 g, 53.2 mmol), Na2CO3 (11.1 g, 106 mmol) and acetonitrile (100 mL) were added to a 500 mL three-neck round bottom flask under nitrogen atmosphere and the resulting heterogeneous mixture was heated at 90° C. for 16 h under nitrogen atmosphere. The resulting mixture was then cooled to room temperature and filtered through a pad of Celite® and the filtrate was concentrated to dryness in vacuo to give a concentrate. The concentrate was subjected to silica gel chromatography (0-10% MeOH / DCM) to give dimethyl 6,6'-((18-(acetoxymethyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (5.0 g).

[0349] Step 10: In a 250 mL round bottom flask under nitrogen atmosphere was added a stir bar, dimethyl 6,6'-((18-(acetoxymethyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (5.0 g, 7.4 mmol), KCO (0.10 g, 0.74 mmol) and methanol (50 mL) and the resulting mixture was stirred at room temperature for 10 min. The mixture was then concentrated to dryness under vacuum and the resulting residue was purified by silica gel chromatography (0-10% MeOH / DCM) to give 6,6'-((18-(hydroxymethyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (3.0 g).

[0350] Step 11: A stir bar, 6,6'-((18-(hydroxymethyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (2.0 g, 3.1 mmol), DCM (20 mL) and triethylamine (1.2 g, 9.5 mmol) were added to a 100 mL three-neck round bottom flask under nitrogen atmosphere and the resulting mixture was cooled to 10° C. The mixture was treated portionwise with MsCl (0.48 g, 6.3 mmol) and after the addition was complete the reaction vessel was allowed to come to room temperature and stirred for 30 min during which time a precipitate formed. The heterogeneous mixture was diluted with DCM (50 mL), washed with cold aqueous HCl (1 M, 50 mL x 3) and ice-cold water (50 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give a gummy solid. The gummy solid was purified by neutral alumina column chromatography (0-10% MeOH / DCM) to give dimethyl 6,6'-((18-(((methylsulfonyl)oxy)methyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (1.5 g).

[0351] Step 12: A solution of dimethyl 6,6'-((18-(((methylsulfonyl)oxy)methyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (0.69 g, 3.2 mmol) and DMF (5 mL) was added dropwise over 5 min at 0° C. under nitrogen to a 25 mL three-neck round bottom flask containing a suspension of sodium hydride (162 mg, 60% in mineral oil, 4.22 mmol) in DMF (0.5 mL). After the addition was complete, the reaction mixture was allowed to come to room temperature and stirred for 15 min. The reaction mixture was then re-cooled to 0° C. and treated dropwise over 5 min with a solution of tert-butyl (2-(2-mercaptoethoxy)ethyl)carbamate (1.50 g, 2.11 mmol) and DMF (3 mL). After the addition was complete, the reaction mixture was allowed to warm slowly to room temperature and then stirred for 1 h. The reaction was then slowly treated with saturated NH4Cl before being extracted with ethyl acetate (3×10 mL). The combined extracts were washed with water (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give an oil. The oil was purified by preparative HPLC (column: XBRIDGE C18 19×150 m) 5.0 μm, mobile phase: 0.1% TFA aqueous solution / acetonitrile, flow rate: 15.0 mL / min) to give cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (0.2 g).

[0352] Step 13: A stir bar, cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (0.20 g, 0.24 mmol), MeOH (1.0 mL), and HCl in methanol (4 M, 1.2 mL, 4.8 mmol) were added to a 25 mL one-neck round bottom flask at 0° C., and the resulting mixture was allowed to reach room temperature and stirred for 2 h. The volatiles were removed in vacuo to give dimethyl 6,6'-((18-(((2-(2-aminoethoxy)ethyl)thio)methyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (150 mg), which was used without purification.

[0353] Step 14: A stir bar, dimethyl 6,6'-((18-(((2-(2-aminoethoxy)ethyl)thio)methyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (40 mg, 0.054 mmol), aqueous LiOH (1.6 mL, 0.1 N, 0.16 mmol) and MeOH (0.5 mL) were added to an 8 mL reaction vial at room temperature and the resulting mixture was stirred overnight. The pH of the reaction mixture was adjusted to about pH 6.5 with acetic acid, then concentrated to dryness under vacuum at room temperature, and the resulting concentrate was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm 5.0 μm, mobile phase: 10 mM aqueous ammonium acetate / ACN, flow rate: 15.0 mL / min) to give Example 11: 6,6′-((18-(((2-(2-aminoethoxy)ethyl)thio)methyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecyne-4,13-diyl)bis(methylene))dipicolinic acid (23 mg). LC-MS APCI:C 34 H 51 Calculated for N5O9S, 705.34, observed m / z [M+H] + 706.4.

[0354] Step 15: A stir bar, dimethyl 6,6'-((18-(((2-(2-aminoethoxy)ethyl)thio)methyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (70 mg, 0.95 mmol), 11,12-didehydro-γ-oxodibenz[b,f]azocine-5(6H)-butyric acid (29 mg, 0.95 mmol), triethylamine (29 mg, 0.76 mmol), HATU (54 mg, 0.14 mmol) and DCM (0.5 mL) were added to a 25 mL three-neck round bottom flask at 0° C. under nitrogen atmosphere. The resulting mixture was allowed to come to room temperature and stirred overnight. The reaction mixture was diluted with water (10 mL) and extracted with dichloromethane (10 mL × 3). The combined extracts were washed with 10% aqueous NaHCO3 (10 mL), brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give an oil. The oil was purified by silica gel chromatography (0-10% MeOH / DCM) to give N-acyl-DBCO tagged dimethyl 6,6'-((18-(((2-(2-aminoethoxy)ethyl)thio)methyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (10 mg).

[0355] Step 16: A stir bar, N-acyl-DBCO tagged dimethyl 6,6'-((18-(((2-(2-aminoethoxy)ethyl)thio)methyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinate (10 mg, 0.01 mmol), aqueous LiOH (0.3 mL, 0.1 N, 0.03 mmol) and methanol (0.25 mL) were added to an 8 mL reaction vial at room temperature and the resulting mixture was stirred overnight. The reaction mixture was adjusted to about pH 6.5 with acetic acid and concentrated to dryness at room temperature under reduced pressure, and the resulting concentrate was purified by preparative HPLC (column: XBRIDGE C18 (19 × 150 mm) 5.0 μm, mobile phase: 10 mM aqueous ammonium acetate / ACN, flow rate: 15.0 mL / min) to obtain a toluene-containing eluate. Example 12: N-Acyl-DBCO tagged 6,6'-((18-(((2-(2-aminoethoxy)ethyl)thio)methyl)tetradecahydro-4H,13H,17H-cyclopenta[b][1,4,10,13]tetraoxa[7,16]diazacyclooctadecine-4,13-diyl)bis(methylene))dipicolinic acid (3 mg). LC-MS APCI:C 53 H 64 NO 11 S calculated: 992.44, observed m / z [MH] - :991.4.

[0356] Example 13 6-((16-(1-(6-carboxypyridin-2-yl)-8-isothiocyanatooctyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid

[0357] [ka]

[0358] [ka]

[0359] Step 1: A 500 mL three-neck round bottom flask purged and maintained with an inert atmosphere of nitrogen was charged with a solution of 8-((tert-butoxycarbonyl)amino)octanoic acid (20.0 g, 77.1 mmol) in dichloromethane (200 mL), N,O-dimethylhydroxylamine (7.0 g, 115 mmol), diisopropylethylamine (29.90 g, 231 mmol). Then, HATU (43.9 g, 115 mmol) was added with stirring at 0° C. The resulting solution was stirred at room temperature for 1 h. The reaction was then quenched by adding 200 mL of water. The resulting solution was extracted with dichloromethane (100 mL×2). The combined organic layer was washed successively with HCl (1 M) (300 mL×2), aqueous NH4CO3 solution (400 mL×3) and brine (400 mL). After drying over anhydrous Na2SO4, concentration gave tert-butyl (8-(methoxy(methyl)amino)-8-oxooctyl)carbamate as a pale yellow oil (15.4 g, 66% yield).

[0360] Step 2: A 500 mL three-neck round bottom flask purged and maintained with an inert atmosphere of nitrogen was charged with a solution of 2.6-dibromopyridine (23.0 g, 927 mmol) in THF (400 mL). It was cooled to -78°C and n-BuLi (60.4 mL, 927 mmol) was added dropwise quickly. After stirring for 10 min, tert-butyl (8-(methoxy(methyl)amino)-8-oxooctyl)carbamate (14.0 g, 463.5 mmol) in THF (40 mL) was added dropwise with stirring at -78°C. The resulting solution was stirred at room temperature for 30 min. The reaction was quenched by the addition of 500 mL of water. The resulting solution was extracted with ethyl acetate (200 mL x 2). The combined organic layers were washed with brine (400 mL), dried over anhydrous sodium sulfate and concentrated to dryness to give the crude product. Silica gel chromatography (0-10% ethyl acetate in petroleum ether) afforded tert-butyl (8-(6-bromopyridin-2-yl)-8-oxooctyl)carbamate as a pale yellow solid (11.8 g, 50% yield).

[0361] Step 3: In a 1 L high pressure reaction vessel maintained under an inert atmosphere of nitrogen, tert-butyl (8-(6-bromopyridin-2-yl)-8-oxooctyl)carbamate (11.5 g, 28.8 mmol, 1.0 equiv.) in MeOH (500 mL) was added, followed by Pd(dppf)Cl2 (2.1 g, 2.88 mmol), TEA (8.7 g, 86.4 mmol). CO (20 atm) was then introduced. The resulting solution was stirred at 100° C. for 16 h. The reaction solution was filtered and used directly in the next step.

[0362] Step 4: The above MeOH solution was cooled to 0° C. and NaBH4 (1.08 g, 28.8 mmol) was added. The resulting solution was stirred at room temperature for 1 h. The reaction was quenched by the addition of 500 mL of aqueous NH4CO3 and extracted with ethyl acetate (300 mL×2). The combined organic layers were washed with brine (600 mL), dried over anhydrous Na2SO4, and concentrated to give methyl 6-(8-((tert-butoxycarbonyl)amino)-1-hydroxyoctyl)picolinate as a brown oil (10 g).

[0363] Step 5: A 250 mL three-neck round bottom flask purged and maintained under an inert atmosphere of nitrogen was charged with a solution of methyl 6-(8-((tert-butoxycarbonyl)amino)-1-hydroxyoctyl)picolinate (10 g) in DCM (100 mL). After cooling to 0° C., TEA (7.9 g, 78.9 mmol) and mesyl chloride (3.6 g, 31.5 mmol) were added. The resulting solution was stirred at room temperature for 1 h. The mixture was concentrated under vacuum. MeCN (100 mL) was added and concentrated under vacuum. The crude product, methyl 6-(8-((tert-butoxycarbonyl)amino)-1-((methylsulfonyl)oxy)octyl)picolinate, was used as is in the next step.

[0364] Step 6: To a solution of the above crude product methyl 6-(8-((tert-butoxycarbonyl)amino)-1-((methylsulfonyl)oxy)octylpicolinate in ACN (100 mL) was added NaI (4.3 g, 28.9 mmol). The resulting solution was stirred at 80° C. for 1 h. The mixture was filtered and concentrated. The crude product was purified by flash preparative HPLC (column C18, mobile phase, HO / ACN=50 / 50% to HO / ACN=20 / 80% in 30 min). 4 g of methyl 6-(8-((tert-butoxycarbonyl)amino)-1-iodooctyl)picolinate was obtained as a brown oil.

[0365] Step 7: To a solution of methyl 6-(8-((tert-butoxycarbonyl)amino)-1-iodooctyl)picolinate (3.0 g, 6.12 mmol) in DCM (200 mL) was added methyl 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (3.0 g, 7.34 mmol), diisopropylethylamine (3.9 g, 30.61 mmol). The resulting solution was stirred at 80° C. for 16 h. The reaction was concentrated. The crude product was purified by flash preparative HPLC (column C18, mobile phase, A: HO (0.05% TFA), B: CAN, 20% B to 40% B in 20 min). Thereby, 1.9 g of methyl 6-(8-((tert-butoxycarbonyl)amino)-1-(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)octyl)picolinate was obtained as a brown oil.

[0366] Step 8: To a stirred solution of methyl 6-(8-((tert-butoxycarbonyl)amino)-1-(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)octyl)picolinate (1.7 g, 2.19 mmol, 77% by LCMS) in DCM (8.5 mL) at 0° C. was added HCl / dioxane dropwise. The resulting solution was stirred at room temperature for 1 h. The reaction was quenched by portionwise addition of aqueous NH4CO3 (20 mL×3). The resulting solution was extracted with dichloromethane (100 mL×2). The combined organic layers were washed with brine (400 mL), dried over anhydrous Na2SO4 and concentrated to give 1.3 g of methyl 6-(8-amino-1-(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)octyl)picolinate as a brown oil.

[0367] Step 9: To a solution of methyl 6-(8-amino-1-(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)octyl)picolinate (1.0 g, 1.48 mmol) in DCM (17 mL) under N2, was added 1,1'-thiocarbonylbis(pyridin-2(1H)-one) (0.38 g, 1.63 mmol). The resulting solution was stirred at room temperature for 1 h. This was concentrated to give 1.6 g of methyl 6-((16-(1-(6-(methoxycarbonyl)pyridin-2-yl)-8-thiocyanatooctyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate as a brown oil.

[0368] Step 10: To a solution of methyl 6-((16-(1-(6-(methoxycarbonyl)pyridin-2-yl)-8-thiocyanatooctyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (1.40 g, 1.42 mmol) in ACN (4 mL) was added HCl (6 M) (7 mL). The resulting solution was stirred in an oil bath at 50 °C for 5 h. It was diluted with 10 mL of HO. The crude product was purified by flash preparative HPLC (column, C18, mobile phase, A: HO (0.05% TFA), B: ACN, 20% B to 36% B in 20 min, detector UV @ 210 nm). The product fractions were concentrated to remove ACN. The aqueous phase was adjusted to pH 7-8 with aqueous NaHCO3. It was purified again by flash-preparative HPLC (column, C18, mobile phase, A: HO, B: ACN, 95% B to 100% B in 20 min). The product solution was concentrated to remove CAN and then lyophilized. This gave 190 mg of 6-((16-(1-(6-carboxypyridin-2-yl)-8-thiocyanatooctyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid as a brown solid. 1 H NMR(300MHz,D2O)δ7.91(s,4H),7.54(s,2H),4.52(d,J=17.9Hz,3H),3.77(d,J=9. 3Hz, 8H), 3.56-3.41 (m, 18H), 2.11 (s, 2H), 1.51 (s, 2H), 1.17 (s, 7H), 0.97 (s, 1H). MS(ES,m / z):688.3(M+H + ).

[0369] Example 14 6-((16-(1-(6-carboxypyridin-2-yl)-2-(2-(2-isothiocyanatoethoxy)ethoxy)ethyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid

[0370] [ka]

[0371] [ka]

[0372] Step 1: To a stirred solution of 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-oic acid (10.00 g, 37.98 mmol) and diisopropylethylamine (14.73 g, 113.94 mmol) in dichloromethane (100 mL) at 0° C. under nitrogen atmosphere, [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (15.16 g, 39.88 mmol), N,O-dimethylhydroxylamine (5.55 g, 56.97 mmol) were added dropwise. The resulting mixture was stirred at room temperature for 1 h and then poured into saturated aqueous NH4Cl solution. The resulting mixture was extracted with dichloromethane (100 mL×2). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by chromatography (column, C18, mobile phase A: H2O: 0.05% TFA, B: ACN, gradient from 20% B to 40% B in 20 min, detector: UV@210 nm). tert-Butyl (3-methyl-4-oxo-2,6,9-trioxa-3-azaundecan-11-yl)carbamate was obtained as a pale yellow oil (9.90 g, 85% yield).

[0373] Step 2: To a solution of 2,6-dibromo-pyridine (13.3 g, 56.1 mmol) in THF (260 mL) in a 500 mL three-neck round bottom flask at -78°C under nitrogen atmosphere, n-BuLi (28.0 mL, 56.1 mmol) was added dropwise. The solution was stirred at -78°C for 10 min. A solution of tert-butyl (3-methyl-4-oxo-2,6,9-trioxa-3-azoundecan-11-yl)carbamate (7.0 g, 28.0 mmol) in THF (30 mL) was added dropwise to the reaction at -78°C and stirred at room temperature for 30 min. To this was added water / ice (200 mL) at 0°C to quench the reaction. The aqueous layer was extracted with ethyl acetate (100 mL x 3). The combined extracts were dried over Na2SO4 and concentrated under vacuum. The residue was purified by chromatography (column, C18, mobile phase, mobile phase A: H2O: 0.05% TFA, B: ACN, gradient from 38% B to 58% B in 20 min, detector: UV@210 nm). tert-Butyl (2-(2-(2-(6-bromopyridin-2-yl)-2-oxoethoxy)ethoxy)ethyl)carbamate was obtained as a yellow solid (4.6 g, 50% yield). MS (ES, m / z): 425, 427 (M+Na + ).

[0374] Step 3: In a 250 mL high pressure reactor, tert-butyl (2-(2-(2-(6-bromopyridin-2-yl)-2-oxoethoxy)ethoxy)ethyl)carbamate (4.0 g, 18.1 mmol), triethylamine (5.5 g, 54.3 mmol), Pd(dppf)Cl2 (1.3 g, 1.8 mmol) and MeOH (40 mL) were added. The reaction solution was degassed and filled with N2. Then, CO (10 atm) was introduced. The resulting solution was stirred at 100 °C overnight. The reaction mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by chromatography (column, C18, mobile phase A: H2O: 0.05% TFA, B: ACN, gradient from 38% B to 58% B in 20 min, detector: UV @ 210 nm). Methyl 6-(2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-oil)picolinate was obtained as a brown oil (2.4 g, 63% yield). MS (ES, m / z): 405 (M+Na+ ).

[0375] Step 4: To a solution of methyl 6-(2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)picolinate (2.30 g, 6.01 mmol) in MeOH (46 mL) at 0° C. under N2 atmosphere was added NaBH4 (0.23 g, 6.01 mmol). The resulting solution was stirred at room temperature for 1 h and quenched by adding 50 mL of saturated aqueous NH4HCO3. The resulting solution was extracted with ethyl acetate (30 mL×2). The combined organic layers were washed with brine (60 mL), dried over Na2SO4, and concentrated. 2.2 g of crude product methyl 6-(13-hydroxy-2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)picolinate was obtained as a brown oil.

[0376] Step 5: To a solution of methyl 6-(13-hydroxy-2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)picolinate (2.2 g, 5.72 mmol) in dichloromethane (22 mL) was added triethylamine (1.74 g, 17.16 mmol) and MsCl (0.79 g, 6.86 mmol) at 0° C. under N2 atmosphere. The resulting solution was stirred at room temperature for 1 h and quenched with H2O (22 mL). The resulting mixture was extracted with dichloromethane (20 mL×2). The combined organic layers were washed with brine (40 mL), dried over Na2SO4, and concentrated. Obtained 2.2 g of crude product methyl 6-(2,2-dimethyl-13-((methylsulfonyl)oxy)-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)picolinate as a brown oil.

[0377] Step 6: To a solution of methyl 6-(2,2-dimethyl-13-((methylsulfonyl)oxy)-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)picolinate (2.2 g, 4.75 mmol) in ACN (22 mL) under N2 atmosphere, NaI (0.78 g, 5.23 mmol) was added. The resulting solution was stirred at 80° C. for 1 h. The mixture was filtered and concentrated. The crude product was purified by chromatography (column, C18, mobile phase A: HO, B: ACN, gradient from 50% B to 80% B in 30 min, detector: UV@210 nm). Methyl 6-(13-iodo-2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)picolinate was obtained as a brown oil (1.2 g). MS (ES, m / z): 517 (M+Na + ), 495(M+H + ).

[0378] Step 7: A solution of methyl 6-(13-iodo-2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)picolinate (840 mg, 1.69 mmol) and methyl 6-(1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (839 mg, 2.03 mmol) in ACN (16.8 mL) was stirred overnight at 80° C. under nitrogen atmosphere. The cooled reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by chromatography (column, C18, mobile phase A: HO, B: ACN, gradient from 40% B to 60% B in 20 min, detector: UV@210 nm). Methyl 6-((16-(13-(6-(methoxycarbonyl)pyridin-2-yl)-2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate was obtained as a brown oil (450 mg). MS (ES, m / z): 700 (M+Na + ), 678(M+H + ).

[0379] Step 8: To a solution of methyl 6-((16-(13-(6-(methoxycarbonyl)pyridin-2-yl)-2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (450 mg, 579 mmol) in dichloromethane (2.5 mL) at 0° C., HCl / dioxane (2.5 mL, 4 M) was added. The resulting solution was stirred at room temperature for 20 min. The reaction was quenched by adding saturated aqueous Na2CO3 solution. The aqueous layer was extracted with DCM:IPA (5:1) (30 mL×2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to give the crude product methyl 6-(2-(2-(2-aminoethoxy)ethoxy)-1-(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)ethyl)picolinate (330 mg). The crude product was used directly in the next step.

[0380] Step 9: A solution of methyl 6-(2-(2-(2-aminoethoxy)ethoxy)-1-(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)ethyl)picolinate (300 mg, 0.44 mmol) and 1-(2-oxopyridine-1-carbothioyl)pyridin-2-one (113.08 mg, 0.48 mmol) in dichloromethane (3 mL) was stirred at room temperature under nitrogen atmosphere for 1 h. The resulting mixture was concentrated under reduced pressure to give the crude product methyl 6-(2-(2-(2-isothiocyanatoethoxy)ethoxy)-1-(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)ethyl)picolinate (380 mg). This crude product was used directly in the next step.

[0381] Step 10: A solution of methyl 6-(2-(2-(2-isothiocyanatoethoxy)ethoxy)-1-(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)ethyl)picolinate (380 mg, 0.52 mmol) and HCl (1.9 mL, 6 M) in dichloromethane (1.9 mL) was stirred at 50 °C under nitrogen atmosphere for 3 h. The resulting mixture was concentrated under reduced pressure and basified to pH 6-7 with saturated aqueous NaHCO3. The residue was purified by chromatography (column, C18, mobile phase A: H2O with 0.05% TFA, B: ACN, gradient from 20% B to 36% B in 20 min, detector: UV@210 nm). The product fractions were then concentrated under vacuum to remove MeCN. The solution was again purified by chromatography (column, C18, mobile phase A: HO, B: ACN, gradient 95% B to 100% B (20 min). The solution was concentrated to remove most of the MeCN, and the aqueous solution was lyophilized to give 6-((16-(1-(6-carboxypyridin-2-yl)-2-(2-(2-isothiocyanatoethoxy)ethoxy)ethyl)-1,4,10,13 tetraoxa-7,16 diazacyclooctadecan-7-yl)methyl)picolinic acid as a brown solid (130 mg). 1 H NMR(300MHz,D2O)8.03-7.84(m,2H),7.57(dd,J=22.3,7.4Hz,1H),5.00(s,0H),4.59(s,1H) ,4.20(dd,J=23.4,9.5Hz,1H),3.82(d,J=15.4Hz,4H),3.70-3.58(m,6H),3.58-3.49(m,6H). MS(ES,m / z):692.3(M+H + ).

[0382] Example 15 6,6'-(((S-2-(((5-(((((1R,8S,9r-bicyclo[6.1.0]nona-4-yn-9-yl)methoxy)carbonyl)amino)pentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinic acid

[0383] [ka]

[0384] [ka]

[0385] Step 1: At 0° C. under a nitrogen atmosphere, a solution of tert-butyl (5-mercaptopentyl)carbamate (0.30 g, 1.0 mmol) and DMF (3.0 mL) was added dropwise over 5 min to a 50 mL three-neck round bottom flask containing a suspension of sodium hydride (0.07 g, 60% in mineral oil, 2 mmol) in DMF (3.0 mL). After complete addition, the reaction mixture was allowed to reach room temperature and stirring was continued for 15 min. The reaction mixture was then cooled back to 0° C. and treated dropwise over 10 min with a solution of dimethyl 6,6′-((2-(((methylsulfonyl)oxy)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S-dipicolinate (0.6 g, 0.9 mmol) and DMF (3.0 mL). After complete addition, the reaction mixture was allowed to warm slowly to room temperature and stirring was continued for 1.5 h. The reaction mixture was then carefully treated with saturated aqueous NH4Cl (1.0 mL) and concentrated to dryness to give an oil. The oil was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm, 5.0 μm, mobile phase: 0.1% Purification with aqueous TFA / acetonitrile, flow rate: 15.0 mL / min) gave dimethyl 6,6'-((2-(((5-((tert-butoxycarbonyl)amino)pentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.25 g).

[0386] Step 2: A stir bar, dimethyl 6,6'-((2-(((5-((tert-butoxycarbonyl)amino)pentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.25 g, 0.32 mmol), MeOH (1.0 mL), and HCl in methanol (4 M, 1.5 mL, 6.3 mmol) were added to a 25 mL round bottom flask at 0°C, which was then allowed to come to room temperature and the mixture was stirred for 3 h. The volatiles were then removed under reduced pressure to give dimethyl 6,6'-((2-(((5-aminopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.21 g), which was used without purification.

[0387] Step 3: Stir bar, dimethyl 6,6'-((2-(((5-aminopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S-dipicolinate (0.15 g, 0.22 mmol), ((1R,8S,9r)-bicyclo[6.1.0]non-4-yn-9-yl)methyl 4-nitrophenyl carbonate (68 mg, 0.22 mmol), triethylamine (66 mg, 0.65 mmol), and a mixture of DCM (2 mL) and DMF (0.1 mL). was added to a 25 mL three-neck round bottom flask at 0° C. under a nitrogen atmosphere. The resulting solution was allowed to warm slowly to room temperature and stirred overnight. The mixture was then concentrated to dryness to give dimethyl 6,6'-(((S-2-(((5-((((1R,8S,9r)-bicyclo[6.1.0]non-4-yn-9-yl)methoxy)carbonyl)amino)pentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinate (0.1 g), which was used without purification.

[0388] Step 4: A stir bar, dimethyl 6,6'-(((S-2-(((5-(((((1R,8S,9r)-bicyclo[6.1.0]non-4-yn-9-yl)methoxy)carbonyl)amino)pentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinate (0.10 g, 0.12 mmol), aqueous LiOH (3.5 mL, 0.1N, 0.35 mmol), and MeOH (0.5 mL) were added to an 8 mL reaction vial and the resulting mixture was stirred at room temperature overnight. The reaction mixture was then treated with acetic acid until the pH was about 6.5, followed by concentration to dryness in vacuum at room temperature to give an oil, which was purified by preparative HPLC (column: XBRIDGE C18 Purification using a 19×150 mm, 5.0 μm, mobile phase: 0.1% formic acid / ACN in HO, flow rate: 15.0 mL / min) gave 6,6′-(((S)-2-(((5-((((1R,8S,9r)-bicyclo[6.1.0]non-4-yn-9-yl)methoxy)carbonyl)amino)pentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinic acid (42 mg).

[0389] (Example 16) N-Acyl-DBCO tagged 6,6'-((2-(((5-aminopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinic acid

[0390] [ka]

[0391] [ka]

[0392] Step 1: A stir bar, dimethyl 6,6'-((2-(((5-((tert-butoxycarbonyl)amino)pentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (0.12 g, 0.15 mmol), MeOH (0.5 mL), and HCl in methanol (4 M, 0.75 mL, 3.0 mmol) were added to a 25 mL round bottom flask at 0° C., then brought to room temperature and stirred for 2 h. The volatiles were removed in vacuo to give dimethyl 6,6'-((2-(((5-aminopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (70 mg), which was used without purification.

[0393] Step 2: A stir bar, dimethyl 6,6'-((2-(((5-aminopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (50 mg, 0.070 mmol), 11,12-didehydro-γ-oxodibenz[b,f]azocine-5(6H)-butanoic acid (20 mg, 0.070 mmol), triethylamine (21 mg, 0.21 mmol), HATU (38 mg, 0.10 mmol), and DCM (0.5 mL) were added to a 25 mL three-neck round bottom flask under nitrogen atmosphere at 0° C., followed by bringing to room temperature and stirring overnight. The reaction mixture was treated with water (10 mL) and extracted with dichloromethane (10 mL × 3), and the combined extracts were washed with 10% aqueous NaHCO3 (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give an oil. The oil was purified by silica gel chromatography (0-10% MeOH / DCM) to give N-acyl-DBCO tagged dimethyl 6,6'-((2-(((5-aminopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (16 mg).

[0394] Step 3: A stir bar, N-acyl-DBCO tagged dimethyl 6,6'-((2-(((5-aminopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinate (16 mg, 0.016 mmol), aqueous LiOH (0.49 mL, 0.1 N, 0.049 mmol), and MeOH (0.25 mL) were added to an 8 mL reaction vial and the mixture was stirred at room temperature overnight. The reaction mixture was then treated with acetic acid until the pH was about 6.5 and concentrated to dryness under vacuum at room temperature to give a concentrate which was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm 5.0 μm, mobile phase: 10 mM aqueous ammonium acetate / ACN, flow rate: 15.0 mL / min) to give N-acyl-DBCO tagged 6,6′-((2-(((5-aminopentyl)thio)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))(S)-dipicolinic acid as an off-white solid (5 mg). LC-MS APCI:C 51 H 62 NO 10 S calculated: 950.42, observed m / z [M+H] + 951.4. 1 H NMR(400MHz,D2O):δ7.81-7.75(m,4H),7.52-7.17(m,10H),4.97-4.90(m,1H),4.80(s,4H),4.14(s,3H),3.77-3.46(m,16H),3 .10(s,7H),2.83-2.80(m,2H),2.55-2.53(m,2H),2.42-2.38(m,3H),2.11-2.08(m,3H),1.39-1.35(m,2H),1.20-1.10(m,4H).

[0395] (Example 17) N-Acyl-DBCO tagged 6-((4-((6-aminoethyl)carbamoyl)phenyl)16-((6-carboxypyridin-2-yl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (TOPA-[C7]-benzimide-DBCO)

[0396] [ka]

[0397] [ka]

[0398] Step 1: To a mixture of methyl 6-formylpicolinate (4.00 g, 24.2 mmol), (4-(tert-butoxycarbonyl)phenyl)boronic acid (10.7 g, 48.5 mmol), PdCl2 (0.21 g, 1.2 mmol), tri(naphthalen-1-yl)phosphine (0.50 g, 1.2 mmol) and potassium carbonate (10.0 g, 72.7 mmol) in a 500 mL three-neck round bottom flask at −78° C. under nitrogen, tetrahydrofuran (100 mL) was added in one portion. The mixture was purged with nitrogen and stirred at room temperature for 30 min, then heated at 65° C. for 24 h. The reaction mixture was cooled to room temperature, filtered through a pad of Celite®, and the filtrate was concentrated to dryness. The crude product was subjected to silica gel chromatography (0-50% EtOAc / petroleum ether) to give methyl 6-((4-(tert-butoxycarbonyl)phenyl)(hydroxy)methyl)picolinate as a yellow oil (2.5 g, 30%).

[0399] Step 2: A stir bar, methyl 6-((4-(tert-butoxycarbonyl)phenyl)(hydroxy)methyl)picolinate (2.50 g, 7.30 mmol), PPh3 (3.43 g, 13.1 mmol), N-bromosuccinimide (2.13 g, 12.0 mmol) and DCM (30 mL) were placed in a 250 mL three-neck round bottom flask at room temperature under nitrogen atmosphere and stirred for 1 h. The reaction solution was loaded onto a silica gel column and purified using 0-30% ethyl acetate in petroleum ether to obtain the compound methyl 6-(bromo(4-(tert-butoxycarbonyl)phenyl)methyl)picolinate as a yellow oil (1.65 g, 56%).

[0400] Step 3: A stir bar, methyl 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (1.52 g, 3.69 mmol), 6-(bromo(4-(tert-butoxycarbonyl)phenyl)methyl)picolinate (1.50 g, 3.69 mmol), Na2CO3 (1.17 g, 11.1 mmol), and acetonitrile (30 mL) were added to a 250 mL three-neck round bottom flask and the resulting heterogeneous mixture was heated at 90° C. for 16 h under nitrogen atmosphere. The reaction mass was then cooled to room temperature, filtered through a pad of Celite®, and concentrated to dryness in vacuo to give the crude product. The crude product was subjected to silica gel chromatography (0-10% MeOH / DCM) to give methyl 6-((4-(tert-butoxycarbonyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate as a brown oil (1.2 g, 44%).

[0401] Step 4: A stir bar, methyl 6-((4-(tert-butoxycarbonyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (1.2 g, 1.6 mmol), TFA (0.62 mL, 8.1 mmol) and DCM (20 mL) were added to a 100 mL three-neck round bottom flask at room temperature and stirred for 1 h. The reaction mixture was concentrated to dryness, and the resulting crude product was subjected to preparative HPLC (column: XBRIDGE C18 (19×150 mm) 5.0 μm, mobile phase: 0.1% TFA aqueous solution / ACN, flow rate: 15.0 mL / min) to obtain 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid as a brown oil (0.8 g, 72%). LC-MS APCI:C 35 H 44 N4O 10Calculated value 680.31, observed value m / z [M+H] + 681.5. Purity by LC-MS: 99.87%. Purity by HPLC: 97.14% (97.01% at 210 nm, 97.20% at 254 nm and 97.21% at 280 nm), Column: Atlantis dC18 (250×4.6 mm), 5 μm, Mobile phase A: 0.1% TFA in water, Mobile phase B: acetonitrile, Flow rate: 1.0 mL / min. 1 H NMR(400MHz,DMSO-d6):δ8.12-8.07(m,4H),8.00-7.98(m,2H),7.75-7.73(m,4H),6.10 (s,1H),4.67(s,2H),3.96(s,3H),3.91(s,3H),3.82(s,8H),3.56(s,8H),3.52(s,8H).

[0402] Step 5: A stir bar, 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (0.25 g, 0.37 mmol), DBCO (0.10 g, 0.37 mmol), triethylamine (0.16 mL, 1.1 mmol), HBTU (0.21 g, 0.55 mmol) and DCM (10 mL) were added to a 25 mL three-neck round bottom flask at room temperature under nitrogen atmosphere at 0° C. and stirred for 16 hours. The reaction was quenched with water (20 mL) and extracted with DCM (3×20 mL). The combined extracts were washed with 10% aqueous NaHCO3 (20 mL), brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the crude product as an oil, which was subjected to silica gel chromatography (0-10% MeOH / DCM) to give TOPA dimethyl ester-[C7]-phenyl-DBCO as a colorless gummy oil (0.12 g, 35%).

[0403] Step 6: A stir bar, TOPA dimethyl ester-[C7]-phenyl-DBCO (0.1 g, 0.1 mmol), aqueous LiOH·HO (3 mL, 0.1 N, 0.3 mmol) and THF / MeOH / HO (4:1:1 v / v / v, 2 mL) were added to an 8 mL reaction vial at room temperature and stirred for 2 h. The reaction mixture was neutralized with aqueous HCl (1 N) to a pH of about 6.5. The reaction mixture was concentrated to dryness in vacuum at room temperature and the resulting crude product was subjected to preparative HPLC (column: XBRIDGE C18 (19×150 mm) 5.0 μm, mobile phase: 10 mM aqueous ammonium acetate / ACN, flow rate: 15.0 mL / min) to give TOPA-[C7]-phenyl-DBCO as an off-white solid (20 mg, 21%). LC-MS APCI:C 51 H 54 NO 10 Calculated value 910.39, observed value m / z [MH] + 909.3. Purity by LC-MS: 92.47%. Purity by HPLC: 90.68% (88.04% at 210 nm, 90.43% at 254 nm and 93.56% at 280 nm), Column: XBRIDGE C8 (50×4.6 mm), 3.5 μm, Mobile phase A: 10 mM ammonium bicarbonate in water, Mobile phase B: acetonitrile, Flow rate: 1.0 mL / min. 1 H NMR(400MHz,DMSO-d6):δ7.84-7.82(m,4H),7.60-7.29(m,12H),7.13-7.10(m,2H), 5.12-5.02(m,2H),3.97(s,2H),3.59-3.44(m,20H),2.85(s,4H),2.73-2.68(m,6H).

[0404] (Example 18) TOPA-[C7]-Benzimide-DBCO-triazole-PSMB-127 antibody conjugate

[0405] [ka]

[0406] Step 1. Azide modification and click reaction of mAb: PSMB127 was site-selectively modified with 100-fold molar excess of 3-azidopropylamine and microbial transglutaminase (MTG, Activa TI) at 37°C. The addition of two azides on the heavy chain of the mAb was monitored by intact mass ESI-TOF LC-MS on an Agilent G224 instrument. Excess 3-azidopropylamine and MTG were removed and the azide-modified mAb (azido-mAb) was purified using a 1mL GE Healthcare MabSelect column. The azido-mAb was eluted from the resin using 100mM sodium citrate (pH 3.0) and then exchanged into 20mM Hepes, 100mM NaCl (pH 7.5) using a 7K Zeba® desalting column. A 10-fold molar excess of TOPA-[C7]-phenyl-DBCO was reacted with site-specific azide-PSMB127 (DOL=2) for 1 hour at 37° C. without shaking. The completion of the DBCO-azide click reaction was monitored by intact mass spectrometry. Excess free chelator was removed by desalting the conjugate into 20 mM Hepes, 100 mM NaCl, pH 7.5 on a Zeba® 7K desalting column, followed by three 15-fold serial dilution steps and concentration into 20 mM Hepes, 100 mM NaCl, pH 7.5 using a 30K MWCO Amicon concentrator device by spinning at 3800×g. This gave the final site-specific TOPA-[C7]-phenyl-DBCO-PSMB127 conjugate with CAR=2. The final conjugate was confirmed to be monomeric by analytical size exclusion chromatography using a Tosoh TSKgel G3000SWxl 7.8mm x 30cm, 5u column, column temperature: room temperature, column eluted with DPBS buffer (x1, calcium and magnesium free), flow rate: 0.7mL / min, 18min run, injection volume: 18μL.

[0407] [Table 7]

[0408] The final conjugate was confirmed to be monomeric by analytical size exclusion chromatography eluting with 10 mM sodium acetate at a 5-fold molar excess. The metal solution was added to TOPA-[C7]-phenyl-DBCO-PSMB127 (6.8 μM antibody, 34 μM metal ion) in 10 mM NaCl (pH 5.2) and incubated for 2 hours at 37°C. Excess metal was removed by desalting on a Zeba® column (ThermoFisher®) followed by two cycles of 10-fold dilution and concentration on a 50K MWCO Amicon concentrator (EMD Millipore®). Chelation was assessed by intact and reduced mass LC-MS.

[0409] Step 3. Stability determination: DTPA induction was performed to determine the stability of the chelate. 50 μL of sample (6.3 μM antibody) was combined with 50 μL of 10 mM DTPA (pH 6.5) and incubated overnight at 37° C. Chelation was assessed by intact and reduced mass LC-MS. LC-MS was performed on an Agilent 1260 HPLC system connected to an Agilent G6224 MS-TOF mass spectrometer. LC was performed on an Agilent RP-mAb C4 column (2.1×50 mm, 3.5 microns) with a flow rate of 1 mL / min, mobile phases 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (Sigma-Aldrich Cat. No. 34688) (B), and a gradient of 20% B (0-2 min), 20-60% B (2-3 min), 60-80% B (3-5.5 min). The instrument was operated in positive electrospray ionization mode, scanning from m / z 600 to 6000. Mass-to-charge spectra were deconvoluted using a maximum entropy algorithm, and the relative abundances of related species were estimated by the peak heights of the deconvoluted masses. Instrument settings included: capillary voltage 3500 V, fragmentor 175 V, skimmer 65 V; gas temperature 325 C, drying gas flow rate 5.0 L / min, nebulizer pressure 30 psig, acquisition mode range 100-7000 with a 0.42 scan rate.

[0410] A shift in MW relative to TOPA-[C7]-phenyl-DBCO-PSMB127 was observed for the cerium and neodymium samples. The intact mass of the conjugate incubated with cerium showed an increase in MW of 139 Da (20% by peak area) or 276 Da (77%) corresponding to the addition of one or two cerium ions. After DTPA induction, the masses remained similar and the abundances were similar (30% and 67% for the +138 and +274 species).

[0411] (Example 19) 6-((16-((6-carboxypyridin-2-yl)(4-isothiocyanatophenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (H2bp18c6 benzyl-phenyl) (TOPA-[C7]-phenyl isothiocyanate and sodium salt forms

[0412] [ka]

[0413] Compound 2 was prepared in a manner similar to existing literature methods, see J. Org. Chem. 1987, 52, 5172.

[0414] [ka]

[0415] Compound 3 was prepared in a manner similar to existing literature methods, see Chemistry-a European Journal, 2015, 21, 10179.

[0416] [ka]

[0417] Preparation of compound 4:

[0418] [ka]

[0419] 1,4,10,13-Tetraoxa-7,16-diazacyclooctadecane (494 g, 1.88 mol, 2.5 equiv), NaCl (44.1 g, 0.75 mol, 1.0 equiv), HO (140 mL, 1 volume relative to compound 3) and acetonitrile (2.1 L, 15 volumes) were charged to a 10 L reactor at 15-20 °C under N2 atmosphere and heated to 65 °C. To the resulting mixture was added a solution of compound 3 (140 g, 0.75 mol) in acetonitrile (280 mL, 2 volumes) dropwise over 1 h at 65 °C. The solution was aged at 65 °C for 0.5 h. LCMS analysis of the mixture indicated the reaction was complete. The mixture was allowed to cool to room temperature and concentrated under reduced pressure. Acetone (700 mL, 5 volumes) was added to the mixture and the suspension was stirred for an additional 1 h. The mixture was filtered (the filtered solid was unreacted compound 2). The filtrate was concentrated under vacuum and then dissolved in DCM (1.4 L, 10 vol). The organic phase was washed with water (3×750 mL) and the organic phase was dried over Na2SO4 and then concentrated under vacuum to give 212 g of compound 4 (63% yield, assay: 85% w / w). LCMS: (ES, m / z): 412.15 [M+H] + 1 H-NMR(300MHz,DMSO-d6,ppm):δ7.98-7.87(m,2H),7.81(dd,J=6.4,2.6Hz,1H ),3.87(s,3H),3.81(s,2H),3.61-3.38(m,16H),2.77(dt,J=19.0,5.2Hz,8H).

[0420] Preparation of compound 7:

[0421] [ka]

[0422] Methyl 6-formylpicolinate 5 (250 g, 1.0 equiv.), (4-((tert-butoxycarbonyl)amino)phenyl)boronic acid 6 (538 g, 1.5 equiv.) and degassed THF (6.5 L, 26 volumes relative to 5) were charged to a 10 L reactor at 15-20 °C under N2 atmosphere. This was followed by the addition of PdCl2 (14.0 g, 0.05 equiv.), tri(naphthalen-1-yl)-phosphane (31 g, 0.05 equiv.) and K2CO3 (650 g, 3.1 equiv.). The resulting solution was stirred at 20 °C for 0.5 h. The mixture was then heated to 65 °C and aged for 17 h. Analysis by LCMS indicated the reaction was complete. The resulting solution was cooled to room temperature and diluted with ice water (2.5 L, 10 volumes) and ethyl acetate (5 L, 20 volumes). The mixture was filtered through a Celite pad. The solution was separated and the lower aqueous layer was discarded. The organic phase was washed with water (2×1.5 L, 12 vol). The layers were separated and the organic layer was dried over Na2SO4 and concentrated under vacuum. The resulting residue was treated with heptane (1.25 L, 5 vol) and the resulting suspension was stirred for 0.5 h. The mixture was filtered and the filter cake was washed with n-heptane (500 mL, 2 vol) to give 530 g (98% yield, LCAP purity: 90%) of the desired product 7 as a yellow solid, which was used directly in the next step without further purification. LCMS: (ES, m / z): 381.10 [M+Na] + 1 H-NMR(300MHz,DMSO-d6,ppm):δ9.27(s,1H),8.03-7.85(m,2H),7.79(dd,J=7.7,1.4Hz,1H),7.39(d,J=8 .4Hz,2H),7.26(d,J=8.4Hz,2H),6.13(d,J=4.0Hz,1H),5.72(d,J=3.9Hz,1H),3.87(s,3H),1.46(s,9H).

[0423] Preparation of compound 8:

[0424] [ka]

[0425] Methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(hydroxy)methyl)picolinate 7 (310 g, 1.0 equiv), triethylamine (219 g, 2.5 equiv) and DCM (6.2 L, 20 volumes relative to 7) were charged to a 10 L reactor at 15-20° C. under nitrogen atmosphere and the solution was cooled to 0° C. Methanesulfonyl chloride (99.2 g, 1.0 equiv) was added dropwise over 30 min while maintaining the temperature at 0° C. The cooling bath was removed and the temperature was allowed to come to ambient temperature and aged at this temperature for 1 h. The solution was concentrated under vacuum at 10-15° C. and then the residue was dissolved in acetonitrile (438 mL, 2 volumes). The resulting solution was concentrated under vacuum to give 518 g (crude) of the desired product 8. The crude product was used directly in the next step without further purification.

[0426] Preparation of compound 9:

[0427] [ka]

[0428] Methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate 8 (212 g, 1.0 equiv., 85% pure by Q-NMR), Na2CO3 (137.6 g, 3.0 equiv.), and acetonitrile (3.56 L, 20 volumes relative to 8) were charged to a 10 L reactor at room temperature under nitrogen, then the mixture was heated to 65° C. and aged for 1 h. A solution of methyl 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate 4 (377.8 g, 2.0 equiv.) in acetonitrile (3 L, 10 volumes) was added dropwise at 65° C. over 0.5 h. The mixture was aged at this temperature until HPLC analysis indicated the reaction was complete. The resulting solution was cooled at room temperature, then filtered, and the filter cake was washed with MeOH (2×1 vol). The filtrate was concentrated under vacuum, and the resulting residue was dissolved in EA (700 mL), and then silica gel (800 g, type: ZCX-2, 100-200 mesh, 2.11 w / w) was added. The mixture was concentrated under vacuum while maintaining the temperature below 35° C. Silica gel (9.6 kg, type: ZCX-2, 100-200 mesh, 26.3 w / w) was packed into a column, followed by the prepared dried silica gel containing the adsorbed crude product 9. The column was eluted with ethyl acetate, petroleum ether, dichloromethane (3:3:1) / methanol, dichloromethane (1:1) (gradient from 100:0 to 90:10, sample collection every 4 L±0.5 L). Fractions were analyzed by TLC (ethyl acetate:ethyl acetate:petroleum ether:dichloromethane:methanol=4:4:1:1). Fractions containing product were combined and concentrated to give 260 g of compound 9 as a yellow solid (HPLC: 94%, QNMR: 92%). An additional 70 g of compound 9 was obtained as a yellow oil (HPLC: 75%, QNMR: 60%). LCMS (ES, m / z): 752.30 [M+H] + Observed value m / z 11H-NMR (400 MHz, CDCl3, ppm): δ 7.53 - 7.32 (m, 3H), 7.28 - 7.18 (m, 3H), 6.86 (d, J = 8.4 Hz, 2H), 6.76 (d, J = 8.4 Hz, 2H), 6.09 (s, 1H), 4.63 (s, 1H), 3.48 (s, 3H), 3.44 (bs, 5H), 3.17 - 2.92 (m, 16H), 2.38 (dq, J = 25.0, 7.2, 6.8 Hz, 8H), 0.97 (s, 9H).

[0429] Preparation of Compound 10:

[0430]

Chemical Structure

[0431] Compound 9 (260 g, QNMR: 92%, 1.0 equiv.), N,O-bis(trimethylsilyl)acetamide (BSA, 6.0 equiv.) and acetonitrile (4 L, 15 vol.) were placed in a 10 L reaction vessel at 15-20 °C under nitrogen atmosphere. The mixture was stirred at 20 °C for 40 min. A solution of TMSOTf (212.9 g, 3.0 equiv.) in acetonitrile (1.3 L, 5 vol.) was added dropwise over 0.5 h while maintaining the internal temperature at 15-20 °C. The resulting solution was aged at 15-20 °C for 1 h. When the in-process analysis (sample preparation: solution system 0.1 mL + ACN 0.9 mL + 1 drop diisopropylethylamine) showed complete conversion of the starting material, the mixture was quenched with diisopropylethylamine (617 g, 15.0 equiv.) while maintaining the temperature at 5-10 °C. The mixture was stirred at 5-10 °C for 20 min and then saturated aqueous NH4Cl (2.6 L, 10 vol) was charged while maintaining the temperature at 5-10 °C. The mixture was aged at this temperature for another 30 min. The aqueous phase (containing solids) was collected and extracted with 2-MeTHF (520 mL, 2 vol). The organic phases were combined, the water content was checked by KF (KF: 9.18%) and then dried with anhydrous Na2SO4 (500 g, 10.0 equiv). The solids were removed by filtration and the filter cake was washed with acetonitrile (2 x 520 mL, 2 vol). The filtrate was then dried with anhydrous Na2SO4 (500 g, 10.0 equiv). After filtration, the filter cake was washed with acetonitrile (2 x 520 mL, 2 vol) and the water content was checked by KF (KF: 8.15%). The acetonitrile / 2-MeTHF extract 10 was used directly in the next step. (The product was not stable to LCMS conditions.)

[0432] Preparation of compound 14 (free acid)

[0433] [ka]

[0434] Methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (6.0 g, 1.0 equiv.) and BSA (9.7 g, 6.0 equiv.) and MeCN (120 mL, 20 vol. for 9) were charged to a 500 mL reaction vessel at room temperature under nitrogen atmosphere. A solution of TMSOTf (5.4 g, 2.3 equiv.) in MeCN (120 mL, 20 vol.) was added dropwise at room temperature over 30 min. The mixture was aged overnight at room temperature. Analysis of the mixture (sample preparation: solution system 0.1 mL + ACN 0.9 mL + 1 drop diisopropylethylamine) indicated that the reaction had reached completion. The mixture was quenched with diisopropylethylamine (15.4 g, 15.0 equiv.) and the temperature was maintained at 0-5 °C. The mixture was stirred at 0-5 °C for 5 min, then saturated NH4Cl solution (60 mL, 10 vol.) was added dropwise while maintaining the temperature at 0-5 °C. The aqueous phase was removed by extraction and the organic phase was collected and used directly in the next step. The organic phase was placed in a 500 mL three-necked round-bottom bottle and a solution of LiOH (1.15 g, 6.0 equiv.) in water (60 mL, 10 vol.) was added to the solution at room temperature. The solution was stirred for 1 h at room temperature. Analysis of the mixture (sample preparation: 0.1 mL solution system + 0.9 mL acetonitrile) showed no complete conversion. More LiOH (576 mg, 3.0 equiv.) was added and the solution was stirred for another 1 h at room temperature. Analysis of the mixture (sample preparation: 0.1 mL of solution system + 0.9 mL of acetonitrile) showed that the reaction had reached completion. Then TCDI (5.6 g, 3.9 eq.) was added and the solution was stirred at room temperature for 1 h. Analysis of the mixture (sample preparation: 0.1 mL of solution system + 0.9 mL of acetonitrile) showed that the reaction had not reached completion. Further TCDI (2.8 g, 2.0 eq.) was added and the solution was stirred at room temperature for another 1 h. Analysis of the mixture (sample preparation: 0.1 mL of solution system + 0.9 mL of acetonitrile) showed that the reaction had reached completion. The reaction solution was separated by reversed-phase Combi-Flash. Method: column C18, A solution H2O (containing 0.01% formic acid), B solution ACN. 5% to 35% in 40 min, flow rate (100 mL / min), product 20 min to 25 min.The solution was collected. The solution was concentrated to remove ACN and separated again by reversed phase Combi-Flash. Method: column C18, A solution H2O, B solution ACN. 5% 10 min, 5%-35% in 5 min, 95% 10 min, flow rate (100 mL / min), product 13-25 min. The solution was collected. The solution was concentrated under reduced pressure below 20°C and dried by lyophilization. This gave 2.5 g (47% yield over 3 steps) of compound 14 as a yellow solid. Compound 14 (6-((16-((6-carboxypyridin-2-yl)(4-isothiocyanatophenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid) had to be stored at -80°C. LCMS: (ES,m / z): 666.3 [M+H]. + 1 H-NMR:(400MHz,D2O,ppm):7.94-7.84(m,4H),7.56-7.40(m,4H),7.16-7.14(m,2H), 5.83(s,1H),4.56(s,2H),3.80-3.75(m,8H),3.60-3.49(m,14H),3.36-3.33(m,2H).

[0435] Preparation of compound 11 (sodium salt):

[0436] [ka]

[0437] The prepared solution of compound 10 in ACN and 2-MeTHF was placed in a 10 L four-necked reaction vessel and the solution was cooled to 5-10 °C. Powdered NaOH (56.9 g, 4.5 equiv.) was added while maintaining the temperature at 5-10 °C. The resulting solution was stirred at 15-20 °C for 0.5 h. Analysis of the mixture (sample preparation: 0.1 mL solution system + 0.9 mL acetonitrile) showed no conversion. Additional powdered NaOH (25.3 g, 2.0 equiv.) was added at 5-10 °C. The solution was aged at 15-20 °C for an additional 0.5 h. A second IPC was analyzed, which showed 50% conversion. A final addition of powdered NaOH (25.3 g, 2.0 equiv.) was added at 5-10 °C. The mixture was stirred at 15-20 °C for an additional 0.5 h. Analysis showed complete conversion of starting material 10. The mixture was filtered and the filter cake was washed with acetonitrile (2 x 520 mL, 2 vol). The final solution (approximately 7.5 L, 28.8 vol) was concentrated to 1-2 vol while maintaining the temperature between 15-20 °C. The residue was then treated with acetonitrile (2 L, 7.7 vol) and the water content was checked by KF (KF: 5.7%). The mixture was filtered and the filter cake was washed with ACN (2 x 520 mL, 2 vol). The solution was then concentrated under vacuum at 15-20 °C to 1-2 vol. The water content was again checked by KF (KF: 5.5%). The solution was diluted with acetonitrile (390 mL, 1.5 vol) and added dropwise to MTBE (2.6 L, 10 vol) over 0.5 h while maintaining the temperature between 15-20 °C. The solvent was decanted to leave a viscous oil, which was redissolved in acetonitrile (520 mL, 2 vol) and added to MTBE (2.6 L, 10 vol). This process was repeated four more times. A viscous oil was obtained, which was finally dissolved in acetonitrile (520 mL, 2 vol), dried, and then concentrated under reduced pressure at 15-20° C. Residual solvent was then removed by evaporation with an oil pump at 15-20° C. After drying, 335 g of compound 11 was obtained as a yellowish solid (QNMR: 70%, 87% overall yield over two steps). LCMS (ES, m / z): 624.3 [M-TfONa-2Na+3H] + 1H-NMR(300MHz,Methanol-d4,ppm):δ7.97(dd,J=7.8,2.1Hz,2H),7.84(t,J=7.7Hz,1H),7.75(t,J=7.8Hz,1H),7.36(dd,J=7.8,1.1Hz,1H),7. 23(d,J=7.7Hz,1H),7.11(d,J=8.5Hz,2H),6.72(d,J=8.5Hz,2H),3.96(s,1H),3.83-3.36(m,18H),3.03-2.62(m,6H),2.55(d,J=14.3Hz,2H).

[0438] Preparation of compound 12 (TOPA-[C7]-phenylisothiocyanate sodium salt):

[0439] [ka]

[0440] TCDI (68.7 g, 1.4 equiv.) and acetonitrile (2.6 L, 8 vol.) were placed in a 10 L reaction vessel under nitrogen atmosphere at 15-20 °C. Compound 11 (330 g, Na) in acetonitrile (660 mL, 2 vol.) was added while maintaining the temperature at 15-20 °C. +A solution of 1,2-dichlorophenyl ether (salt, QNMR: 70%, 1.0 equiv.) was added dropwise over 30 min. The mixture was aged at 15-20 °C for 0.5 h. Analysis of the mixture (sample preparation: 30 μL solution + 300 μL ACN + 1 drop water) showed that the reaction had reached completion. The water content was checked by KF (KF: 0.19%). The solution was dried and concentrated under reduced pressure at 15-20 °C. The resulting residue was dissolved in acetonitrile (945 mL, 2.9 vol.) and the water content was measured by KF (KF: 0.34%). Isopropyl acetate (660 mL, 2 vol.) was added to the solution over 40 min at 15-20 °C. No nucleation was observed, and additional isopropyl acetate (6.6 L, 18 vol) was slowly charged dropwise over 40 min at 15-20° C., resulting in precipitation of product 12, which was collected by filtration as a yellowish solid. The solid was dissolved in acetonitrile (330 mL, 1 vol) and IPAc (6.6 L, 20 vol) was added dropwise over 40 min at 15-20° C. The mixture was filtered to give 230 g of product as a yellowish solid (LCAP: 80.99%, QNMR: 59%, 10% IPAc). The wet cake was dried under vacuum at 15-20° C. for 2 h to give 224 g of crude product 12 as a yellowish solid (LCAP: 80.9%, QNMR: 60.4%, approx. 6% IPAc). The crude product 12 was redissolved in acetonitrile (330 mL, 1 vol) and isopropyl acetate (412 mL, 1.25 vol) was added slowly dropwise over 40 min at 15-20 °C. The resulting mixture was filtered and 12 was recovered (30.5 g, HPLC = 60.9%, Assay: 25.5%). The mother liquor was diluted with isopropyl acetate (6.6 L, 20 vol) added over 40 min at 15-20 °C. The mixture was filtered and the cake was dried to give 173.5 g of crude product 12 as a yellowish solid (LCAP: 85.4%, QNMR: 66%, 3.9% IPAc, RRT1.19 = 3.9%). 190 g of crude product 12 was dissolved in 760 mL of acetonitrile:isopropyl acetate (2:1) and the mixture was passed through a silica gel column (380 g, 2x).The silica was flushed with acetonitrile:isopropyl acetate (2:1, 5.7 L) and then with 12 L of acetonitrile (very little product). The product-containing fractions were concentrated to give 118 g of product 12 as a yellowish solid (LCAP: 95%). The silica pad was then rinsed with MeCN / H2O (12 L, 10:1). The solvent was removed in vacuo to give an additional 60 g of crude product 12 as a yellowish solid, which was dissolved in acetonitrile (1.5 L), stirred for 30 min, and then filtered. The mother liquor was then concentrated to give 24 g of crude product 12 as a yellowish solid (LCAP=92%). Crude product 12 (118 g) and crude product 12 (24 g) prepared as above were dissolved in acetonitrile (330 mL, 1 vol) and isopropyl acetate (6.6 L, 20 vol) was added dropwise over 40 min at 15-20° C. The mixture was then filtered to give 133 g of product 12 as a yellowish solid of suitable purity (LCAP: 95%, QNMR: 60.8%, 7.8% IPAc). Note: Compound 12 required storage at −20° C. LCMS: (ES, m / z): 666.61 [M-TfONa-2Na+3H]. + 1 H-NMR: (400MHz, methanol-d4, ppm): δ8.00(ddd,J=13.8,7.7,1.0Hz,2H),7.84(dt,J=20. 4,7.7Hz,2H),7.58-7.49(m,2H),7.40(dd,J=7.6,1.0Hz,1H),7.36-7.28(m,2H),7.28 -7.20(m,1H),4.96(hept,J=6.3Hz,1H),3.96-3.88(m,1H),3.83(d,J=15.1Hz,1H),3. 70-3.52 (m, 11H), 3.55-3.39 (m, 4H), 3.07-2.73 (m, 6H), 2.62 (dt, J=15.1, 3.6Hz, 2H).

[0441] (Example 20) TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate

[0442] [ka]

[0443] (In the TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate above, the structure does not show the lysine residue of h11B6 linked to the phenylthiourea moiety.)

[0444] TOPA-[C7]-phenylthiourea modification of mAbs: h11b6 mAb (10.2 mg / mL) was diluted to 1 mg / mL in 10 mM sodium acetate pH 5.2 buffer. Just prior to conjugation, the pH was adjusted to pH 9 with sodium bicarbonate buffer (VWR 144-55-8). The pH was confirmed with pH paper. A 10-fold molar excess of disodium salt TOPA-[C7]-phenylisothiocyanate sodium salt (50 mM stock dissolved in water) was then added to h11b6 mAb, and the mixture of antibody and TOPA-[C7]-phenylisothiocyanate sodium salt was incubated for approximately 1 hour at room temperature without shaking. The addition of TOPA-[C7]-phenylisothiocyanate sodium salt was monitored by intact mass ESI-TOF LC-MS on an Agilent® G224 instrument until the CAR value was between 1.5 and 2.0. The mixture was immediately quenched by adding 1M Tris pH 8.5 (Teknova T1085) to a final concentration of 100 mM. Excess free chelator was removed by desalting the reaction in 10 mM sodium acetate pH 5.2 using a 7K Zeba® desalting column. Three sample dilutions to 15 mL were performed to confirm the absence of excess chelator, followed by concentration to 1 mL using a 50,000 MWCO Amicon concentrator. The sample was then concentrated to its final concentration for radiolabeling. The final conjugate was confirmed to be monomeric by analytical size exclusion chromatography on a Tosoh TSKgel G3000SWxl 7.8 mm x 30 cm, 5u column, column temperature: room temperature, column eluted with 0.2 M sodium phosphate (pH 6.8), flow rate: 0.8 mL / min, 18 min run, injection volume: 18 μL.

[0445] Example 21 Ac-225 labeled TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate

[0446] [ka]

[0447] (In the Ac-225 labeled TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate above, the structure does not show the lysine residue of h11B6 linked to the phenylthiourea moiety.) (i) Labeling of TOPA-[C7]-phenylthiourea-h11B6 with Ac-225 in 3M NaOAc buffer: To a solution of NaOAc (3M in HO, 60 μL) in a plastic vial, Ac-225 (10 mCi / mL in 0.1 N HCl, 15 μL) and TOPA-[C7]-phenylthiourea-h11B6 (1.13 mg / mL in 10 mM NaOAc pH=5.5, 441 μL, 0.5 mg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vial was left at 37° C. for 2 hours.

[0448] iTLC of the labeling reaction mixture: 0.5 μL of the labeling reaction mixture was loaded onto iTLC-SG, which was developed with 10 mM EDTA (pH 5-6). The dried iTLC-SG was left at room temperature overnight and then scanned on a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6-bound Ac-225 remained at the origin and any free Ac-225 migrated with the solvent to the solvent front. The iTLC scan showed that 99.9% of TOPA-[C7]-phenylthiourea-h11B6 was bound to Ac-225.

[0449] DTPA derivatization of the labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted on iTLC-SG and developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6 chelated Ac-225 remained at the origin and any free Ac-225 would have migrated with the solvent to the solvent front. The iTLC scan showed that 99.7% of TOPA-[C7]-phenylthiourea-h11B6 was chelated to Ac-225.

[0450] Purification on PD10 column: The PD-10 resin was conditioned with NaOAc buffer (25 mM NaOAc, 0.04% PS-20, pH 5.5) by passing 3×5 mL of NaOAc buffer through the column and discarding the washes. The entire labeling reaction mixture was applied to the reservoir of the column and the eluate was collected in pre-numbered plastic tubes. The reaction vial was washed 3×0.2 mL with NaOAc buffer (25 mM NaOAc, 0.04% PS-20, pH 5.5) and the washes were pipetted into the reservoir of the PD-10 column and the eluate was collected. Each tube contained approximately 1 mL of eluate. Continuous application of NaOAc buffer (25 mM NaOAc, 0.04% PS-20, pH 5.5) to the reservoir of the PD-10 column was performed until a total elution volume of 10 mL was reached. The radiochemical purity of the collected fractions was checked by iTLC. 10 uL of each collected fraction was spotted onto iTLC-SG and developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned on a Bioscan AR-2000 radio-TLC scanner. Pure fractions should have no radioactive signal at the solvent front of the iTLC-SG.

[0451] Refined 225 DTPA induction of Ac-TOPA-[C7]-phenylthiourea-h11B6: 10 μL of fraction #3 collected after the PD-10 column was mixed with 15 μL of 10 mM DTPA solution (pH 6.5) and incubated for 30 min. 10 μL of the mixture was loaded onto iTLC-SG, which was developed with 10 mM EDTA and dried overnight. It was scanned on a Bioscan AR-2000 radio-TLC scanner. No radioactive signal was observed at the solvent front of iTLC-SG, indicating that there was no free Ac-225 in fraction #3.

[0452] Refined 225 HPLC analysis of Ac-TOPA-[C7]-phenylthiourea-h11B6: Fraction #3 collected after the PD-10 column was analyzed by HPLC. HPLC method: Tosoh TSKgel G3000SWxl 7.8 mm x 30 cm, 5 μm column, column temperature: room temperature, the column was eluted with DPBS buffer (x1, calcium and magnesium free), flow rate: 0.7 mL / min, 20 min run, injection volume: 40 μL. After HPLC, fractions were collected at 30 sec or 1 min time intervals. The collected HPLC fractions were left overnight at room temperature. The radioactivity of each of the collected fractions was counted in a gamma counter. HPLC radioactivity traces were constructed from the radioactivity in each HPLC fraction. The HPLC radioactivity traces showed a radioactivity peak corresponding to the TOPA-[C7]-phenylthiourea-h11B6 peak on the HPLC UV trace.

[0453] (ii) Labeling of higher concentrations of TOPA-[C7]-phenylthiourea-h11B6 with Ac-225 in 1.5M NaOAc buffer: To a solution of NaOAc (1.5M in HO with 0.04% PS-20, 63 μL) in a plastic vial, Ac-225 (10 mCi / mL in 0.1 N HCl, 10 μL) and TOPA-[C7]-phenylthiourea-h11B6 (9.36 mg / mL in 10 mM NaOAc pH=5.2, 0.04% PS-20, 36 uL, 337 μg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vial was left at 37° C. for 2 hours.

[0454] iTLC of the labeling reaction mixture: Next, 0.5 μL of the labeling reaction mixture was loaded onto iTLC-SG, which was developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned on a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6-bound Ac-225 remained at the origin, and any free Ac-225 would have migrated with the solvent to the solvent front. The iTLC scan showed that 99.9% of TOPA-[C7]-phenylthiourea-h11B6 was bound to Ac-225.

[0455] DTPA derivatization of the labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted on iTLC-SG and developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6 chelated Ac-225 remained at the origin and any free Ac-225 would have migrated with the solvent to the solvent front. The iTLC scan showed that 99.9% of TOPA-[C7]-phenylthiourea-h11B6 was chelated to Ac-225.

[0456] (iii) Labeling of higher concentrations of TOPA-[C7]-phenylthiourea-h11B6 with Ac-225 in 1M NaOAc buffer: To a solution of NaOAc (1.0M in HO with 0.04% PS-20, 63 μL) in a plastic vial, Ac-225 (10 mCi / mL in 0.1 N HCl, 10 μL) and TOPA-[C7]-phenylthiourea-h11B6 (9.36 mg / mL in 10 mM NaOAc pH=5.2, 0.04% PS-20, 36 uL, 337 μg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vial was left at 37° C. for 2 hours.

[0457] iTLC of the labeling reaction mixture: Next, 0.5 μL of the labeling reaction mixture was loaded onto iTLC-SG, which was developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned on a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6-bound Ac-225 remained at the origin, and any free Ac-225 would have migrated with the solvent to the solvent front. The iTLC scan showed that 99.9% of TOPA-[C7]-phenylthiourea-h11B6 was bound to Ac-225.

[0458] DTPA derivatization of the labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted on iTLC-SG and developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6 chelated Ac-225 remained at the origin and any free Ac-225 would have migrated with the solvent to the solvent front. The iTLC scan showed that 99.9% of TOPA-[C7]-phenylthiourea-h11B6 was chelated to Ac-225.

[0459] Labeling of higher concentrations of TOPA-[C7]-phenylthiourea-h11B6 with Ac-225 in 25 mM NaOAc buffer (containing 0.4% tween-20, pH 5.5): To a solution of NaOAc (25 mM in HO, pH 5.5, 0.04% PS-20, 10 μL) in a plastic vial, Ac-225 (10 mCi / mL in 0.1 N HCl, 5 μL), TOPA-[C7]-phenylthiourea-h11B6 (10.4 mg / mL in 10 mM NaOAc, pH=5.2, 16 uL, 166 μg), and NaOH (0.1 M, 5 μL) were added sequentially. After mixing, the pH was approximately 6.0 by pH paper. The vial was left at 37° C. for 2 hours.

[0460] iTLC of the labeling reaction mixture: Next, 0.5 μL of the labeling reaction mixture was loaded onto iTLC-SG, which was developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned on a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6-bound Ac-225 remained at the origin, and any free Ac-225 would have migrated with the solvent to the solvent front. The iTLC scan showed that 99.9% of TOPA-[C7]-phenylthiourea-h11B6 was bound to Ac-225.

[0461] DTPA derivatization of the labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted on iTLC-SG and developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6 chelated Ac-225 remained at the origin and any free Ac-225 would have migrated with the solvent to the solvent front. The iTLC scan showed that 99.8% of TOPA-[C7]-phenylthiourea-h11B6 was chelated to Ac-225.

[0462] [Table 8]

[0463] Example 22 The following series of experiments was conducted to investigate the effect of the presence of non-radioactive metal impurities associated with the actinium sources of TOPA and DOTA chelating macrocycles. 225 Al, the four most important impurities found in the ORNL source of Ac(NO3)3 3+ , Ca 2+ , Zn 2+ , Mg 2+ was used as a spike standard in the chelation reaction of DOTA and TOPA conjugated to h11b6. The chelation results were monitored by iTLC and then triggered with DTPA.

[0464] Chelation of TOPA-[C7]-phenylthiourea-h11b6 with Ac-225 in the presence of metal impurities (low concentration impurities).

[0465] [ka]

[0466] (In the Ac-225 labeled TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate above, the structure does not show the lysine residue of h11B6 linked to the phenylthiourea moiety.) Ac-225 was dissolved in 0.1M HCl and mixed with AlCl3, CaCl2, ZnCl2, and MgCl2 to form a 5 mCi / mL solution. The concentrations of aluminum, calcium, zinc, and magnesium are 9.76 μg / mCi, 3.83 μg / mCi, 0.61 μg / mCi, and 0.27 μg / mCi, respectively. To a solution of NaOAc (3M in H2O, 20 μL) in a plastic vial, Ac-225 (5 mCi / mL in 0.1N HCl, 10 μL, with added metal impurities) and TOPA-[C7]-phenylthiourea-h11b6 (1.17 mg / mL in 10 mM NaOAc pH=5.5, 143 μL, 0.167 mg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vials were placed at 37° C. for 2 hours.

[0467] iTLC of the labeling reaction mixture: Next, 0.5 μL of the labeling reaction mixture was loaded onto iTLC-SG and developed with 10 mM EDTA solution. The iTLC-SG was dried overnight at room temperature and then scanned on a Bioscan AR-2000 radioactive TLC scanner. Under the elution conditions described herein, Ac-225 bound to TOPA-[C7]-phenylthiourea-h11b6 Ac-225 will remain at the origin (baseline) of the TLC, and any free Ac-225 will migrate with the solvent to the solvent surface. The iTLC scan showed that 99.5% of Ac-225 was bound to TOPA-[C7]-phenylthiourea-h11b6 (scan 1, shown in FIG. 5).

[0468] DTPA derivatization of the labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted onto iTLC-SG and developed with 10 mM EDTA eluent. The iTLC-SG was air-dried and left at room temperature overnight before scanning with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11b6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 99.4% of Ac-225 was bound to TOPA-[C7]-phenylthiourea-h11b6 (scan 2, shown in FIG. 6).

[0469] Metal addition experiment: Labeling of TOPA-[C7]-phenylthiourea-h11b6 with Ac-225 in the presence of metal impurities (higher concentration of impurity, 5-fold increase compared to lower concentration of impurity).

[0470] [ka]

[0471] Ac-225 was dissolved in 0.1M HCl and mixed with AlCl3, CaCl2, ZnCl2, and MgCl2 to form a 5 mCi / mL solution. The concentrations of aluminum, calcium, zinc, and magnesium are 45.0 μg / mCi, 17.3 μg / mCi, 3.01 μg / mCi, and 1.15 μg / mCi, respectively. To a solution of NaOAc (3M in H2O, 20 μL) in a plastic vial, Ac-225 (5 mCi / mL in 0.1N HCl, 10 μL, with added metal impurities) and TOPA-[C7]-phenylthiourea-h11b6 (1.17 mg / mL in 10 mM NaOAc pH=5.5, 143 μL, 0.167 mg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vials were placed at 37° C. for 2 hours.

[0472] iTLC of the labeling reaction mixture: Next, 0.5 μL of the labeling reaction mixture was loaded onto iTLC-SG and developed with 10 mM EDTA solution. The iTLC-SG was dried overnight at room temperature and then scanned on a Bioscan AR-2000 radioactive TLC scanner. Under the elution conditions described herein, Ac-225 bound to TOPA-[C7]-phenylthiourea-h11b6 Ac-225 will remain at the origin (baseline) of the TLC, and any free Ac-225 will migrate with the solvent to the solvent front. The iTLC scan showed that 98.9% of Ac-225 was bound to TOPA-[C7]-phenylthiourea-h11b6 (scan 3, shown in FIG. 7).

[0473] DTPA derivatization of the labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted onto iTLC-SG and developed with 10 mM EDTA eluent. The iTLC-SG was air-dried and left at room temperature overnight before scanning with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11b6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 99.8% of Ac-225 was bound to TOPA-[C7]-phenylthiourea-h11b6 (scan 4, shown in FIG. 8).

[0474] Labeling of DOTA-h11b6 with Ac-225 in the presence of metal impurities (low concentration impurities).

[0475] [ka]

[0476] Ac-225 was dissolved in 0.1M HCl and mixed with AlCl3, CaCl2, ZnCl2, and MgCl2 to form a 5 mCi / mL solution. The concentrations of aluminum, calcium, zinc, and magnesium are 9.76 μg / mCi, 3.83 μg / mCi, 0.61 μg / mCi, and 0.27 μg / mCi, respectively. To a solution of NaOAc (3M in H2O, 20 μL) in a plastic vial, Ac-225 (5 mCi / mL in 0.1N HCl, 10 μL, with added metal impurities) and DOTA-h11b6 (10 mg / mL in 25 mM NaOAc pH=5.5, 16.7 μL, 0.167 mg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vial was left at 37° C. for 2 hours.

[0477] iTLC of the labeling reaction mixture: Next, 0.5 μL of the labeling reaction mixture was loaded onto iTLC-SG and developed with 10 mM EDTA solution. The iTLC-SG was dried overnight at room temperature and then scanned on a Bioscan AR-2000 radioactive TLC scanner. Under the elution conditions described herein, Ac-225 bound to DOTA-h11b6 Ac-225 will remain at the origin (baseline) of the TLC, and any free Ac-225 will migrate with the solvent to the solvent front. The iTLC scan showed that 43.6% of Ac-225 was chelated to DOTA-h11b6 (scan 5, shown in FIG. 9).

[0478] DTPA derivatization of the labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted onto iTLC-SG and developed with 10 mM EDTA eluent. The iTLC-SG was air-dried and left at room temperature overnight before scanning with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, DOTA-h11B6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 18.1% of Ac-225 was chelated to DOTA-h11b6 (scan 6, shown in FIG. 10).

[0479] Metal addition experiment: Labeling of DOTA-h11b6 with Ac-225 in the presence of metal impurities (higher concentration of impurity, 5-fold increase compared to lower concentration of impurity).

[0480] [ka]

[0481] Ac-225 was dissolved in 0.1M HCl and mixed with AlCl3, CaCl2, ZnCl2, and MgCl2 to form a 5 mCi / mL solution. The concentrations of aluminum, calcium, zinc, and magnesium are 45.0 μg / mCi, 17.3 μg / mCi, 3.01 μg / mCi, and 1.15 μg / mCi, respectively. To a solution of NaOAc (3M in H2O, 20 μL) in a plastic vial, Ac-225 (5 mCi / mL in 0.1N HCl, 10 μL, with added metal impurities) and DOTA-h11b6 (10 mg / mL in 25 mM NaOAc pH=5.5, 16.7 μL, 0.167 mg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vial was left at 37° C. for 2 hours.

[0482] iTLC of the labeling reaction mixture: Next, 0.5 μL of the labeling reaction mixture was loaded onto iTLC-SG and developed with 10 mM EDTA solution. The iTLC-SG was dried overnight at room temperature and then scanned on a Bioscan AR-2000 radioactive TLC scanner. Under the elution conditions described herein, Ac-225 bound to DOTA-h11b6 Ac-225 will remain at the origin (baseline) of the TLC, and any free Ac-225 will migrate with the solvent to the solvent front. The iTLC scan showed that 52.7% of Ac-225 was chelated to DOTA-h11b6 (scan 7, shown in FIG. 11).

[0483] DTPA derivatization of the labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted onto iTLC-SG and developed with 10 mM EDTA eluent. The iTLC-SG was air-dried and left at room temperature overnight before scanning with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, DOTA-h11B6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 14.0% of Ac-225 was chelated to DOTA-h11b6 (scan 8, shown in FIG. 12).

[0484] Example 23

[0485] [ka]

[0486] Labeling of TOPA-h11b6 with Ce-134: To a solution of Ce-134 in 0.1 M HCl (65 μL, 0.245 mCi) in a plastic vial, 0.1 M NaOH (45 μL) was added, followed by a mixed solution of TOPA-h11b6 (10.4 mg / mL in 10 mM NaOAc pH=5.2, CAR=1.72, 160 μL) and NaOAc (0.5 M in HO, 930 μL). After mixing, the pH was approximately 6.5 by pH paper. The vial was incubated in a Thermomixer at 300 rpm for 2 hours at 37°C.

[0487] iTLC of the labeling reaction mixture: At 30 min and 1 h, 2 μL of the reaction solution was spotted onto a TLC strip (SA) and eluted with 10 mM EDTA solution (pH approx. 6). Scanning of the iTLC on an AR-2000 radioactive TLC scanner showed that 96.7% of Ce-134 was chelated to TOPA-h11b6 at 30 min and 97.1% was chelated at 1 h.

[0488] Purification on PD10 column: PD-10 resin was conditioned in formulation buffer (25 mM NaOAc, 0.04% PS-20, pH 5.5) by passing 5 mL x 3 of formulation buffer through the column and discarding the wash. The entire labeling reaction mixture was applied to the reservoir of the column and the eluate was collected in a plastic vial labeled "Load". An additional 2 mL of formulation buffer was added and the flow-through was collected in the same "Load" vial. The column was eluted with an additional 2 mL of formulation buffer into a vial labeled "Elution". Finally, the column was finally eluted with another 2 mL of formulation buffer into a vial labeled "Elution2". The radioactivity in vial "Elution" was measured with a Biodex dose calibrator to be 0.176 mCi (72% radiochemical yield).

[0489] 134 Ce-TOPA-h11b6 and 134 Analysis of Ce-DOTA-h11b6: Refined134 Ce-TOPA-h11b6 and 134 iTLC analysis of the Ce-DOTA-h11b6 product showed different results depending on the time period between the iTLC development and the time the TLC scan was performed. As shown in Figure 13, a TLC scan immediately after the iTLC development showed a peak at the solvent front. A rescan of the iTLC after 1 hour showed the absence of a solvent front peak (Figure 14). On this basis, it was concluded that the solvent front peak was due to the release of free La-134 formed during the decay of Ce-134 by electron capture to the solvent front. The free La migrates from the cheated cerium-134 to the solvent surface where it eventually decays completely to barium-134 after about 10 half-lives or about 1 hour.

[0490] Refined 134 DTPA induction of Ce-TOPA-h11b6: Immediately after purification, 25 uL of purified product in vial "Elution" was incubated with 50 uL of either 10 mM EDTA, pH 6 or 10 mM DTPA, pH 7 for 30 minutes at 37°C and 300 rpm. 2 μL of the mixture was spotted onto a TLC strip (SA) and eluted with 10 mM EDTA solution (pH 6). Scanning of the iTLC on an AR-2000 radioactive TLC scanner showed 91.0% recovery after EDTA induction. 134 Ce-TOPA-h11b6 showed 89.0% after DTPA induction.

[0491] purification 134 Stability of Ce-TOPA-h11b6: purification 134 Ce-TOPA-h11b6 was stored at 2-8° C. Radiochemical purity was assessed by iTLC. The radiochemical purity at 4 hours was 99.1% (FIG. 15).

[0492] Labeling of DOTA-h11b6 with Ce-134:

[0493] [ka]

[0494] To a solution of Ce-134 in 0.1 M HCl (65 μL, 0.245 mCi) in a plastic vial, 0.1 M NaOH (45 μL) was added, followed by a mixed solution of DOTA-h11b6 (10 mg / mL, 25 mMol NaOAc, CAR=2.3, 100 μL) and NaOAc (0.5 M in HO, 990 μL). After mixing, the pH was approximately 6.5 by pH paper. The vial was incubated in a Thermomixer at 300 rpm for 2 hours at 37°C.

[0495] iTLC of the labeling reaction mixture: At 30 min and 1 h, 2 μL of the reaction solution was spotted onto TLC strips (SA) and eluted with 10 mM EDTA solution, pH approx. 6. Scanning of the iTLC on an AR-2000 radioactive TLC scanner showed 98.8% DOTA-h11b6-bound Ce-134 at 30 min and 97.4% at 1 h.

[0496] Purification on PD10 column: PD-10 resin was conditioned in formulation buffer (25 mM NaOAc, 0.04% PS-20, pH 5.5) by passing 5 mL x 3 of formulation buffer through the column and discarding the wash. The entire labeling reaction mixture was applied to the reservoir of the column and the eluate was collected in a plastic vial labeled "Load". An additional 2 mL of formulation buffer was added and the flow-through was collected in the same "Load" vial. The column was eluted with an additional 2 mL of formulation buffer into the vial labeled "Elute". Finally, the column was finally eluted with another 2 mL of formulation buffer into the vial labeled "Elute 2". The radioactivity in vial "Elute" was measured with a Biodex dose calibrator to be 0.164 mCi (67% radiochemical yield).

[0497] Refined 134 DTPA induction of Ce-DOTA-h11b6: Immediately after purification, 25 uL of purified product in the vial "Elution" was incubated with 50 uL of either 10 mM EDTA, pH 6 or 10 mM DTPA, pH 7, at 37°C and 300 rpm for 30 minutes. 2 μL of the mixture was spotted onto a TLC strip (SA) and eluted with 10 mM EDTA solution (pH 6). Scanning of the iTLC on an AR-2000 radioactive TLC scanner showed 90.0% elution after EDTA induction. 134 Ce-TOPA-h11b6 showed 89.4% after DTPA induction.

[0498] purification 134 Stability of Ce-DOTA-h11b6: purification 134 Ce-DOTA-h11b6 was stored at 2-8° C. Radiochemical purity was assessed by TLC. The radiochemical purity at 4 hours was 96.3% (FIG. 16).

[0499] Immediately after synthesis (0 hours) and 24 hours after synthesis, purified 134 Determination of immunoreactive fraction of Ce-DOTA-h11b6: Preparation of control beads: Two 2 ml Eppendorf tubes, labeled C1 and C2, were each rinsed with 1 mL of 1% PBSF and the rinse was discarded. To each rinsed tube, 300 μL of 1% PBSF was added. To C1 and C2, 40 uL of Dynabeads Streptavidin T1 (MS0013) was added.

[0500] QC sample preparation: To a 2 ml Eppendorf tube, 1 mL of 1% PBSF was added, rinsed, and the rinse was discarded. An additional aliquot of 1% PBSF (1000 μL) was added, followed by a sample of 134Ce-TOPA-h11b6 (5 μL). The tube was capped and gently swirled.

[0501] Preparation of reference vials: To each of three 2 ml Eppendorf tubes labeled RF1, RF2, and RF3, 1 mL of 1% PBSF was added and the rinse was discarded. To each rinsed tube, 700 μL of 1% PBSF was added. To each of the three tubes, an aliquot (25 μL) of the QC sample was added.

[0502] To check the accuracy of the method, the following was used: A gamma counter was calibrated to Ac-225. Each of the three reference vials was placed in the gamma counter. The relative standard deviation % was calculated to be <10%.

[0503] Preparation of P1, P2 and C1 & C2 tubes for incubation: Two 2 ml Eppendorf tubes, labeled P1 and P2, were each rinsed with 1 mL of 1% PBSF and the rinse was discarded. To each rinsed tube, 1% PBSF (300 μL) was added. To P1 and P2, pre-thawed and pre-mixed biotinylated hk2-FXa coated Dynabeads (40 μL) were added. To each of the two tubes, an aliquot of QC sample (25 μL) was added. To tubes C1 and C2, an aliquot of QC sample (25 μL) was added. All four tubes were incubated at room temperature for 30 minutes on a shaker at 50 RPM and 14 degree tilt.

[0504] After incubation, each tube was centrifuged at 100g for 15 seconds. The tubes were placed in a magnetic rack to immobilize the beads, and the supernatant was removed from each tube (365 μL) and transferred to separate tubes labeled P1-SUP, P2-SUP, C1-SUP, and C2-SUP. To each of the centrifuged tubes, 1% PBSF (365 uL) was added again, recentrifuged again, returned to the magnetic rack, and the supernatant was once again removed and transferred to tubes labeled P1R1, P2R1, C1R1, and C2R1. This process was repeated, and the supernatant was once again removed and placed in tubes labeled P1R2, P2R2, C1R2, and C2R2. Finally, 1% PBSF (365 uL) was added to tubes P1, P2, and C1 and C2, and the contents were vortexed to create a suspension. The contents were then transferred to tubes labeled P1BD, P2BD, C1BD and C2BD. The tubes were rinsed again with 1% PBSF (365 μL) and transferred to P1R2, P2R2, C1R2 and C2R2 and capped.

[0505] Tubes RF1, RF2, RF3, BCK1, BCK2, BCK3, C1, C1-SUP, C1R1, C1R2, C1BD, C2, C2-SUP, C2R1, C2R2, C2BD, P1, P1-SUP, P1R1, P1R2, P1BD, P2, P2-SUP, P2R1, P2R2 and P2BD were placed in a gamma counter and counted.

[0506] Background was subtracted from all measurements. The average reference count was determined. Non-specific binding was calculated by dividing the average of C1BD and C2BD by the average reference RF1, RF2 and RF3 divided by 3. Total binding was calculated by dividing the average of P1BD+P2BD by the average reference. Immunoreactivity was calculated by subtracting total non-specific binding from total binding and multiplying by 100. The results of the Immunoreactive Fraction (IRF) at 0 hours (95.5%) and 24 hours (96.5%) after synthesis are shown in Tables B and C: Table B: 134 Immunoreactive fraction at T=0 hours for Ce-TOPA-h11b6, and Table C: 134 Immunoreactive fraction at T=24 hours for Ce-TOPA-h11b6.

[0507] (Example 24)

[0508] [ka]

[0509] PSMB1154, a human IgG1 mAb that binds to human prostate-specific membrane antigen (PSMA), was reacted with TOPA-NCS essentially as described in Example 20 to yield the TOPA-PSMB1154 conjugate.

[0510] Radiolabeling of TOPA-PSMB1154 with Ce-134: 134 CeCl3 (30 mCi in 1.55 mL of 0.1 N HCl, specific activity = 13169 Ci / g) was received from Oak Ridge National Laboratory.

[0511] To a solution of NaOAc (1M, 1.15 mL, pH=8.3) in a plastic vial was added the above 134CeCl3 solution in 0.1 N HCl (600 μμL, 10 mCi). The mixture was measured to have a pH=6.0. TOPA-PSMB1154 (214 μL, 11.2 mg / mL, 2.4 mg) was added and the reaction was left at 25° C. for 30 minutes. An aliquot (2 μL) of the reaction solution was spotted onto an iTLC strip and the TLC was developed with 10 mM EDTA solution (pH approx. 6). A scan of the iTLC 2 hours after its development on an AR-2000 radioactive TLC scanner showed 99.7% TOPA-PSMB1154-bound Ce-134.

[0512] In PD10 column 134 Purification of Ce-TOPAPSMB1154: The PD-10 resin was conditioned in formulation buffer (25 mM NaOAc, 0.04% PS-20, pH 5.5) by passing 5 mL x 3 of formulation buffer through the column and discarding the wash. The entire labeling reaction mixture was applied to the reservoir of the column and the column was eluted with formulation buffer. The product received after the PD-10 column was diluted to 4.0 mL with formulation buffer (25 mM NaOAc, 0.04% PS-20, pH 5.5). The diluted solution was filtered through a 0.2 μm filter to obtain the formulation solution. 134 Ce-TOPA-PSMB1154 was obtained. The radioactivity concentration of the formulation solution was 1.8 mCi / mL, and the measured pH was 5.50.

[0513] formulation 134 DTPA induction of Ce-TOPA-PSMB1154: Formulation Solution 134 An aliquot of Ce-TOPA-PSMB1154 (25 μL) was incubated with 10 mM DTPA, pH=6 (50 μL) for 30 min at room temperature. The mixture (2 μL) was spotted onto an iTLC strip and the TLC was developed with 10 mM EDTA solution (pH approx. 6). Scanning of the iTLC 2 h after its development on an AR-2000 radioactive TLC scanner showed 99.9% TOPA-PSMB1154-bound Ce-134.

[0514] Formulation Solution 134 Ce-TOPA-PSMB1154 was kept at 2-8° C. for about 24 hours. After it was equilibrated to room temperature, DTPA induction according to the above procedure showed 99.4% TOPA-PSMB1154-bound Ce-134.

[0515] Formulations at t=0 and t=24 hours 134 HPLC analysis of Ce-TOPA-PSMB1154: HPLC system: Agilent / Lablogic Flow RAM (FR-1A). HPLC method: Column: AdvanceBio SEC 300A, 2.7 μm, 7.8 × 300 mm, mobile phase: phosphate buffer, pH 6.8, flow rate: 1 mL / min, column temperature: 25 °C, injection volume: 20 μL.

[0516] At time t=0, the drug product 134 The radiochemical purity of Ce-TOPA-PSMB1154 was 99.7% and the corresponding chemical purity by UV trace at 280 nm was 99.8%.

[0517] The formulation solution was kept for approximately 24 hours at 2-8° C. After equilibrating to room temperature, 100 μL of the formulation solution was analyzed by HPLC.

[0518] At t=24 hours, 134 The radiochemical purity of Ce-TOPA-PSMB1154 was 98.3% and the corresponding chemical purity by UV trace at 280 nm was 96.5%.

[0519] formulation 134 HPLC IRF assay of Ce-TOPA-PSMB1154: 55 μL of the drug product solution was mixed with 40 μL of the antigen solution (1.03 mg / mL). The mixture was allowed to stand at room temperature for 20 minutes. HPLC radioanalysis of the solution showed a 96.5% 134 The radiochromatogram showed that Ce-TOPA-PSMB1154 was bound.

[0520] In human serum, cynomolgus monkey serum, and mouse serum, 134 Stability of Ce-TOPA-PSMB1154: Human, mouse, and cynomolgus serum were removed from a -20°C refrigerator and allowed to thaw at room temperature for 2 hours. Serum was filtered through a 0.2 μm filter before use in stability studies. Formulation buffer (25 mM NaOAc + 0.04% PS-20, pH 5.5) was also sterilized by filtering through a 0.2 μm filter before use in stability studies.

[0521] Formulation Solution 134 To an aliquot of Ce-TOPA-1154 (0.1 mL, approximately 145 uCi) was added 1.35 mL of filtered formulation buffer. 134Using a dilute solution of Ce-TOPA-1154 (0.1 mCi / mL), the following four solutions were prepared: 1. 134 A diluted solution of Ce-TOPA-1154 (0.1 mCi / mL, 0.1 mL) + 0.1 mL of filtered formulation buffer. The mixed solution was stored in a refrigerator at 4°C. 2. 134 A diluted solution of Ce-TOPA-1154 (0.1 mCi / mL, 0.1 mL) + 0.1 mL of filtered human serum. The mixture was kept at 37°C. 3. 134 A diluted solution of Ce-TOPA-1154 (0.1 mCi / mL, 0.1 mL) + 0.1 mL of filtered mouse serum. The mixture was kept at 37°C. 4. 134 A diluted solution of Ce-TOPA-1154 (0.1 mCi / mL, 0.1 mL) + 0.1 mL of filtered cynomolgus monkey serum. The mixture was maintained at 37°C.

[0522] iTLC without DTPA induction: 5-10 μL of each of the four solutions (1, 2, 3, and 4) were spotted onto iTLC strips at t=0, 24, and 96 hours, respectively. Each TLC was developed using 10 mM EDTA. Each TLC was scanned on a Lablogic Scan-RAM Radio TLC scanner >1 hour after development.

[0523] iTLC with DTPA induction: At t = 0, 24, and 96 hours, 30 μL of each of the above four solutions (1, 2, 3, and 4) was mixed with 10 μL of 10 mM DTPA solution (pH 6.5), respectively. The solutions were incubated at room temperature for 30 minutes, after which 5-10 μL of each solution was spotted onto an iTLC strip, respectively. Each TLC was developed using 10 mM EDTA. Each TLC was scanned on a Lablogic Scan-RAM Radio TLC scanner >1 hour after its development.

[0524] Radioactivity at the TLC starting point is 134The radioactivity at the solvent surface is free or loosely bound Ce-134. The table below shows the serum stability results.

[0525] [Table 9] The results are as follows: 134 Expressed as % of Ce-TOPA-1154. ( * ): The low signal-to-noise ratio affected the data accuracy.

[0526] (Example 25)

[0527] [ka]

[0528] Radiolabeling of TOPA-B23B62 with Ce-134: 134 CeCl3 (30 mCi in 1.55 mL of 0.1 N HCl, specific activity = 13169 Ci / g) was received from Oak Ridge National Laboratory.

[0529] To a solution of NaOAc (1M, 1.15 mL, pH=8.3) in a plastic vial was added the above 134CeCl3 solution in 0.1 N HCl (600 μμL, 10 mCi). The mixture was measured to have a pH=6.0. TOPA-B23B62 (245 μL, 9.8 mg / mL, 2.4 mg) was added and the reaction was left at 25° C. for 30 min. An aliquot (2 μL) of the reaction solution was spotted onto an iTLC strip and the TLC was developed with 10 mM EDTA solution (pH approx. 6). Scanning of the iTLC 2 hours after its development on an AR-2000 radioactive TLC scanner showed 99.7% TOPA-B23B62-bound Ce-134.

[0530] In PD10 column 134 Purification of Ce-TOPA-B23B62: The PD-10 resin was conditioned in formulation buffer (25 mM NaOAc, 0.04% PS-20, pH 5.5) by passing 5 mL x 3 of formulation buffer through the column and discarding the wash. The entire labeling reaction mixture was applied to the reservoir of the column, and then the column was eluted with formulation buffer. The product received after the PD-10 column was diluted to 4.0 mL with formulation buffer (25 mM NaOAc, 0.04% PS-20, pH 5.5). The diluted solution was filtered through a 0.2 μm filter to obtain the formulation solution. 134 Ce-TOPA-B23B62 was obtained. The radioactivity concentration of the formulation solution was 1.2 mCi / mL, and the measured pH was 5.56.

[0531] formulation 134 DTPA induction of Ce-TOPA-B23B62: Formulation Solution 134 An aliquot of Ce-TOPA-B23B62 (25 μL) was incubated with 10 mM DTPA, pH=6 (50 μL) for 30 min at room temperature. The mixture (2 μL) was spotted onto an iTLC strip and the TLC was developed with 10 mM EDTA solution (pH approx. 6). Scanning of the iTLC 2 h after its development on an AR-2000 radioactive TLC scanner showed 99.9% TOPA-B23B62-bound Ce-134.

[0532] The formulation solution was kept for approximately 24 hours at 2-8° C. After it was equilibrated to room temperature, DTPA induction according to the procedure described above showed 99.4% TOPA-B23B62-bound Ce-134.

[0533] Formulations at t=0 and t=24 hours 134 HPLC analysis of Ce-TOPA-B23B62: HPLC system: Agilent / Lablogic Flow RAM (FR-1A). HPLC method: Column: AdvanceBio SEC 300A, 2.7 μm, 7.8 × 300 mm, mobile phase: phosphate buffer, pH 6.8, flow rate: 1 mL / min, column temperature: 25 °C, injection volume: 20 μL.

[0534] At time t=0, the drug product134 The radiochemical purity of Ce-TOPA-B23B62 was 98.8% and the corresponding chemical purity by UV trace at 280 nm was 99.2%.

[0535] The formulation solution was kept for approximately 24 hours at 2-8° C. After equilibrating to room temperature, 100 μL of the formulation solution was analyzed by HPLC.

[0536] At t=24 hours, 134 The radiochemical purity of Ce-B23B62 was 91.8% and the corresponding chemical purity by UV trace at 280 nm was 89.2%.

[0537] formulation 134 HPLC IRF assay of Ce-TOPA-B23B62: 55 μL of drug product solution was mixed with 40 μL of antigen solution (1.03 mg / mL). The mixture was allowed to stand at room temperature for 20 minutes. HPLC radioanalysis of the solution revealed no binding to the antigen. 134 No binding of Ce-TOPA-B23B62 was observed.

[0538] (Example 26) Tumor cell culture: The human prostate cancer cell line LNCaP-C4-2B-luc was obtained from MD Anderson Cancer Center. Cell surface PSMA antigen expression was confirmed by internal analysis in LNCaP-C4-2B cells. LNCaP-C4-2B-luc cells were grown in RPMI 1640+GlutaMAX containing 10% heat-inactivated fetal bovine serum and harvested during logarithmic growth. On the day of tumor implantation, LNCaP-C4-2B-luc cells were cultured at 1×10 in chilled 50% Cultrex / 50% serum-free medium. 7 Resuspend at a concentration of 1 x 10 cells / mL in 0.1 mL. 6Tumor cells were delivered to male non-obese diabetic (NOD) severe combined immunodeficient (scid) gamma or NOD.CgPrkdc mice. scid Il2rg tm1Wjl The cells were subcutaneously transplanted into the right flank of . / SzJ(NSG) mice (The Jackson Laboratory). The day of transplantation was designated as day 0.

[0539] On day 19 after tumor cell implantation, all groups had a tumor size of 133 mm 3 Mice were randomized according to tumor volume into groups of 4 animals each, so that the tumor volume had a mean value of 0.01 to 0.01. 134 Ce-TOPA-1154 or 134 They received a single IV injection of Ce-TOPA isotype control antibody. To compensate for the low Ig environment in immunodeficient NSG mice, all mice received a Fragment crystallizable (Fc) block at 0.2 mg / mouse IP and a human immunoglobulin injection at 10 mg / mouse IP at least 30 minutes prior to antibody administration.

[0540] Example 27 PET / CT Imaging: 8MBq in 200μl PBS 134 Ce]-Topa-1154 or 8MBq[ 134 Longitudinal small animal PET / CT imaging (GNEXT2, Sofie, Dulles, VA) was performed after iv injection of either [Ce]-Topa-isotype. Animals were anesthetized with 1.5% isoflurane (Covetrus, North Dublin, OH) in O2 (1 L / min) during injection and PET / CT imaging. PET data were acquired for 15 m (early time point) and 30 m (late time point) and CT was acquired using standard settings.

[0541] CT-based attenuation correction and normalization, dead time, positron branching ratio ( 134Images were reconstructed using an ordered subset expectation-maximization algorithm with La = 1.27) and decay correction.

[0542] Image generation and analysis were performed using PMOD (Switzerland) (Figure 19). Volumes Of Interest (VOI) were generated over the heart, liver, and tumor using CT scanning, but no partial volume correction was applied. Count rates in processed images were converted to percentage of injected activity per gram of tissue (% of IA / g) using system calibration coefficients obtained by imaging a cylinder filled with injection solution of known concentration (1 Mbq / ml). Graphs were generated using GraphPad Prism v8 (San Diego, CA) (Figure 20).

[0543] While the foregoing specification, together with examples given for purposes of illustration, teaches the principles of the invention, it will be understood that the practice of the invention encompasses all ordinary variations, adaptations and / or modifications that come within the scope of the following claims and equivalents thereto.

[0544] Throughout this application, various publications are cited. The disclosures of these publications are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

Claims

1. Formula (I-M + ): 【Chemistry 1】 [In the formula, M + However, cerium-134 ( 134 1. The radioactive metal ion is R 1 is hydrogen and R 2 But, -L 1 -R 4 and Or, R 1 But, -L 1 -R 4 And R 2 is hydrogen, R 3 is hydrogen, Or, R 2 and R 3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, said 5- or 6-membered cycloalkyl being -L 1 -R 4 and optionally replaced by L 1 is absent or is a linker, R 4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand. or a pharma- ceutically acceptable salt thereof.

2. Formula (II-M + ): 【Chemistry 2】 [In the formula, M + However, cerium-134 ( 134 1. The radioactive metal ion is L 1 is absent or is a linker, R 4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.

2. The radioactive metal complex of claim 1, wherein:

3. Formula (III-M + ): 【Chemistry 3】 [In the formula, M + However, cerium-134 ( 134 1. The radioactive metal ion is L 1 is absent or is a linker, R 4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.

2. The radioactive metal complex of claim 1, wherein:

4. M + However, cerium-134 ( 134 1. The radioactive metal ion is R 1 But, -L 1 -R 4 and R 2 and R 3 together with the carbon atom to which they are attached form a 5-membered cycloalkyl; L 1 is absent or is a linker, R 4 2. The radiometal complex of claim 1, or a pharma- ceutically acceptable salt thereof, wherein is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.

5. M + However, cerium-134 ( 134 1. The radioactive metal ion is R 1 is H, R 2 and R 3 together with the carbon atom to which they are attached, -L 1 -R 4 forming a 6-membered cycloalkyl substituted with L 1 is absent or is a linker, R 4 2. The radiometal complex of claim 1, or a pharma- ceutically acceptable salt thereof, wherein is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand. 【Request 6】 【Chemical 4】 【Chemistry 5】 wherein n is 1 to 10; M + However, cerium-134 ( 134 2. The radioactive metal complex of claim 1, wherein the radioactive metal ion is

7. 13. An immunoconjugate comprising the compound of claim 1 conjugated to an antibody or antigen-binding fragment thereof.

8. The antibody or antigen-binding fragment thereof is linked to R via a triazole moiety. 4 The immunoconjugate of claim 7, wherein the

9. 【Chemical 6】 is selected from the group consisting of During the ceremony, L 1 is absent or is a linker, An immunoconjugate wherein the mAb is an antibody or an antigen-binding fragment thereof.

10. The immunoconjugate of claim 9, wherein the mAb is h11B6 or PSMB-127.

11. 【Chemical 7】 is selected from the group consisting of The immunoconjugate of claim 9 , wherein the mAb is an antibody or an antigen-binding fragment thereof.

12. The immunoconjugate of claim 11, wherein the mAb is h11B6 or PSMB-127.

13. A radioimmunoconjugate, wherein the radiometal complex of claim 1 is conjugated to an antibody or an antigen-binding fragment thereof.

14. The antibody or antigen-binding fragment thereof is linked to the R of the radiometal complex via a triazole moiety. 4 14. The radioimmunoconjugate of claim 13, wherein the radioimmunoconjugate is linked to

15. The radioimmunoconjugate of claim 13, wherein the antibody is h11B6 or PSMB-127.

16. 【Chemical 8】 is selected from the group consisting of During the ceremony, M + However, cerium-134 ( 134 1. The radioactive metal ion is L 1 is absent or is a linker, A radioimmunoconjugate wherein the mAb is an antibody or an antigen-binding fragment thereof.

17. The radioimmunoconjugate of claim 16, wherein the mAb is h11B6 or PSMB-127.

18. 【Chemical 9】 is selected from the group consisting of During the ceremony, M + However, cerium-134 ( 134 Ce), and A radioimmunoconjugate wherein the mAb is an antibody or an antigen-binding fragment thereof.

19. The radioimmunoconjugate of claim 18, wherein the mAb is h11B6 or PSMB-1154.

20. A pharmaceutical composition comprising the radioimmunoconjugate of claim 13 and a pharma- ceutically acceptable carrier.

21. 21. A method of selectively targeting tumor cells for radioimaging in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 20.

22. A method for imaging a neoplastic disease or disorder in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition described in claim 20.

23. 21. A method of imaging prostate cancer cells in a patient, comprising administering to the patient an effective amount of the pharmaceutical composition of claim 20 and detecting the distribution of the radioimmunoconjugate in the patient using a nuclear imaging technique (e.g., Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT)), wherein the radioimmunoconjugate comprises an antibody targeting a prostate cancer antigen.

24. 1. A method for imaging prostate cancer cells in a patient, comprising: The structure: 【Chemistry 10】 [In the formula, M + However, cerium-134 ( 134 Ce), and the mAb is a Prostate-Specific Membrane Antigen (PSMA)-targeting antibody or a KLK2-targeting antibody. administering to said patient an effective amount of a radioimmunoconjugate having the formula:

25. 25. The method of claim 24, further comprising using nuclear imaging techniques to detect distribution of said radioimmunoconjugate within said patient.

26. 26. The method of claim 25, wherein the nuclear imaging technique is selected from Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT).

Citation Information

Patent Citations

  • Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer

    WO2020106886A1

  • Macrocyclic chelators and methods of use thereof

    WO2020229974A1